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An estimated 2 billion people, one-third of the global population, 
are infected with Mycobacterium tuberculosis (M.tb.), the bacterium that 
causes tuberculosis (TB) (Keshavjee and Seung, 2008). Spread through the 
air, this infectious disease kills 1.8 million people each year, or 4,500 each 
day (WHO, 2009a). TB is the leading killer of people with HIV, and it is 
also a disease of poverty—the vast majority of TB deaths occur in the devel-
oping world (WHO, 2009a). Exacerbating the devastation caused by TB 
is the growing threat of drug-resistant strains of the disease in many parts 
of the world. The development of drug resistance is a predictable, natural 
phenomenon that occurs when microbes adapt to survive in the presence 
of drug therapy (Nugent et al., 2010). Although antibiotics developed in 
the 1950s are effective against a large percentage of TB cases, resistance 
to these first-line therapies has developed over the years, resulting in the 
growing emergence of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) TB, and even totally drug-resistant (TDR) TB (see Box 1-1 
for definitions). 
In recognition of the grave threat posed worldwide by drug-resistant 
TB, in November 2008 the Institute of Medicine’s (IOM’s) Forum on Drug 
1 The workshop was organized by an independent planning committee whose role was 
limited to the identification of topics and speakers. While the Forum on Drug Discovery, 
Devel opment, and Translation conceived the idea for the workshop, this summary was pre-
pared by the rapporteurs as a factual account of the presentations and discussions that took 
place at the workshop. Statements, recommendations, and opinions expressed are those of the 
individual presenters and participants, are not necessarily endorsed or verified by the Forum 
or the National Academies, and should not be construed as reflecting any group consensus.
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BOX 1-1a
The Nature of the Threat
Definitions
 Multidrug-resistant tuberculosis (MDR TB) is caused by bacteria 
resistant to isoniazid and rifampicin, the two most effective first-line anti-
TB drugs, originally introduced in the 1950s. 
 Extensively drug-resistant tuberculosis (XDR TB) is resistant to 
the same drugs as MDR TB (isoniazid and rifampicin), as well as any 
fluoroquinolone (levofloxacin, moxifloxacin, or ofloxacin) and at least one 
second-line injectable drug (kanamycin, amikacin, or capreomycin). 
 Totally drug-resistant tuberculosis (TDR TB) is TB for which no 
effective treatments are available.
Pathways for Infection
 MDR/XDR TB results from either primary infection with a drug- 
resistant strain of TB (i.e., transmitted by person-to-person contact) or 
acquired infection with such a strain that occurs in the course of a 
patient’s treatment, resulting, for example, from failure to ensure regular 
treatment with high-quality drugs. Amplified resistance, or the enhance-
ment of existing drug resistance as a result of initiating an inappro priate 
drug regimen at the beginning of care, is a significant challenge created 
by providing an incorrect combination of drugs. Even when an empirically 
appropriate drug regimen is selected at the beginning of treatment, by 
the time drug susceptibility information is available, resistance may be 
amplified.
Treatment
 Treatment of MDR and XDR TB requires 2 years or more of daily, 
directly observed treatment with drugs that are less potent, more toxic, 
and much more expensive than those used to treat drug-susceptible TB. 
Despite the challenges, aggressive treatment with second-line drugs has 
produced successful outcomes in MDR and XDR TB patients. However, 
TDR TB is a growing threat. The spread of TDR TB is especially omi-
nous as it would return the globe to the pre-antibiotic era with respect to 
this disease. Identifying and addressing barriers to effective and timely 
diagnosis and treatment of drug-resistant TB supports prevention of 
the further emergence of strains of TB with broad-spectrum resistance 
 (Keshavjee and Seung, 2008).
aThe information in this box was originally presented at the Forum’s 2008 workshop on 
drug-resistant TB (IOM, 2009).
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Discovery, Development, and Translation held a workshop titled “Address-
ing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of 
the Challenge,” which brought together experts in drug-resistant TB and 
public health to speak frankly and openly about the problem.2 That work-
shop led to plans for four additional workshops in countries with a high 
burden of drug-resistant TB. The first of these workshops, summarized in 
this volume, was held in Pretoria, South Africa, on March 3−4, 2010, with 
subsequent workshops being planned for Russia, China, and India. The 
workshop brought together about 65 disease experts, community leaders, 
policy makers, and patient advocates from South Africa, other countries in 
southern Africa, and the United States for 2 days of intensive discussions. 
The workshop was supported in part by the Doris Duke Foundation, by the 
Howard Hughes Medical Institute, and by the U.S. Department of State. 
THE BURDEN OF DRUG-RESISTANT TB
Based on global drug resistance surveillance data, it is estimated that 
3.6 percent of global TB cases, or a total of 440,000 cases, were MDR 
TB in 2008 (95 percent confidence interval, 390,000−510,000) (WHO, 
2010a). However, a number of TB experts at this and prior workshops, 
noted that the available data on drug-resistant TB are inadequate and yield 
a gross underestimation of the true global burden of disease. Surveillance 
systems do not exist or are not capable of valid and reliable reporting 
in many developing countries where the MDR TB burden is likely to be 
substantial. Even the most recent global surveillance data on MDR TB do 
not include 79 countries—41 percent of all countries in the world (WHO, 
2010a). According to the World Health Organization (WHO), although the 
estimate of 440,000 MDR TB cases for 2008 indicates a decrease relative 
to 2006 (best estimate of 489,000 cases), this change reflects the reporting 
of new data, changes in TB incidence, and the use of updated diagnostic 
methods and should not be considered reflective of a true decline in MDR 
TB cases (WHO, 2010a). 
Data on the burden of XDR TB are even more limited because many 
countries lack the laboratory and infrastructure capacity necessary to test 
MDR TB patients routinely for susceptibility of their infecting organism 
to second-line drugs. (The relationship between the estimated incidence of 
drug-resistant TB and diagnostic tools is further discussed in Chapter 2.) 
Unfortunately, the drug susceptibility testing that many countries are ill-
equipped to conduct is the basis for providing optimal patient care for 
2  The summary of that workshop (IOM, 2009) and the accompanying white paper ( Keshavjee 
and Seung, 2008) provided background for and informed the development of and proceedings 
at the workshop summarized in this volume.
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MDR and XDR TB patients. It is through such testing that physicians 
determine which drugs are likely to be effective against a particular drug 
resistance profile. A number of workshop participants noted that the vast 
majority of MDR and XDR TB cases are undetected and thus untreated 
with appropriate second-line drugs. Among the small proportion of patients 
who are being treated with second-line drugs, many are not taking the right 
drugs to effectively treat their drug resistance profile.
WORKSHOP OBJECTIVES
The objectives of the workshop were to learn from the experiences of the 
southern African public health community in its fight against drug- resistant 
TB, and to draw lessons regarding best practices and novel approaches 
that can be applied both within and beyond the region. The workshop 
was cohosted by the IOM and the Academy of Science of South Africa 
(ASSAf). As Roseanne Diab, executive officer of ASSAf, said in welcoming 
participants, the partnership between the IOM and ASSAf was particularly 
appropriate given ASSAf’s close association with the National Academies 
over the past 5 years through the African Science Academy Development 
Initiative (ASADI). Enriqueta Bond, chair of the ASADI board, also par-
ticipated in the workshop. As moderator of the closing session, Bond facili-
tated a discussion of the new scientific knowledge presented at the meeting 
and how this new evidence can inform future policy actions (see Chapter 8). 
Diab also assured the delegates that ASSAf would take the outcomes of the 
workshop forward for closer engagement with government.3
THE PROBLEM AND PRIORITIES
In her opening remarks, Gail Cassell, Forum co-chair, Eli Lilly and 
Company (retired), provided a summary of the problem and themes arising 
from the 2008 workshop. She noted that strains of M.tb. that are resistant 
to the drugs conventionally used to treat TB have become well established 
in many countries. Accurate estimates of the prevalence of MDR, XDR, and 
TDR TB are not possible because of a lack of laboratory capacity in many 
3 The National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes 
of Health (NIH), held a meeting focused on TB research March 1−2, 2010, the 2 days prior to 
the IOM workshop. This meeting was co-sponsored by the Medical Research Council (MRC) 
of South Africa and the Howard Hughes Medical Institute and focused on TB research in drug 
discovery and development, diagnostics, vaccines, and biomarkers as well as the identifica-
tion of opportunities for TB research collaboration in Africa. Topics and meeting participants 
overlapped between the NIAID and IOM meetings in South Africa, creating synergies and 
connections for future collaborations in the areas of TB research and policy. Appendix B of 
this report includes a summary of the NIAID meeting.
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of these countries, but current estimates are sure to be grossly understated 
(see Chapter 2). Not all of the countries with the highest burden of TB 
participate in surveys by the WHO, the existing data are 2 to 3 years old, 
and many of the data are derived from modeling rather than surveillance. 
Thus the total number of cases of drug-resistant TB is certainly higher 
than the official WHO estimate (for MDR TB, 440,000 new cases in 2008 
[WHO, 2010a]).
Furthermore, Cassell observed, the number of patients receiving appro-
priate treatment for drug-resistant TB is distressingly small. WHO estimates 
that worldwide only 7 percent of MDR TB patients are diagnosed (WHO, 
2010a), and only about 1 percent of estimated MDR TB cases globally are 
enrolled in MDR TB treatment programs that use quality-assured drugs 
(programs approved by the Green Light Committee [GLC]). Thus even 
among those patients who are being treated, many are not receiving the 
drugs that address their drug resistance profile, which reduces the effective-
ness of treatment.
Until recently, the perception was that resistant strains of TB were too 
weak to achieve high rates of transmission, and therefore that infection 
control was not the highest priority. However, new evidence indicates that 
human-to-human spread is more common than previously appreciated. 
Demonstrating infection in patients may take months, during which time 
they can spread the resistant organism within their households, to patients 
and health care workers, and to others in the community. Furthermore, 
the spread of TB has been greatly exacerbated by the HIV epidemic. The 
high prevalence of HIV threatens to make drug-resistant TB a more conta-
gious, rapidly progressing, and highly lethal disease. Cassell suggested that, 
because the reality of drug-resistant TB is worse than the general percep-
tion, the urgent need for action will not be recognized until it is too late 
unless the perception changes to reflect the reality of the threat.
In Cassell’s view, the presentations and discussions at the 2008 work-
shop yielded several themes:
• To address the problem of drug-resistant TB head-on, it will be 
important to recognize that TB strains resistant to all approved 
drugs are growing rapidly in number, although the number is cur-
rently unknown. 
• Revolutionary and rapid changes are warranted to redress the cur-
rent absence or limited availability of effective infection control 
strategies in health care and community settings in order to reduce 
the transmission of drug-resistant TB.
• The development and widespread deployment of accurate diag-
nostics and treatment based on drug susceptibility testing will help 
support the maximal effectiveness of existing drugs.
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Cassell also noted that the 2008 workshop highlighted the tremen-
dous challenge drug-resistant TB poses for drug developers. If patients 
with TDR TB are to be successfully treated, three to four new classes of 
antibiotics will be needed simultaneously. The drug discovery process has 
a 90 percent failure rate from target identification to regulatory approval; 
it has a 50 percent failure rate even in phase III trials. The average time for 
drug discovery and development from target identification to approval is 
10 to 14 years, and probably considerably longer for TB drugs when the 
follow-up period is taken into account. The average cost to develop a single 
new drug, from discovery to approval, is more than $1.5 billion, and this 
does not include postlaunch surveillance for adverse events, manufacturing 
compliance, drug delivery, and so on. The technical and financial obstacles 
to the development of new drugs are so great that no one government, 
institution, or company has enough resources or expertise to succeed on 
its own. Only through the collaboration of all sectors can such challenges 
be overcome.
Cassell summed up by stating that the failure to acknowledge the 
new realities of drug-resistant TB and to act rapidly will be catastrophic 
for many countries. Furthermore, the volume of international travel and 
immigration, legal and otherwise, means that drug-resistant TB represents 
a grave threat to the public health of all countries, not just those in which 
TB is prevalent today. Members of the scientific and medical communities 
must communicate the realities of drug-resistant TB to the public and to 
policy makers, and they must translate data into policies commensurate 
with the magnitude of the problem. Cassell expressed the hope that this 
workshop summary, along with those of the three workshops to follow on 
this vitally important topic, will provide a base of information to help move 
such efforts forward.
ORGANIZATION OF THIS REPORT
This report summarizes the main points made at the workshop dur-
ing both the formal presentations and the discussions among participants. 
Observations and recommendations made at the workshop do not represent 
the formal positions of the IOM or ASSAf; however, they have provided 
valuable input to the Forum on Drug Discovery, Development, and Transla-
tion and to the IOM as both bodies deliberate on future initiatives. Presen-
tations at the workshop addressed the following topics:
• the incidence of drug-resistant TB in southern Africa, including the 
relationship between TB and HIV infection (Chapter 2); 
• the molecular epidemiology of the epidemic and the challenges of 
monitoring and tracking the spread of drug-resistant TB (Chapter 3);
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• growing understanding of the modes of transmission of drug-
resistant TB and experience with infection control programs 
(Chapter 4);
• diagnosis of drug-resistant TB, as well as opportunities for the 
expansion of laboratory capacity and point-of-care diagnosis 
(Chapter 5);
• treatment of drug-resistant TB, including the capacity of current 
health systems to address the needs of TB patients, the limited 
numbers of patients receiving appropriate treatment, and the devel-
opment of new drugs (Chapter 6);
• the devastating spread of drug-resistant TB among children and the 
unique challenges this group poses for prevention and treatment 
(Chapter 7); and
• the major viewpoints expressed at the workshop and next steps 
suggested by workshop participants (Chapter 8).
Each chapter of the report opens with a box listing the key messages 




The Incidence of Drug-Resistant TB  
in Southern Africa
Gerald Friedland, Yale School of Medicine, reviewed recent data on 
the incidence of drug-resistant TB worldwide, stressing that these data are 
inadequate and underestimate the reality of the situation. Friedland noted 
that knowledge of the true extent of the MDR/XDR TB epidemic is ham-
pered by a lack of in-country laboratory capacity and the inadequacies of 
the existing health system infrastructure. 
Key Messages
•  The precise incidence of drug-resistant TB in southern Africa is cur-
rently unknown, but it has become a major health problem in the 
region.
•  The increased incidence of MDR TB, XDR TB, and HIV infection 
places a tremendous burden on the region’s health care systems.
•  An outbreak of XDR TB in Tugela Ferry, KwaZulu-Natal Province, 
South Africa, reported in 2006, raised great concern about transmis-
sion in health care, community, and household settings.
•  Since 2006, cases of XDR TB have occurred in all provinces of South 
Africa and in all surrounding countries.
•  The HIV epidemic in southern Africa has exacerbated the spread and 
virulence of drug-resistant TB.
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According to the World Health Organization (WHO), the number of 
new TB cases globally was 9.4 million in 2008 (WHO, 2009a). The disease 
killed 1.8 million people in that year, or 4,500 per day. While the highest 
number of cases of MDR TB (estimated annual numbers of new cases) is in 
Asia, the greatest per capita rates are in Africa (WHO, 2010a). No accurate 
and up-to-date data concerning the prevalence of MDR and XDR TB are 
available for most African countries. However, WHO estimates that more 
than 75,000 new MDR TB cases will occur in Africa in 2010 (Figure 2-1). 
By WHO estimates, 440,000 global cases of MDR TB arose in 2008; 
about 5.4 percent of these cases were XDR TB. About 15 percent of all 
TB cases, or 1.4 million, are associated with HIV infection. The 450,000 
deaths caused by HIV-associated TB represent 26 percent of TB deaths and 
23 percent of HIV deaths. 
After briefly examining the relationship between reported incidence 
rates and the diagnostic tools used, this chapter summarizes information 
presented at the workshop on the incidence and burden of drug-resistant 
TB in South Africa. It then summarizes presentations and discussions that 
looked more closely at the outbreak of MDR and XDR TB in KwaZulu-
Natal Province and that addressed coinfection with HIV/AIDS in southern 
Africa.
RELATIONSHIP BETWEEN REPORTED 
INCIDENCE AND DIAGNOSTIC TOOLS1
There is evidence that differences in the reported incidence of drug-
resistant TB could be attributable, at least in part, to the diagnostic tools 
used in particular areas. Sturm reported that since 2005, the Church of 
Scotland Hospital (CoSH) in Tugela Ferry has been the only health care 
facility in KwaZulu-Natal Province to use culture diagnostics for all pos-
sible TB cases. The Msinga subdistrict, in which CoSH is located, is also the 
region in the province with the highest reported number of cases of XDR 
TB. Yet the incidence of drug-resistant TB in the Msinga subdistrict would 
not be expected to differ from that in the province’s other subdistricts and 
districts. The main difference appears to be that in the Msinga subdistrict, 
culture and drug susceptibility testing is done on all first contacts. Else-
where, many patients die before a specimen is taken or the results of drug 
susceptibility testing become available.
Research also has found an association between the number of new 
cases of TB diagnosed by culture and the reported percentage of drug-
resistant TB. In 2007, data on the presence of the F15/LAM4/KZN strain of 
1  This section is based on the presentation of Adriaan Willem Sturm, Nelson Mandela 
School of Medicine, University of KwaZulu-Natal.
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FIGURE 2-1 More than 75,000 new cases of MDR TB are estimated to have 
 occurred in Africa in 2010. 







M.tb. were published (Pillay and Sturm, 2007). This had been the dominant 
strain of MDR TB since 1994, and it had evolved into an XDR TB strain 
by 2001. The data suggest that the more new cases of TB are diagnosed 
by cultured specimens in a health district, the higher is the percentage of 
drug-resistant TB found in that district.2 In addition, the districts with the 
highest rates of MDR and XDR TB are those that house or have a strong 
link with academic centers, which send greater numbers of specimens for 
culture relative to other facilities. 
For every patient who is diagnosed with and treated for MDR TB in 
southern Africa, it is likely that several more are diagnosed and not treated. 
2  It was also noted that the impact of recently diagnosed cases on the proportion of drug 
resistance can be biased by nosocomial (health care facility-based) outbreaks.
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Further, an even larger number of those infected with MDR TB are never 
diagnosed because diagnostic capabilities are inadequate or because these 
people die without ever having been seen and diagnosed through the health 
care system. The metaphor Friedland used—which became a theme for 
the workshop—is that the number of cases of drug-resistant TB seen in 
southern Africa represents the “ears of the hippo,” a very small portion of 
a much larger entity that cannot be seen. 
MDR AND XDR TB IN SOUTH AFRICA
According to several workshop presenters, drug-resistant TB imposes 
a tremendous health burden throughout southern Africa. Tomás Zimba of 
Mozambique’s Maputo Central Hospital described efforts to control and 
treat MDR TB patients in the country. Zimba explained that challenges in 
dealing with the co-epidemics of HIV and TB in Mozambique are similar to 
challenges experienced throughout the southern Africa region (see Box 2-1). 
Most of the discussion at the workshop focused on the experience in South 
Africa, however, where the incidence of MDR TB now exceeds 25 cases 
per 100,000 people in certain areas, according to Neel Gandhi of Tugela 
Ferry Care and Research Collaboration (TF CARES) and Albert Einstein 
College of Medicine. 
To illustrate the burden of drug-resistant TB in South Africa, Martie 
van der Walt, Medical Research Council of South Africa (MRC), described 
the experience of King George V Hospital, the referral center for drug-
resistant TB in KwaZulu-Natal Province. From February to August 2006, 
211 patients with a positive culture on admission for drug-resistant pul-
monary TB began their first course of therapy for MDR TB. Most of these 
patients were very ill at baseline, weighing below 50 kg (110 pounds) at the 
start of treatment, and mortality was common. Among these 211 patients, 
4 of 12 with XDR TB and 16 of 199 with MDR TB died during the first 
6 months of treatment (Kvasnovsky et al., 2008). 
Richard Chaisson, Center for Tuberculosis Research, The Johns 
 Hopkins University, noted that one of the United Nations’ Millennium 
Development Goals is to halve the amount of mortality and morbidity 
caused by infectious diseases relative to 1990 levels (UN, 2010). In large 
parts of Africa, this goal is becoming more distant for TB, according to 
Chaisson. In 1990, just 2 countries in Africa had a TB incidence greater 
than 300 per 100,000 population. This number had risen to 23 countries 
by 2005; in that same year, 6 countries had an incidence greater than 500 
per 100,000 population, and 2 had an incidence greater than 1,000 per 
100,000. 
According to Chaisson, these figures translate into unmanageable num-
bers of patients presenting to the health care system. From 2005 to 2008, 
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BOX 2-1 
Problems of Dealing with Drug-Resistant TB in Mozambiquea
 The experience of Mozambique illustrates the problems facing many 
areas of southern Africa in dealing with the epidemic of drug-resistant TB, 
according to Zimba. Almost constant warfare during the three  decades 
from 1965 to 1994 created severe disruptions in the country’s health care 
system, just as political instability elsewhere in southern Africa has ham-
pered health care delivery. Only 45 percent of the population has access 
to health care. Of Mozambique’s 22 million people, 12.5 percent of adults 
are estimated to be infected with HIV (UNAIDS, 2008) (see the discussion 
of TB and HIV coinfection later in this chapter).
 Southern Africa has adopted the WHO guidelines for diagnosis 
and treatment of TB, using microscopy as the standard for diagnosis and 
follow-up of TB cases. In Mozambique, the national TB control program 
was launched in 1977. The country has seen some success in expand-
ing Directly Observed Treatment Short course (DOTS) to the community 
(community-based DOTS [C-DOTS]) and improving access for people in 
underserved areas (USAID, 2009). However, drug resistance has proven 
to be a great problem in the country.
 There are 255 laboratories in Mozambique that can diagnose TB 
using microscopy. But there is only one National Reference Laboratory 
that conducts culture and drug susceptibility testing for first-line anti-TB 
drugs. Samples for diagnosis from the district and provincial laboratories 
are transported to the National Reference Laboratory in the capital city 
of Maputo. Three months can pass before those laboratories receive 
feedback and the patient is informed of the diagnosis.
 A 1998−1999 nationwide survey of 709 culture-positive TB cases in 
Mozambique found that 3.4 percent of new cases were MDR (Mac-Arthur 
Jr et al., 2001). Drug resistance was more common among those with 
a history of prior treatment. A 2002−2003 report from the  Mozambique 
national TB program similarly indicated that 3 percent of new TB cases 
were MDR (Nunes et al., 2005). In 111 samples from HIV-infected 
 patients, 9 percent were found to have MDR TB. About 6 percent of new 
TB cases in patients infected with HIV, as well as 16 percent of TB cases 
among previously treated patients, were MDR.
 In 2009 there were an estimated 1,700 cases of MDR TB among 
notified pulmonary TB cases in Mozambique (WHO, Global Tuberculosis 
Control 2010; Annex 3). According to Zimba, however, it is known that 
the Mozambique national TB program has in the past seriously under-
estimated the numbers of new cases of MDR TB. The actual number of 
cases of primary MDR TB in Mozambique remains unknown.
aThis box is based on the presentation of Tomás Zimba, Maputo Central Hospital, Mozambique.
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the largest hospital in South Africa, Chris Hani Baragwanath Hospital 
in Soweto, had between 6,500 and 6,800 new TB admissions per year. 
 Inpatient mortality was 18 percent at 2 weeks, or about 1,200 deaths per 
year. Nine percent of those dying of TB had MDR TB, representing about 
110 MDR TB deaths per year.
Estimating the contribution of TB to mortality in South Africa is dif-
ficult. This issue is addressed in Box 2-2.
Van der Walt presented data from the Preserving Effective TB Treatment 
with Second-line drugs (PETTS) study, which is a prospective cohort study 
of approximately 1,800 MDR TB patients in nine countries at 27 clinical 
sites and 17 laboratories. The objective of the study is to determine the 
frequency, timing, and risk factors for acquired resistance to second-line 
drugs in diverse MDR TB control programs. The study also is seeking to 
determine the effect of acquired second-line resistance on patient outcomes. 
Four provinces of South Africa, including KwaZulu-Natal, are participat-
ing in this study. A follow-up of the patients enrolled in the study has been 
performed every month to collect a culture and update a database used to 
monitor acquisition of resistance.
Van der Walt noted that cross-resistance3 to second-line drugs is espe-
cially problematic in South Africa. MDR TB patients in South Africa are 
three times more likely than their counterparts from other PETTS sites/
countries to have cross-resistance to all the injectable drugs for TB at base-
line. The PETTS study has shown that XDR TB was present at baseline in 
10.3 percent of cases in 2005 (Kvasnovsky et al., 2009), while a 2005–2006 
analysis of the PETTS cohort found that 1 percent of drug-resistant TB 
cases were TDR.4
OUTBREAK OF MDR AND XDR TB IN 
KWAZULU-NATAL PROVINCE5
KwaZulu-Natal Province, which comprises 11 health districts divided 
into a number of subdistricts, has a population of about 9.6 million people. 
The province has an enormous TB burden, and MDR and XDR TB strains 
are present throughout.
3  The development of resistance to first-line drugs can lead to resistance to second-line drugs 
because of the similar molecular basis of the first- and second-line drugs (Maus et al., 2005).
4  The warning signs of TDR TB include low cure rates, high mortality rates, and a very 
slow rate of conversion that cannot be attributed to HIV alone. The management of XDR 
and TDR TB raises many ethical dilemmas, van der Walt observed. Complex questions in-
clude whether such patients should be subjected to particular kinds of infection control, up 
to permanent isolation.
5  This section is based on the presentation of Neel Gandhi, Tugela Ferry Care and Research 
Collaboration (TF CARES) and Albert Einstein College of Medicine.
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BOX 2-2 
Estimating the Contribution of TB to Mortality in South Africaa
 According to Tuoane-Nkhasi, information on the contribution of TB 
to mortality in South Africa can be obtained from the country’s civil reg-
istration system based on registered deaths in the country. A medical 
practitioner must indicate the cause of death on the death notification 
form. Methods for analyzing cause-of-death data include the following:
 •  Cause of death is classified using the coding of the International 
Classification of Diseases, 10th revision (ICD-10). Causes of 
deaths classified as MDR TB and XDR TB have been included in 
the South African death notification system only since 2006.
 •  The underlying cause of death is derived automatically using the 
Automated Classification of Medical Entities (ACME). Causes that 
cannot be derived automatically are determined by experienced 
ICD-10 coders trained in deriving the underlying causes of death.
 •  The causes of death are ranked according to their frequency. In the 
ranking process, deaths due to symptoms, signs, and  abnormal 
clinical findings not elsewhere classified are excluded since this 
group includes ill-defined conditions for which no classifiable diag-
nosis is recorded.
 About 85 percent of all deaths in the country are registered. The 
levels and trends of registered deaths from 1997 to 2007 in South 
 Africa show that about 10 percent of deaths were among children aged 
0−4. The majority of these deaths occurred during the first year in the 
postneonatal period. The annual number of child deaths increased con-
sistently from 1997 to 2006, with a slight decrease in 2007. There were 
more male than female deaths among children, and more infant deaths 
occurred in  KwaZulu-Natal and Gauteng than in the other provinces. In 
2007, 11 death notification forms indicated that MDR or XDR TB was 
the underlying cause of death among children aged 0−4. Of the 10 lead-
ing underlying causes of death in that age group, TB was ranked sixth, 
accounting for 2.5 percent of deaths. Respiratory and cardiovascular 
disorders specific to the perinatal period were indicated as the leading 
cause of death.
 For both males and females aged 15−64, TB has been the leading 
underlying cause of death in South Africa since 1997. Since 2002, about 
12 percent of all deaths in the country have been caused by respiratory 
TB, but the death notification forms usually do not specify whether this 
diagnosis was confirmed either bacteriologically or histologically. In 2006, 
continued
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the underlying cause of death among 607 people was identified as MDR 
TB; in 2007, this number decreased slightly to 597. 
 There are a number of sources of uncertainty in these statistics:
 •  underregistration of deaths, particularly among children and in 
rural areas;
 •  late registration of deaths;
 •  content errors and omissions;
 •  misreporting and insufficient reporting of causes of death on death 
notification forms;
 •  the time lag between the actual event, registration, and the publica-
tion of statistics; and
 •  limited information for in-depth analysis of mortality.
 Information from South Africa’s civil registration system is useful 
in providing numbers of deaths and their causes each year, but the 
 statistics produced depend on the quality of the data input to the system. 
According to Tuoane-Nkhasi, concerted efforts of the public, the Depart-
ment of Home Affairs, the Department of Health, and Statistics South 
Africa are required to improve these data.
aThis box is based on the presentation of Maletela Tuoane-Nkhasi, Statistics South Africa.
BOX 2-2 Continued
In 2006, a group led by Gandhi reported on 53 cases of XDR TB in 
Tugela Ferry in the Msinga subdistrict, which has a population of about 
200,000 traditional Zulu people living largely in poverty (Gandhi et al., 
2006). In June 2005, within a few months of the discovery of the first XDR 
TB case in Tugela Ferry, 5 other facilities in KwaZulu-Natal had cases. By 
December 2005, a further 18 facilities had reported cases; by June 2006, 
the total was 32 facilities; by December 2006, the total was 39; and by 
March 2007, it was 42. The latest estimates are that more than 60 facilities 
in KwaZulu-Natal have reported at least one case of XDR TB. In addition, 
every province in South Africa and all neighboring countries have reported 
cases of XDR TB.
MDR TB has undergone a similarly dramatic increase in KwaZulu-
Natal Province. Gandhi noted that there were 2,654 cases of MDR TB in 
2007 alone, representing a prevalence of 26 cases per 100,000 population. 
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According to Friedland, given the widespread distribution and continu-
ing appearance of new cases of both MDR and XDR TB as of 2010, the 
situation is more appropriately defined as an epidemic than as a series of 
outbreaks.
The rapid increase in drug-resistant TB in KwaZulu-Natal Province was 
not consistent with the relatively small numbers of MDR TB cases among 
patients who had no prior history of treatment according to a 2001–2002 
survey of drug-resistant TB in South Africa, the last survey conducted in the 
province prior to the outbreak of drug-resistant TB in 2006 (Weyer et al., 
2004). That survey found, for example, that just 1.7 percent of patients with 
no history of prior TB treatment in KwaZulu-Natal Province had MDR 
TB. The outbreak of XDR TB in the province therefore raised the question 
of whether the 2001−2002 data underrepresented the extent of MDR TB 
infection.
The study reported by Gandhi, which received international attention, 
found that XDR TB in that population was highly fatal. All but one of the 
patients died (98 percent mortality), with a median survival of just 16 days 
from sputum collection.6 The study revealed high clustering rates, with 
85 percent having genetically similar TB strains. The study also found that 
half of the patients had never been previously treated for TB, and more 
than 95 percent of patients with XDR TB had never been treated for MDR 
TB. Thus, these patients had not had the long-term exposure to second-
line drugs that would be expected to lead to resistance. The study authors 
concluded that the transmission of XDR TB strains from person to person 
was likely.7
More recently, high levels of mortality have been confirmed in a much 
larger group of patients from Tugela Ferry with coinfection rates of HIV 
with MDR and XDR TB of 90 and 98 percent, respectively (Gandhi et al., 
2010). MDR TB 1-year mortality was 71 percent, with a median survival of 
60 days; XDR TB 1-year mortality was 83 percent, with a median survival 
of 28.5 days. Mortality was highest in the 30 days after sputum collection—
prior to diagnosis of drug-resistant TB by conventional culture and drug 
susceptibility testing methods (Gandhi et al., 2010). Because these methods 
typically take 6−8 weeks to yield a result, the majority of drug-resistant TB 
patients in this high HIV-prevalence setting die before they are diagnosed 
6  This severe mortality may be partially explained by the fact that all the patients whose 
HIV status was known were HIV-positive.
7  Transmission of drug-resistant strains has been seen in the past, when numerous outbreaks 
of MDR TB occurred in congregate settings in the early 1990s. As in more recent outbreaks, 
HIV coinfection was extremely high in the outbreaks of the 1990s (Wells et al., 2007). The 
prior outbreaks, too, had a very high mortality rate, ranging from 72 to 98 percent, with most 
deaths occurring within 4 to 8 weeks of collection of sputum culture.
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and treated.8 Gandhi suggested that a comprehensive response to the high 
mortality seen in MDR and XDR TB patients should include 
• prevention of the development of drug resistance through the 
expansion of DOTS and infection control strategies;
• implementation of rapid diagnostics to reduce the time to diagnosis 
from 6−8 weeks to 1−10 days and use of intensified case finding to 
locate patients at earlier stages of disease; and
• empiric use of second-line drugs in HIV-infected patients suspected 
of MDR or XDR TB, as well as integration of antiretroviral ther-
apy into MDR and XDR TB treatment programs to facilitate early 
and widespread use. 
Recent studies have demonstrated that survival decreases with an 
increasing degree of drug resistance. MDR TB patients with resistance to 
only isoniazid and rifampicin do better than those with additional first-
line drug resistance. Likewise, XDR TB patients with resistance to only 
four or five drugs do better than those with resistance to all six drugs 
tested. Further more, resistance is increasing. At Tugela Ferry, the propor-
tion of XDR TB isolates with resistance to six drugs increased steadily and 
consistently over a 2-year period, with a six-drug pattern being identified 
among more than 95 percent of patients by 2007 (Moll et al., 2007). When 
data from a different study performed in 2008–2009 are added, the six-
drug phenotype constitutes 100 percent of the XDR TB strains. When the 
2008–2009 group was tested for additional resistance to ethionamide and 
capreomycin, the vast majority of these XDR TB strains were found to be 
resistant not only to the six drugs previously identified but to all eight drugs 
tested. Further studies are required to understand the correlates of survival 
among those patients whose infection is resistant to eight drugs. 
Other investigators have found high levels of resistance in the XDR 
TB seen in KwaZulu-Natal Province (Pillay and Sturm, 2007). Of 52 
isolates of the F15/LAM4/KZN XDR TB strains, 100 percent were found 
to have mutations in the rss gene conferring resistance to streptomycin, 
 kanamycin, amikacin, and capreomycin. In addition, 69 percent were found 
to have mutations in the pcnA gene conferring resistance to pyrazinamide. 
Most of the isolates were resistant to isoniazid, rifampicin, ethambutol, 
 pyrazinamide, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin, 
and ethionamide. That level of resistance leaves very few antibiotics that 
can be used to treat the disease.
8  WHO and International Standards for Tuberculosis Care (ISTC) guidelines recommend 
that an empiric regimen of second-line drugs should be used in suspected MDR TB patients 
(TBCTA, 2009).
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TB AND HIV COINFECTION IN SOUTHERN AFRICA9
TB has become epidemic in the setting of a generalized HIV epidemic 
in southern Africa, and HIV infection has had a strong influence on the 
increased numbers of drug-resistant TB cases in the region. As several 
workshop participants emphasized, where there are high rates of HIV 
coinfection, the potential exists for the explosive spread of drug-resistant 
TB. Thus a theme of the workshop presentations and discussions was that 
understanding the dynamics of the TB epidemic in southern Africa requires 
knowledge of the ongoing HIV epidemic. Chaisson offered the following 
metaphor to illustrate the relationship between TB and HIV: if the TB cases 
seen in hospitals are the tip of an iceberg of TB infection, then the iceberg 
is floating in an ocean of HIV. 
Drug-resistant TB in the context of southern Africa’s HIV epidemic 
raises many important clinical issues, including
• the lack of diagnostic capacity to detect TB and perform drug sus-
ceptibility testing, with many patients dying before the extent of 
their drug resistance can be assessed;
• infection control;
• TB infections that test negative on sputum smears and extra-
pulmonary TB;
• the availability of treatments, including second-line drugs;
• drug toxicity;
• treatment with antiretrovirals and the challenges of managing mul-
tiple medications and their interactions; and
• immune reconstitution inflammatory syndrome (IRIS).10
Chaisson noted that default rates (the rate at which patients cease to 
continue prescribed treatments) in South Africa have been up to 20 percent 
of patients on second-line anti-TB treatment, with no difference between 
HIV-positive and HIV-negative groups. A retrospective study of 2,070 
patients on standardized MDR TB treatment in nine provinces of South 
Africa between 2000 and 2004 revealed that patients coinfected with HIV 
were three times more likely to die than patients without HIV (van der Walt 
et al., 2007). According to Chaisson, it is not known whether the deaths 
were due to poor treatment outcomes, including the development of XDR 
TB, or the failure to receive appropriate therapy. 
9  This section is based on the presentation of Chaisson.
10 IRIS is an inflammatory response in HIV-infected patients that is triggered by the initiation 
or reinitiation of antiretroviral therapy or a change to a more active antiretroviral therapy 
regimen.
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Looking at South Africa in particular, Chaisson noted that it has made 
remarkable progress in extending antiretroviral therapy among its popu-
lation. The current challenge is to meet the global standard of care for 
providing antiretroviral therapy to TB patients coinfected with HIV, as it 
has been shown that survival is dramatically improved when antiretrovirals 
are given during rather than after TB therapy (Abdool Karim et al., 2010).
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Surveillance and Tracking 
of Drug-Resistant TB
Systematic surveillance and tracking of drug-resistant TB helps in 
understanding the overall burden of the disease and can inform research 
and practice in diagnosis, treatment, and infection control. Speakers at the 
workshop described various approaches being taken to advance the track-
ing of drug-resistant TB in South Africa. This chapter summarizes those 
presentations. The first section reviews the use of genetic fingerprinting 
methodologies to understand the genotype and physiology of the vari-
ous drug-resistant TB strains found in South Africa. The second section 
describes a clinical screening tool that has been developed to intensify TB 
case finding. The final section addresses the need for information systems 
to increase laboratory capacity.
Key Messages
•  Improved case finding requires regular, comprehensive global sur-
veillance for drug-resistant TB, as well as improved planning and 
evaluation.
•  A comprehensive HIV clinical record integrated with a simple TB 
screening questionnaire and routine HIV care elements can lead to 
improved tracking and be beneficial for quality and continuity of care.
•  A strengthened information infrastructure for TB laboratories could 
support both the detection and treatment of drug-resistant TB.
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GENETIC ANALySIS OF DRUG-RESISTANT STRAINS1
Emergence of Beijing Strain
In South Africa and most of the world, three standardized methods are 
being adopted to classify TB strains by genotype. Warren and his colleagues 
have been applying these methods in numerous settings throughout South 
Africa to elucidate the mechanisms driving the drug-resistant TB epidemic 
in different regions.
An early study revealed a complex population structure of drug- resistant 
strains in the Western Cape Province of South Africa, with some strain 
genotypes being highly dominant (i.e., Beijing, LAM, and Low Copy Clade) 
(Streicher et al., 2001). A more detailed examination of this data set demon-
strated the evolutionary history of an outbreak strain (DRF 150) (Victor et 
al., 2007). The study found that isoniazid resistance occurred first, followed 
by streptomycin resistance. With the subsequent introduction of rifampicin, 
many of these strains acquired rifampicin resistance on different occasions. 
Most important, the strains that had acquired additional mutations confer-
ring resistance to ethambutol and pyrazinamide were the most dominant.
At about the same time, a preliminary study found that the Beijing/
R220 strain was widespread in the Western Cape (Johnson et al., 2006). 
Warren and his colleagues conducted a follow-up study of the drug-resistant 
strains in the Western Cape to determine whether there had been a change 
in the drug-resistant TB epidemic from 2002−2003 to 2005−2006 ( Johnson 
et al., 2010). The number of identified cases was found to be doubling 
approximately every 8 years. Of significant concern was their observation 
that 90 percent of all drug-resistant cases tested were smear positive and 
thus indicative of being highly infectious, leading to extensive transmis-
sion. Stratification of the data by drug resistance pattern showed that the 
observed increase was strongly driven by MDR TB. The Beijing/R220 strain 
contributed to 42 percent of this increase, with a doubling time of 2.4 years 
(Johnson et al., 2010).
A third outbreak strain was identified in an urban setting in Cape 
Town, South Africa (van Rie et al., 1999). This strain (strain U) is a mem-
ber of the Beijing genotype and showed a doubling time of approximately 
5 years. Thus, as in KwaZulu-Natal (see Chapter 2), the increase in drug-
resistant TB in the Western Cape Province was driven by a small number 
of specific strains. The implication is that the current TB control program 
is unable to prevent ongoing transmission of these highly resistant strains.
Studies from the Eastern Cape are limited. An initial study showed the 
spread of an atypical Beijing strain (Strauss et al., 2008). This finding was 
1  This section is based on the presentation of Rob Warren, Stellenbosch University.
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surprising, since it had been assumed that the strain was not spreading (as 
was observed in the Western Cape). According to Warren, the collation of 
genotyping data supports the notion that the population structure of drug-
resistant strains differs among the provinces of South Africa. However, insuf-
ficient data are available from the Northern Cape and Limpopo Provinces, 
as well as Namibia and Botswana, with which to make accurate assessments 
of the population structure of drug-resistant TB in southern Africa.
Genetic Analysis of XDR TB
Since the outbreak at Tugela Ferry was disclosed, XDR TB has been 
identified in all the provinces of South Africa, particularly in the Western 
Cape, which has a very high incidence of drug-resistant TB. DNA finger-
printing of MDR and XDR TB strains has shown that the main outbreak 
strains seen in the Western Cape (discussed above) are those that evolve 
into the pre-XDR and XDR group. At first glance, the DNA fingerprinting 
data suggest ongoing transmission of pre-XDR2 and XDR TB—a situation 
analogous to the Tugela Ferry outbreak. Warren pointed out, however, that 
genetic fingerprinting has certain limitations, and not all interpretations are 
necessarily correct. The discriminatory power of the DNA fingerprinting 
method can be improved by sequencing of the target genes conferring drug 
resistance. Using this approach, Warren and his colleagues showed that 
MDR TB strains with associated pyrazinamide and ethambutol resistance 
are spreading and that most XDR TB is acquired. According to Warren, 
these findings clearly indicate that patients with MDR TB are not being 
managed aggressively enough. This conclusion contrasts with the case of 
the Tugela Ferry outbreak, for which ongoing transmission due to poor 
infection control (hospital and community) was identified.
Strains with isoniazid resistance and associated cross-resistance to 
 ethionamide have become the dominant population in the XDR TB group. 
This may be explained by the fact that patients with MDR TB received a 
standardized treatment regimen that included ethambutol, pyrazinamide, 
ethionamide, ofloxacin, and amikacin or kanamycin. Only two of these 
drugs would have been active, given that MDR TB was found to be strongly 
associated with resistance to ethambutol and pyrazinamide and that cross-
resistance to ethionamide was common in the Western and Eastern Cape 
Provinces. Warren suggested that cross-resistance between isoniazid and 
2  Pre-XDR TB refers to MDR TB plus one-half of the resistance equation for XDR TB. As 
defined in Chapter 1 (Box 1-1), XDR TB is resistant to the same drugs as MDR TB (isoniazid 
and rifampicin), as well as any fluoroquinolone (levofloxacin, moxifloxacin, or ofloxacin) 
and at least one second-line injectable drug (kanamycin, amikacin, or capreomycin). Pre-
XDR TB is MDR TB that displays resistance to one of the fluoroquinolones or a second-line 
injectable drug.
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ethionamide would be easily identified using the line probe assay (LPA) 
diagnostic test and that this information (which already exists) should be 
made available to expert MDR TB clinicians. 
Warren concluded by noting that XDR TB is a major component of 
the drug-resistant TB epidemic in the Eastern Cape Province. In the MDR 
TB group, the atypical Beijing strain is seen in only 26 percent of the popu-
lation, and is strongly selected in the pre-XDR and XDR TB population 
(accounting for approximately 90 percent of cases). This selection is driven 
by isoniazid/ethionamide cross-resistance and the associated standardized 
treatment regimen (see above). Of further concern is the significant asso-
ciation between the atypical Beijing strain and aminoglycocide resistance 
in pre-XDR and XDR TB strains in the Eastern Cape. In these strains, 
 aminoglycoside resistance occurs through a mutation in the rrs gene. This 
mutation also leads to capreomycin resistance, thereby potentially com-
promising the XDR TB treatment regimen. Finally, Warren showed that 
pre-XDR and XDR TB strains are moving between provinces, emphasizing 
the need for rigorous TB control in both the Eastern and Western Capes.
INTENSIFIED TB CASE FINDING3
According to Verkuijl, the South African national guidelines recommend 
a three-tiered approach to establishing collaborative TB−HIV activities. 
First is to establish coordinating bodies to organize surveillance, planning, 
monitoring, and evaluation. Second is to decrease the burden of TB in people 
living with HIV/AIDS through the internationally recommended “three I’s” 
strategy: intensified TB case finding, isoniazid preventive therapy, and infec-
tion control. Third is to decrease the burden of HIV in TB patients through 
HIV counseling and testing for TB patients, HIV prevention, cotrimoxazole 
preventive therapy, enrollment of coinfected patients into HIV care and sup-
port, and access to antiretroviral therapy for coinfected patients.
Verkuijl’s presentation focused on the first of the “three I’s”: intensi-
fied TB case finding through a method of TB symptom screening that was 
developed in the Eastern Cape. The identified need to shift from an acute 
to a continuing care model led to the development of a comprehensive HIV 
adult clinical record (ACR) through a partnership between the Department 
of Health and several nongovernmental organizations. The objective was 
to achieve uniformity in recording patient data and to help site staff track 
patients’ clinical progress and social support needs. A four-page version was 
piloted, and a revised eight-page record is now being implemented. Staff 
are being trained and mentored regularly to ensure the correct use of the 
3  This section is based on the presentation of Sabine Verkuijl, International Center for AIDS 
Care and Treatment Programs, Mailman School of Public Health, Columbia University.
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ACR. A six-question TB screening questionnaire is integrated into the ACR 
in such a way that clinicians can record information on TB symptoms at 
every visit. The six questions concern
• weight loss (unintended),
• cough for more than 2 weeks (including haemoptysis),
• night sweats for more than 2 weeks,
• fever for more than 2 weeks,
• swollen lymph nodes, and 
• respiratory symptoms and/or chest pains.
These questions should be asked at each visit, and if the conditions are 
present, boxes in the ACR should be ticked accordingly. Patients presenting 
with any of the TB symptoms should be further investigated to confirm or 
rule out active pulmonary or extrapulmonary TB. Patients without symp-
toms are eligible for isoniazid preventive therapy. The ACR also includes 
room for findings from the physical examination and sputum results (two 
smears and one culture), as well as other results, including those of x-rays, 
needle aspirate biopsies, and drug susceptibility testing.
Currently, the ACR is being revised to accommodate the new guidelines 
for antiretroviral therapy. The record complements existing monitoring and 
evaluation systems; in addition, an electronic database, mirroring the ACR, 
is currently being piloted in East London. This database will provide a link 
with the District Health Information System, the national monitoring and 
evaluation system.
The ACR addresses all the steps that need to be taken during the TB 
screening process, from symptom screening to management of patients with 
TB. If a patient has positive symptoms upon screening, the ACR indicates 
that investigations need to be done. If TB is diagnosed, the ACR indicates that 
TB treatment and cotrimoxazole prophylactic treatment need to be started.
The ACR captures information from each clinical visit. For example, it 
includes entries for the clinician to mark if a patient is on TB treatment at 
the time of that visit. This feature helps prompt the clinician to monitor the 
clinical response to TB treatment and can assist in identifying patients not 
responding to first-line treatment. This integrated screening tool provides 
for quality and continuity of care through
• screening for active TB at every visit for patients enrolled in HIV 
care (who are not yet eligible for antiretroviral therapy) and for 
patients on antiretroviral therapy,
• early diagnosis and treatment of active TB,
• identification of TB-associated IRIS,
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• monitoring of TB investigation results and TB treatment progress 
and outcomes,
• improved practical integration of HIV and TB programs, and
• identification of patients eligible for isoniazid preventive therapy.
In addition, the tool benefits prevention and early diagnosis of drug-
resistant TB by monitoring the clinical progress of patients on first-line TB 
treatment, assisting with the identification of TB patients with suspected 
drug resistance, and monitoring breakthrough TB disease in patients on 
isoniazid preventive therapy. It allows for the monitoring and evaluation 
of the entire TB screening process using standard pre-antiretroviral therapy 
and antiretroviral therapy registers. The indicators that can be collected 
from the ACR include, for example:
• proportion of patients screened (among those enrolled in HIV or 
antiretroviral therapy care),
• proportion of patients who screened positive (among those screened),
• proportion of patients with investigations performed (among those 
screening positive),
• proportion of patients diagnosed with active TB (among those 
screening positive),
• proportion of patients starting on TB treatment (among those 
diagnosed with active TB), and 
• proportion of patients starting on cotrimoxazole (among those 
diagnosed with active TB).
To illustrate the effectiveness of the tool, the proportion of patients 
in the Qaukeni Local Service Area (O.R. Tambo District) who were 
screened improved from less than 50 percent to more than 76 percent 
after use of the tool began. The proportion of new TB cases diagnosed 
among patients newly enrolling in HIV care gradually increased from 1.6 
to 5.8 percent. Similarly, the proportion of patients with TB among the 
cohorts of patients starting HIV care, which includes patients already on 
TB treatment upon enrollment in HIV care, steadily increased from 4.5 
to just over 20 percent.
According to Verkuijl, lessons learned include the following:
• A TB screening questionnaire integrated into a comprehensive HIV 
clinical record reminds clinicians to “think TB” at all times.
• The ACR facilitates effective monitoring of TB screening among 
HIV patients at enrollment and subsequent visits.
• The ACR facilitates proactive TB screening, leading to increased 
TB case finding.
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• The TB screening questionnaire can be used to monitor the clinical 
progress of TB patients on first-line regimens and identify patients 
with suspected drug-resistant TB.
• Routine TB screening is critical in identifying breakthrough TB 
disease in patients on isoniazid preventive therapy.
• The ACR can be linked with the District Health Information Sys-
tem through an electronic database.
Verkuijl offered the following recommendations:
• TB and HIV should be managed by a comprehensively trained 
health care provider (“under one ceiling”).
• TB and HIV clinical records should be kept together for improved 
clinical management.
• The electronic ACR database should be finalized based on the 
results of the current pilots for adoption in the Eastern Cape to 
ensure that the link with the District Health Information System is 
available in all facilities.
INFORMATION SySTEMS TO ENHANCE 
LABORATORy CAPACITy4
The World Health Organization (WHO) Global Laboratory Initiative 
(GLI) has identified the need for an “urgent and massive scale-up of labo-
ratory services” (WHO, 2010b). More specifically, it has stated that “the 
critical lack of TB laboratory capacity constitutes a global crisis, requiring 
a paradigm shift in providing laboratory policy guidance, quality assur-
ance, and knowledge creation within a global and integrated laboratory 
network.”
Nordenberg identified some of the issues related to the urgent informa-
tion needs of TB laboratories:
• Laboratory capacity is desperately insufficient.
• Laboratory capacity building efforts rarely take into account the 
development of data and information management capabilities.
• Laboratory services are microbe- or specimen-focused, in contrast 
to clinical and population health programs.
• The sensitivity and specificity profiles of emerging diagnostics may 
differ from those of existing diagnostics, rendering surveillance 
trend estimates difficult to interpret.
4  This section is based on the presentation of Dale Nordenberg, Novasano Health and 
Science.
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• There is a critical need to integrate laboratory information systems 
with those of clinical and population health programs.
• There is a critical need as well for information systems to track 
operational activities focused on drug-susceptible and drug- resistant 
TB, such as infection control programs and drug supply chains, as 
well as to support performance improvement programs. 
• Information services and products must be thought of as a supply 
chain that moves information in a highly structured way. Building 
information supply chains is work-intensive, but their public health 
impact could be enormous.
These issues represent a large-scale problem that requires a large-scale 
solution. Unfortunately, according to Nordenberg, solutions that support 
 capacity building for laboratory information management across many 
countries and thousands of laboratories have not been available.
The GLI addresses data and information needs in terms of TB diag-
nostics (WHO, 2010b). Information derived from diagnostics needs to be 
delivered to the right places at the right times. Nordenberg noted that, 
although WHO’s New Diagnostics Working Group of the Stop TB Part-
nership has developed an effective workflow model for the development of 
new diagnostic tests to support TB control programs globally, this model 
lacks reference to the necessary data and information supply chains that 
are critical to optimize the public health impact of emerging TB diagnostics 
(WHO, 2009b). This omission represents a major information chasm that 
requires urgent attention, according to Nordenberg.
Several years ago, the Association of Public Health Laboratories and 
the Public Health Informatics Institute identified 16 essential business pro-
cesses for U.S. public health laboratories (Association of Public Health 
Laboratories and Public Health Informatics Institute, 2003). These unique 
functions highlight the different workflows that exist in the laboratory as 
opposed to the clinic or public health program office. Therefore, labora-
tory information systems that support these unique workflows will be most 
effective in supporting the laboratory’s public health mission. Given that 
the laboratory is the source for much of the information used to control TB 
and MDR and XDR TB, as well as other diseases, laboratory information 
management systems are central to any health care system. Regardless of 
what scientific or diagnostic work is being done in laboratories, the data 
and information they produce must be linked to clinical and public health 
programs.
Laboratories need to manage data and information more systemati-
cally, said Nordenberg. Public health programs require at least three criti-
cal supply chains to be successful: people, products, and information. The 
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information supply chain is complex. Information must be viewed as an 
intervention, not a technology, as it drives the right therapy to the right 
patient, prevents the emergence of drug-resistant strains, enables patients 
to be treated more cost-effectively, and improves operations. A disciplined 
approach to data and information provisioning will facilitate measurement 
of the quality and impact of the data and information. Such an approach 
will also enable performance improvement of the information supply chain 
to optimize public health impact.
Analyzing information gaps can be a means to achieve several impor-
tant objectives:
• designing the model information supply chain for control of TB/
drug-resistant TB;
• assessing gaps within one or more communities;
• quantifying the impact of the gaps in terms of treatment timeliness, 
treatment appropriateness, the drug supply chain, and so on;
• calculating the cost of the gaps in terms of the spread of disease, 
the emergence of resistance, morbidity and mortality, and other 
negative outcomes; and
• developing information supply chains for drug-sensitive and drug-
resistant TB at the community, district, provincial, and national 
levels.
The building of laboratory information management capacity globally 
is being undertaken through participation in public−private partnerships. 
An example is the Laboratory Information for Public Health Excellence 
(LIPHE) program based at the CDC Foundation. This program is a grow-
ing collaboration that includes the Centers for Disease Control and Preven-
tion (CDC), Eli Lilly, Fondation Merieux, the GLI, and WHO. LIPHE has 
created a set of processes and a framework designed to enable laboratories 
to work together to define best practices. The platform may vary, but stan-
dardization of the information is encouraged to facilitate sharing across 
communities, regions, and countries. Currently, however, no efforts are 
under way to develop an information supply chain model for TB. 
According to Nordenberg, all the components needed to develop a 
robust model for information flow in TB control programs are available. 
Information products can be identified based on the questions that need to 
be answered to support TB control programs. Information supply chains 
can then be designed to deliver these information products. Once TB infor-
mation supply chains have been designed and implemented, it will be 
possible to develop models that can quantify the public health impact of 
suboptimal information supply chains (e.g., data on missed diagnoses, 
30 DRUG-RESISTANT TUBERCULOSIS IN SOUTHERN AFRICA
delayed treatments, propagation of drug-resistant TB, increased hospitaliza-
tions, increased cost of drugs, and increased mortality). These data should 
help make the development of effective TB information supply chains a 
priority along with the development of new therapeutics, new diagnostics, 
improved infection control practices, and other critical components of an 
effective TB control program. 
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Transmission and Infection Control
Key Messages
•  Experiments have demonstrated that MDR TB is transmitted through 
the air from individual to individual.
•  The outbreak of XDR TB in Tugela Ferry demonstrated the potential 
for XDR TB to be transmitted in a health care setting.
•  The infection control program in Tugela Ferry has demonstrated that 
transmission can be substantially reduced through administrative, 
environmental, and personal protection controls.
•  By improving cure rates and decreasing default rates, community-
based care and treatment in Tugela Ferry has likely reduced the 
transmission of drug-susceptible and drug-resistant TB.
•  Health care workers are at particular risk for contracting TB and need 
much higher levels of education and environmental protection than 
they currently receive.
•  Household contacts of active TB cases, vulnerable populations in 
poorly ventilated congregate settings (such as prisons and drug treat-
ment programs), and certain vocational workers, particularly migrant 
workers and miners, also are at a high risk of contracting TB. Special 
efforts are warranted to reach and protect such groups.
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Drug resistance arises through either acquired resistance or transmis-
sion. As discussed in Chapter 3, there is evidence that transmission plays an 
important role in the development of MDR TB. Of the 511,000 individuals 
estimated by the World Health Organization (WHO) to have MDR TB in 
2007, 57 percent had never previously been treated for TB and thus could 
not have acquired resistance from prior treatment. The remaining 43 per-
cent were retreatment cases; however, it is known that reinfection through 
transmission also occurs in this population. This chapter reviews what is 
known about the transmissibility of TB from person to person, as well as 
experience with infection control programs to reduce or eliminate transmis-
sion. Overall, many presenters emphasized that a number of fundamental 
questions about transmission remain unanswered and that, if infection 
control is to be successful, much more research and evaluation of these 
issues will be necessary.
TRANSMISSIBILITy OF TB1
According to Mphahlele, experiments done for more than half a cen-
tury have demonstrated great variability in the infectivity of patients with 
TB. Guinea pigs have often been used in these studies because they are 
highly susceptible to infection by human M.tb., more so than mice and 
rabbits and perhaps as much as AIDS patients; in addition, their immuno-
logical response is similar to that of humans. 
Beginning in the 1950s, Riley and colleagues exposed guinea pigs to 
untreated TB patients to measure the infectiousness of M.tb. Of the 156 
guinea pigs, 71 were found to be infected at the end of the 2-year study, dem-
onstrating the ease of transmission in the absence of direct contact (Riley 
et al., 1959). Recent studies conducted at the Airborne Infection Research 
(AIR) facility in Witbank, Mpumalanga Province, South Africa, examined 
both the infectivity of MDR TB and the question of whether transmission 
can be interrupted. The infectivity experiment, which involved 360 guinea 
pigs exposed to 26 MDR TB patients, revealed that some infecting MDR 
and XDR TB strains may be immunogenic but not sufficiently virulent to 
cause progressive disease in guinea pigs and that guinea pigs may be clearing 
TB infection. In that study, 75 percent of the guinea pigs became infected, 
and of those strains recovered from the guinea pigs, only two matched the 
strains of patients. Despite large positive skin test results, however, many 
of the guinea pigs showed no histological evidence of residual TB infection, 
and the burden of TB infection was higher among recent large skin test 
con verters than among more remote converters. Many of the guinea pigs 
1  This section is based on the presentation by Matsie Mphahlele, Medical Research Council 
of South Africa.
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appeared to have had “transient” TB infection, which is consistent with the 
results of skin test and interferon-gamma release assay conversions reported 
in the older literature.2
Other studies have demonstrated some of the factors associated with 
the transmission of M.tb. among individuals, finding, for example, that 
transmission in a hospital setting can be widespread within a brief period 
of time (Haley et al., 1989). Another study that looked at TB transmission 
on airplanes revealed that duration of exposure and proximity to the index 
case have an effect on transmission (Kenyon et al., 2009).
The infection control experiment done at the AIR facility assessed the 
efficacy of an infection control intervention. In a two-phased study, ultra-
violet (UV) radiation was switched on and off on alternate days in two 
animal rooms. When the UV radiation was switched on, air was transmitted 
to the intervention group of guinea pigs; when the UV radiation was off, air 
was transmitted to the control group of guinea pigs. In the first phase of the 
study, after 4 months of exposure, 9 guinea pigs in the control group were 
infected and none in the intervention group, showing 100 percent protec-
tion. In the second phase, after 3 months of exposure, 48 guinea pigs were 
infected in the control group and 15 in the intervention group, showing 
85 percent protection.
Mphahlele observed that the findings of the AIR studies indicate a 
global need to better understand transmission of MDR and XDR TB 
through basic research. She noted that future studies planned for the AIR 
facility will address the efficacy of surgical masks for patients; novel inter-
ventions, such as inhaled antibiotics; transient TB infection, strain varia-
tion, and XDR TB transmission; and determination of when MDR and 
XDR TB patients become noninfectious.
INFECTION CONTROL IN HOSPITAL AND 
OTHER HEALTH CARE SETTINGS
The 2006 study of 53 patients with XDR TB in Tugela Ferry described 
in Chapter 2 provided evidence for nosocomial3 transmission (Gandhi et 
al., 2006). Evidence supporting the suggestion that infections had been 
acquired largely in the health care setting included four findings: (1) most 
patients had been admitted to the hospital during the preceding 2 years, 
(2) initial community contact tracing uncovered few additional cases, 
2  Riley and colleagues also observed small, nonprogressive reactions not consistently associ-
ated with disease on autopsy. Reversion of skin test results is known to occur in humans after 
prompt treatment for latent TB infection and among the elderly. Also, with interferon-gamma 
release assays, reversions have been observed with and without treatment.
3  Nosocomial infections are infections that are a result of treatment in a hospital or a health 
care service unit.
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(3) health care workers were among those who died from XDR TB, and 
(4) genotyping showed a similar strain in 83 percent of patients. Accord-
ing to Friedland, since that time, a number of other studies have confirmed 
transmission within the hospital setting from patients identified as having 
had XDR TB. TB infection is transmitted not only from patient to patient 
but also from patient to health care worker and from health care worker to 
patient. WHO and the Centers for Disease Control and Prevention (CDC) 
have formulated procedures for reducing nosocomial transmission through 
infection control measures. Infection control protocols are divided into 
three categories: administrative, environmental, and personal protection.
Infection Control Practices Reported by Health 
Care Workers in Five Primary Care Sites4
Shean reported on the preliminary results of an ongoing study of 
latent and active TB in 267 health care workers at five primary care sites, 
conducted by Dr. Shahieda Adams. Information had been collected on 
occupational and environmental determinants of TB infection, including 
infection control practices at work sites (Adams et al., 2010). In the  studied 
population, the majority were female (78 percent), and all worked at 
community health centers or primary care clinics. The majority reported 
having had a BCG vaccination,5 6 percent were diabetic, 15 percent were 
current smokers, and 27 percent reported using alcohol. A questionnaire 
on infection control practices was administered. HIV status could be dis-
closed to researchers, but participants were also encouraged to be tested; 
72 percent of the respondents were willing to be tested for HIV at the time 
of the questionnaire. Those who had received previous TB treatment made 
up 18 percent of the group, and 31 percent had at least one current TB 
symptom. The majority of health care workers reported having daily con-
tact with TB patients (89 percent), and 32 percent had some level of health 
qualification. Table 4-1 shows the percentage of the health care workers 
who reported that various infection control measures were in place in the 
facilities in which they worked. 
Tests done on the health care workers showed that
• 31 percent were positive on a screen of symptoms,
• 19 percent were HIV-positive (either reported as or tested positive),
4  This section is based on the presentation of Karen Shean, Lung Infection and Immunity 
Unit, University of Cape Town (UCT) Department of Medicine.
5  Bacillus Calmette-Guérin (or Bacille Calmette-Guérin, BCG) is a vaccine against TB that is 
prepared from a strain of the attenuated live bovine TB bacillus, Mycobacterium bovis, which 
has lost its virulence in humans by being specially cultured in an artificial medium for years.
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TABLE 4-1 Percentage of Health Care Workers Reporting Various 
Infection Control Measures
Measure Percent Reporting
Infection control policy 66
Ventilation measures (natural/mechanical) 93
UV lights in facility 12
Cough etiquette 81
Early triage 57
Separation of TB patients 71
Onsite diagnostic services 85
Disposable surgical masks 94
N-95 respiratorsa 89
aA workshop participant noted that it is essential for introduction of N-95 respirators into 
any infection control program to be accompanied by fit testing to ensure that the respirators 
can be used most effectively. 
SOURCE: Shean, 2010.
• 10 percent were positive on a chest x-ray,
• 84 percent were skin test positive,
• 66 percent were positive on the QuantiFERON-TB Gold In-Tube 
(QFT-GIT) test, and
• 57 percent were positive on the T-SPOT.TB test.6
Shean reported that active TB was found in five of the health care workers. 
Infection Control Practices at Church of Scotland Hospital7
Friedland spoke about important work on transmission performed at 
the Church of Scotland Hospital (CoSH) in Tugela Ferry. CoSH is a rural 
district hospital with 350 beds, including male and female medical and TB 
wards of about 40 beds each. Both inpatient and outpatient facilities are 
overcrowded in a congregate area conducive to airborne transmission of 
TB. The local community has a 17.5 percent prevalence of HIV-positive 
adults and a TB−HIV coinfection rate of more than 90 percent. The TB 
case rate is 1,100 per 100,000 population per year. 
CoSH has implemented infection control measures in each of the three 
WHO/CDC categories (administrative, environmental, and personal protec-
tion) as part of its infection control program:
6  The QFT-GIT and T-SPOT.TB tests are two diagnostic methods that use interferon-gamma 
release assays to detect both latent and active M.tb. in a patient’s blood sample (Mazurek et 
al., 2010).
7  This section is based on the presentation of Gerald Friedland, Yale School of Medicine.
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• Administrative
 —  A dedicated infection control officer was appointed.
 —  Cough officers were placed in all ambulatory care areas to 
separate out suspected TB cases.
 —  A TB infection control policy was ratified.
 —  Reductions in admissions and lengths of stay were accomplished.
• Environmental
 —  Isolation wards were created for male and female MDR TB 
patients.
 —  Extractor fans were installed.
 —  Natural ventilation was assessed, and an open-window policy 
was implemented.
 —  The DOTS office was moved to the periphery of the hospital, 
and all patients were offered voluntary counseling and testing.
 —  A well-ventilated antiretroviral therapy clinic was relocated to 
the periphery of the hospital, and all patients were screened 
by a cough officer.
 —  Remediable environmental flaws were evaluated.
• Personal protection
 —  Staff surveys were conducted regarding infection control knowl-
edge, attitudes, and practices.
 —  TB education sessions were held.
 —  Regular staff screenings were performed by the occupational 
health officer.
 —  The use of N95 respirators was introduced, along with fit test-
ing and staff education regarding fit checks.
 —  Voluntary counseling and testing was promoted for staff and 
inpatients, with provision for antiretroviral therapy and the 
option for health care workers to transfer discreetly to lower-
risk areas.
In addition, a series of simple and inexpensive evaluations was per-
formed, including
• assessment of lengths of stay and admissions by review of TB ward/
hospital registers,
• cough officer program results,
• unannounced audits of ventilation and open windows,
• unannounced audits of N95 respirator use by health care workers,
• voluntary counseling and testing of staff and patients, and
• screening of health care workers for TB.
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Outcome measures in inpatient TB wards showed dramatic results. In 
2005, 88 percent of patients screened were culture positive, and 64 percent 
of the patients screened (16 of 25 patients) had MDR or XDR TB. In 2009 
in the same wards, 59.3 percent of patients screened were culture posi-
tive, and only 7.4 percent of the patients screened (2 of 27 patients) had 
MDR or XDR TB. Thus, the effective implementation of administrative, 
environmental, and personal protection infection control measures created 
a hospital environment in which a decline in drug-resistant TB cases was 
possible and ultimately became reality.
A mathematical model was used to evaluate the infection control pro-
gram by estimating the number of XDR TB cases that could be averted by 
the implementation of different combinations of infection control strategies 
(Basu et al., 2007). The model showed that using combinations of the avail-
able infection control measures over the period from 2007 to 2012 could 
result in preventing 48 percent of new cases. The model also showed that 
of the estimated 1,300 new cases of XDR TB, 3 percent would be among 
health care workers, and that 75 percent of those new cases among health 
care workers could be prevented through the use of natural ventilation; 
the use of N95 respirators; and voluntary counseling and testing for HIV, 
with redeployment of HIV-positive staff. The model showed further that 
the provision of antiretrovirals to eligible HIV-positive individuals would 
avert 24 percent of new XDR TB cases. Of note, involuntary confinement 
would increase transmission by 3 percent by bringing together individuals 
with strains of differing resistance.
Discussion
In the workshop discussions of the implementation of infection control 
protocols, it was noted that available transmission control strategies and 
technologies, such as early diagnosis, triage and separation, natural ventila-
tion, UV masks on patients, and treatment, need to be implemented. Once 
implemented, those interventions need to be evaluated to determine their 
efficacy. Monitoring and further direction by infection control practitioners 
will be required in areas where the interventions have not been successful 
to improve the measures and reinforce the importance of infection control. 
In addition, it will be necessary to develop novel effective transmission 
control interventions.
Another theme of the discussion was related to behavior change and 
best practices for health care workers. It was noted that infection control 
training for nurses is lacking, as is systemic training capacity. Large-scale, 
long-term training in infection control is required for the South African 
context. Other interventions that have shown some success include such 
simple measures as using checklists and having an infection control practi-
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tioner. Finally, discussants suggested that there needs to be a general shift 
away from the concept of centralized infection control and toward a model 
in which each person in a health care unit is considered to be individually 
responsible for infection control.
CONTACT TRACING AND COMMUNITy-BASED 
INFECTION CONTROL PRACTICES8
In his presentation, Marra suggested that, although addressing the issue 
of transmission in the hospital is of critical importance, community-based 
interventions to combat the transmission of MDR and XDR TB are needed 
as well. According to Marra, contact tracing, which includes education in 
and awareness of infection control, should be part of the normal TB con-
trol program, and infection control should be part of every intervention. 
In Tugela Ferry, for example, health care workers have been visiting the 
households of MDR and XDR TB index cases to offer TB screening and 
education about the disease and its prevention, demonstrating the feasibility 
of household contact investigation.9 The household contact investigation 
and infection control strategy applied in Tugela Ferry, which started in 
2006, involves
• visiting the homes of all index MDR and XDR TB patients;
• taking the global positioning system (GPS) coordinates of each 
home; and
• screening all household contacts by obtaining a TB symptom his-
tory, collecting sputum from all sputum producers, bringing all 
suspected TB cases to CoSH for evaluation by a medical doctor, 
8  This section is based on the presentation of Claudio Marra, Tugela Ferry Care and 
 Research Collaboration (TF CARES).
9  The characteristics of the 508 MDR and XDR TB index cases showed that 51 percent were 
female, the median age was 34, 64 percent had smear-positive sputum, and 50 percent of the 
households had a previous history of treatment. During the period of observation, 81 percent 
of cases died. A total of 1,766 household contacts of the MDR and XDR TB index cases were 
evaluated at baseline, 66 percent of whom were female and most of whom were between the 
ages of 13 and 24. The results of the culture and drug sensitivity tests showed a transmission 
rate of 3.7 percent in a family. However, only 44 percent of MDR and 59 percent of XDR 
index cases were concordant with the type of drug resistance that was discovered. This means 
the household transmission figure of 3.7 percent could be lower, with transmission also occur-
ring outside the household. Among the households to which the 508 index cases belonged, 
89 percent had no cases of TB, while 11 percent had one or more cases. However, since this 
study identified only active TB cases, many more household contacts could have been infected 
with TB. A workshop participant also noted that there is a large amount of discordance in 
M.tb. isolates between coprevalent cases in the household. This discordance could have impli-
cations for preventive therapy in households.
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and having a chest x-ray taken (currently, 4,000 contacts are in a 
central database).
Most of the MDR and XDR TB cases were situated in Msinga, the 
subdistrict in which Tugela Ferry is located, in close proximity to the hos-
pital, while fewer cases were found in the surrounding subdistricts. The 
greatest number of cases was found in 2007. The study evaluated but did 
not find associations with the terrain, access to health care, and the number 
of people sharing a home.
According to Marra, the infection control program in Tugela Ferry, 
the household contact investigation of MDR and XDR TB families, and 
the strengthening of the normal TB program have met with considerable 
 success. The cure rate has risen from 70 to 82 percent, and a default rate 
that had been around 20 percent is now close to zero. No patients have 
been lost to follow-up. Marra stressed that the introduction of rapid diag-
nostic tests to reduce the infectious period is essential, and community 
spread of MDR and XDR TB needs to be further investigated.
In the discussion following Marra’s presentation, Jason Farley, Johns 
Hopkins University School of Nursing and Johns Hopkins AIDS Service, 
noted that infection control in the community requires a tremendous invest-
ment of resources and research. Moreover, it depends not only on the health 
care infrastructure but also on the infrastructure of individual households. 
To prepare patients for discharge from the hospital, this household infra-
structure must be assessed and appropriate education ensured. Shean said 
that in the Western Cape, such cases are dealt with by a review board that 
makes decisions based on assessments of the home and the community by 
social workers, with the involvement of families to ensure treatment liter-
acy. UV lights and mechanical ventilation are sometimes installed in homes. 
Friedland suggested that various practical approaches can be applied, such 
as keeping patients outdoors as much as possible, separating TB patient 
sleeping quarters, and implementing cough etiquette. 
PARTICULAR CHALLENGES FOR HEALTH CARE WORKERS10
In her presentation, Shean observed that sub-Saharan Africa has 
11 percent of the world’s population, 25 percent of the global burden of 
disease, and just 3 percent of the world’s health care workers. This limited 
number of health care workers presents one of the greatest challenges to 
health care systems in the region. Furthermore, the situation is becoming 
worse. The ratio of registered nurses to patients in South Africa decreased 
from 120 per 100,000 population in 2000 to 109 per 100,000 in 2005. 
10  This section is based on the presentation of Shean.
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The HIV crisis is rapidly depleting current health care workforces, with an 
average of 15.7 percent of nurses in four provinces of South Africa being 
HIV-positive (Shisana et al., 2003). Moreover, drug-resistant TB has placed 
a significant additional strain on the overwhelmed TB control programs in 
high-burden areas. And according to Shean, the national policy of admit-
ting all XDR TB patients to the hospital until they are smear negative has 
added to the challenge of providing access to affordable and appropriate 
infection control in health care facilities.
Very few data are available on the incidence and treatment-related out-
comes of XDR TB in health care workers. A retrospective review of case 
records of passively detected XDR TB cases diagnosed between 1992 and 
2008 from three provinces in South Africa found 36 health care workers 
who were sputum culture positive for XDR TB (Jarand et al., 2010). One 
case was diagnosed in 1996, with an incremental increase until 2008, when 
14 cases were diagnosed, 80 percent of whom were on antiretrovirals. Ten 
of the health care workers had bilateral disease, and the mean number of 
drugs in the XDR TB treatment to which resistance was found was six. The 
majority of the health care workers worked in district hospitals. Thirty-four 
percent of the health care workers died, with a median of 3.7 months from 
diagnosis to death. These numbers reveal that XDR TB is an important 
risk for health care workers globally, particularly those who work in high-
burden areas. Factors contributing to the risk of infection include
• the concentration of organisms in the source case (associated with 
severity of disease);
• the duration of exposure to air contaminated with tubercle bacilli;
• the type of health care facility; and
• comorbid diseases, such as HIV/AIDS, diabetes, or cancer.
A personal challenge facing health care workers is the fear of being 
diagnosed with TB or HIV infection, which would lead to marginalization 
by colleagues and the possible loss of one’s job. Notwithstanding this chal-
lenge, drug-resistant TB should be considered in any health care worker 
suspected of TB, irrespective of HIV status, and implementation of infection 
control measures and rapid diagnostic testing for all health care workers 
suspected of TB are necessary. At the same time, health care institutions 
must support and protect health care workers by helping them cope with 
stressful situations and by acknowledging their sometimes dangerous and 
difficult work conditions, said Shean. Workable plans for emergency situ-
ations need to be in place. Employers are responsible for providing a safe 
working environment, which includes necessary and sufficient information, 
human resources, protective equipment, and supplies.
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TRANSMISSION AND INFECTION CONTROL AMONG 
MINERS AND MIGRANT WORKERS IN LESOTHO11
Lesotho is a land-locked mountainous country surrounded by South 
Africa. Its population is 1.8 million, with an HIV prevalence rate of 23.2 
percent and a TB incidence rate of 544 per 100,000 population. The number 
of people living with HIV is 270,000; 22,000 are on antiretroviral therapy, 
and 81,000 still need it. The TB−HIV coinfection rate is about 64 percent, 
and the number of TB deaths is 107 per 100,000 population per year. The 
unemployment rate is 45 percent, and 56 percent of the population lives on 
less than $2 per day. In 2007 the textile and apparel industry employed about 
46,000 workers in three districts of the country. In addition, Lesotho contrib-
utes more than 50,000 migrant workers to the South African mining industry, 
and thousands of migrant workers stay and work illegally in South Africa.
Thotolo stressed that in fighting TB, it is necessary to address the 
cross-border movement of migrant workers. At times, these workers visit 
their families in Lesotho without informing their clinics or doctors, thereby 
putting family members at risk. Illegal workers generally do not present 
at clinics upon realizing they are ill; instead, they treat themselves with 
traditional remedies and return to their homes when the illness is at an 
advanced stage. Some patients claim that they are refused TB treatment 
in South Africa because they are unable to present the necessary identity 
documents. Factors that contribute to the spread of drug-resistant TB in 
these workers include the following:
• Unauthorized home visits by patients sometimes interrupt and 
undermine treatment.
• Houses are overcrowded and have poor ventilation.
• Infection control is inadequate, particularly in relation to cough 
etiquette in public transport and crowded public places.
• Medical TB treatment is combined with remedies offered by tradi-
tional healers.
• Loss of income leads to poverty and malnutrition among the entire 
household.
According to Thotolo, transborder control of drug-resistant TB can be 
improved by
• establishing better systems for the prevention, diagnosis, and treat-
ment of TB and HIV for mine workers, ex-miners, and their fami-
lies in Lesotho and South Africa;
11  This section is based on the presentation of Maketekete Alfred Thotolo, Adventist Devel-
opment and Relief Agency.
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• establishing linkages between TB and HIV programs in and 
between Lesotho and South Africa, as well as between the public 
and private sectors, including traditional healers;
• building capacity among individuals and communities affected by 
the cross-border TB/HIV epidemic, including treatment literacy 
training; and
• addressing the legal, human rights, and socioeconomic issues affect-
ing TB and HIV control among mine workers, ex-miners, and their 
families through an advocacy program. 
The Department of Health’s Tuberculosis Strategic Plan for South 
Africa, 2007–2011 states that the South African gold mining industry prob-
ably has the highest incidence of TB in the world—between 3,000 and 7,000 
per 100,000 population per year (DoH, 2007). The mining companies need 
to take the burden of TB in mine workers seriously and invest in the fight 
against the disease. In particular, the “three I’s”—intensified TB case finding, 
isoniazid preventive therapy, and infection control (see Chapter 3)—need to 
be advocated on behalf of migrant populations.
In May 2008, the AIDS and Rights Alliance for Southern Africa 
(ARASA) convened a meeting in Johannesburg together with mining com-
panies, trade unions, the ministries of health of both countries, and activist 
groups to discuss the prevention and treatment of TB. An outcome of the 
meeting was a recommendation for collaboration between the ministry of 
health in Lesotho and the mining companies in South Africa so that when 
patients are referred to TB facilities in Lesotho, proper documentation con-
cerning previous treatment will be made available and special procedures 
followed.
Warren observed that in South Africa, the mines have a far more effi-
cient TB control policy than do communities. Among miners, all patients 
are diagnosed, hospitalized, and treated, and DOTS management is excep-
tionally good. Despite this infrastructure, and even though a high propor-
tion of patients are cured, outbreaks of drug-resistant TB are still observed. 
These data have been interpreted to imply that the treatment of patients 
with standardized regimens for MDR TB inadvertently leads to the emer-
gence of XDR TB. It could not, however, be discerned whether transmission 
occurred in the household, in the compounds where the miners lived, in the 
hospitals, or in the mines. 
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Diagnosis of Drug-Resistant TB
TB patients progress from exposure to cure in discrete steps: infec-
tion, symptoms, clinic visit, diagnosis, treatment onset, conversion from 
an active infection to a noncontagious state, and cure. To decrease trans-
mission, the time between each of these stages needs to be reduced. The 
workshop addressed challenges in the capacity of the health care system in 
a high-burden country such as South Africa to meet the need for rapid and 
effective diagnosis of TB. Diagnostics not only can help reduce the interval 
between presenting at a clinic and diagnosis, but also can be used within a 
comprehensive program to address and perhaps reduce the earlier and some 
of the later intervals in the progression of TB. Thus diagnostics can play 
a key role in curbing the epidemic if they are dramatically improved and 
Key Messages
•  An inability to diagnose drug-resistant TB rapidly and accurately is 
contributing to the severity of the TB epidemic. 
•  The ideal diagnostic test will produce a result in less than 24 hours, 
be inexpensive, distinguish the drug susceptibility of TB strains, and 
be accurate and easy to perform.
•  A strengthened health care infrastructure in South Africa would sup-
port detection and treatment of drug-resistant TB.
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used proactively. This chapter summarizes the workshop presentations and 
discussions addressing the need for rapid diagnostics, progress on point-of-
care diagnostics, the challenges of laboratory capacity in South Africa, and 
the use of biomarkers to diagnose TB.
NEED FOR RAPID DIAGNOSTICS1
Although some have suggested that greater than 70 percent detection 
and cure rates for TB will constitute success, van Helden suggested that in 
fact, this will not be enough. If only 70 percent of infected individuals are 
detected and only 70 percent of that group is cured, the overall cure rate 
will be the product of those two numbers, or 49 percent. Furthermore, 
even infected people whose disease resolves will spread the organism before 
they are diagnosed. A mathematical model suggests that if diagnosis takes 
40 days, a rising epidemic will continue, whereas diagnosis within 6 days 
or less will result in the epidemic’s decreasing. 
The need for patients to return to the clinic is a factor. Studies of the 
current system for diagnosis indicate that 20 percent of patients fail to 
return after their first visit to a clinic and thus are lost to follow-up. A 
point-of-care diagnostic device (see the discussion below) could prevent 
those patients from being lost to follow-up at that early stage of diagnosis 
and treatment of their TB. The algorithm used suggests that typically when 
patients present to a clinic or TB facility, a point-of-care test that may be 
40−50 percent sensitive is administered. Positive patients are absorbed into 
therapy, and it may not be necessary that they provide another sputum 
sample. Negative patients that are highly clinically suspicious should be 
managed according to the normal National Health Laboratory Service 
algorithm for that country, suggested van Helden.
Considerations and Trade-Offs in Developing and Adopting Diagnostics
In considering what types of diagnostic tests should be developed and 
adopted within a high-burden country, a number of criteria come into play. 
An ideal needs assessment may have to be evaluated and judged against 
what is realistic. 
To illustrate this point, van Helden used the example of the Ziehl-
Neelsen stain test,2 which is used to evaluate sputum. Many argue that this 
test is appropriate because it is effective, relatively quick, and inexpensive. 
Others argue that it is insufficient, and a test that is better on all criteria 
1  This section is based on the presentation of Paul van Helden, Stellenbosch University.
2  The Ziehl-Neelsen stain, also known as the acid-fast stain, is a special bacteriological stain 
used to identify acid-fast organisms, mainly mycobacteria.
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(more effective, simpler, and even less expensive) should be adopted. Still 
others argue that a test that is more effective and more rapid than Ziehl-
Neelsen should be adopted even if it is more expensive. And, as discussed in 
this chapter, there are strong arguments that anything less than the ability 
to make a point-of-care diagnosis of drug-resistant TB ultimately will not 
succeed against the disease.
A variety of criteria can be applied in considering the desirability of a 
diagnostic test. Speed, cost, sensitivity, and specificity are among the most 
important; one issue is whether speed, sensitivity, or specificity should be 
paramount. Current tests generally are 50 percent sensitive and usually are 
not performed at the point of care. On the other hand, rapid point-of-care 
diagnosis could result in very few TB cases in 5 years’ time; ultimately, such 
lowering of case burden would cost less overall. Indeed, the development 
of new diagnostics will be essential to stem the TB epidemic; saving money 
on cheap, ineffective diagnostics will result in the epidemic’s continuing. In 
considering implementation and efficacy, issues include number of manipu-
lations; repeats (including client returns); invasiveness of sample taking; 
skills, instruments, and personnel required; and central versus decentralized 
laboratory capacity and logistics. 
Problems with Current Diagnostics
The problem with many diagnostic methods currently in use is that 
the answer they provide can be both yes and no, said van Helden (Box 5-1 
describes some of these methods). For example, genotype information can 
reveal that an inhA mutation is present, but in this case isoniazid should not 
be excluded and is still a potentially usable drug. However, when a KatG 
mutation is present, treatment with isoniazid is not recommended. Geno-
typing and phenotyping will give different results, and even phenotypes are 
not yet fully understood.
Results from testing in miners reveal some of the negative consequences 
of reliance on simple diagnostics. The diagnoses were unreliable, and regi-
mens were implemented in a formulaic way, resulting in the development of 
MDR and XDR TB. The epidemic was amplified by transmission of MDR 
TB, after which some individuals progressed to XDR TB. 
Need for Research into New Diagnostic Methods
Other methods need to be considered to yield informative diag nostics. 
Some of the antibody tests used in the 1990s had a sensitivity of 30 to 
70 percent and were simple to use. The sensitivity of lateral flow devices may 
be 77 percent, with a specificity of 93 percent. According to van  Helden, 
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BOX 5-1 
Some Diagnostic Methods Currently in Use for TBa
 Microscopy smear. Experience has shown that microscopy can 
 detect TB, but the sensitivity is variable and can be very low. 
 Culture/phage based. Culturing bacteria takes longer than a smear 
test but is more sensitive. Nevertheless, smear-negative but culture-
positive tests allow for earlier treatment and a reduction in transmission.
 Molecular, bacteria based (e.g., polymerase chain reaction [PCR]). 
Many reports on the performance of PCR in diagnosing TB have  appeared 
since 1985. Positive results from these types of tests do not guarantee live 
bacteria, and repeatability issues have arisen. Specificity and sensitivity 
depend on the kind of sample, the kind of test, and the manufacturer. 
PCR may not be much better than culture for “difficult samples” such as 
pleural fluid or urine, and the sample preparation method can generate 
problems. According to van Helden, PCR also can be very expensive 
unless a cartridge-based test is used, and even the cost of a cartridge-
based PCR test, at about US$40 or more per person, is unaffordable 
in the developing world. PCR has a number of applications beyond the 
diagnosis of TB. Scientists and clinicians can use it as a basic research 
tool, to assign isolates of M.tb. to a particular strain, and to obtain drug 
resistance information. Furthermore, many applications can be automated 
to reduce costs. In the future, for example, multiple fluorescent probes 
might generate considerable information simultaneously, said van Helden.
SOURCE: van Helden, 2010.
aSince the workshop was held, a new, fully automated DNA test (Xpert MTB/RIF) for TB 
has been validated and subsequently recommended by WHO for broad implementation as 
the initial diagnostic for individuals suspected of MDR TB or HIV−TB coinfection. The test 
simultaneously detects TB and rifampicin drug resistance (a reliable indicator for MDR TB) 
in sputum. WHO reports that the Foundation for Innovative New Diagnostics (FIND) has 
negotiated a reduced price for 116 low- and middle-income countries (including South Africa, 
Russia, India, and China) of US$16.86 per test cartridge. The test provides results in 100 
minutes, allowing proper treatment to begin immediately (WHO, 2010d).
more time and effort should have been invested in testing and developing 
these methods, which now need to be reconsidered.
The presence of antibodies implies the presence of antigens and could 
be useful in detecting infection. The Foundation for Innovative New Diag-
nostics (FIND), together with a number of researchers, is investing in the 
advancement of lipoarabinomannan (LAM) tests. Lipids and mycolic acids 
also are potentially interesting antigens because they drop very quickly as 
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the bacterial load disappears. Studies of urine-based tests for LAM show 
that sensitivity is lower in smear-negative patients but increases as CD4 
count decreases,3 making these tests potentially highly useful in the South 
African context.
PROGRESS ON POINT-OF-CARE DIAGNOSTICS4
According to Jacobs, intensified case finding (see Chapter 3) is essential 
in South Africa to reach MDR TB cases that are not yet being treated. Such 
case finding would be dramatically enhanced by tools enabling point-of-care 
diagnoses, but important questions about such tools remain unanswered.
Jacobs remarked that the ideal point-of-care diagnostic test will produce 
a diagnosis in 1 to 24 hours, be inexpensive, distinguish drug- susceptible TB 
from MDR and XDR TB, be accurate and easy to perform, and give frac-
tional drug resistance. One simple approach for a drug susceptibility assay 
relies on the luciferase reporter phage (LRP), also called the “turn on the 
light” assay. A TB sample is divided into five tubes, and different drugs are 
added to four of the tubes, with the fifth serving as a control. If a drug works, 
it kills the cell and the light does not come on; if the cell is drug resistant, 
the light comes on. Despite skepticism from reviewers, this has proven to be 
a simple and inexpensive test. Important questions for this assay, according 
to Jacobs, are
• What are the accuracy and speed of reporter phages for susceptibility 
testing of clinical M.tb. isolates?
• What is the feasibility of performing a phage-based susceptibility 
assay in developing countries?
One evaluation of the use of LRPs in Mexico and South Africa found 
that they provided susceptibility results with an overall accuracy of 99 per-
cent and had a median turnaround time of 3 days, making them the fastest 
phenotypic method available. The future direction of LRPs is toward a 
1-hour test, extended for XDR TB, as well as the development of reporter 
phage assays for susceptibility testing with second-line drugs.
Recently, a reporter phage test based on green fluorescent proteins 
(GFPs) was developed by Jacobs and his collaborator Graham Hatfull from 
3  CD4 (Cluster of Differentiation 4) is a glycoprotein expressed on the surface of T helper 
cells, regulatory T cells, monocytes, macrophages, and dendritic cells. CD4 is a coreceptor 
that assists the T cell receptor (TCR) to activate its T cell following an interaction with an 
antigen-presenting cell.
4  This section is based on the presentation of William R. Jacobs, Howard Hughes Medical 
Institute, Albert Einstein School of Medicine.
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the University of Pittsburgh. This test has been shown to have a number of 
potential advantages, including
• expected low cost,
• monitoring of individual cells for drug resistance,
• fixation of cells for enhanced safety,
• analysis of mixed cultures,
• potential multicolor internal controls, and 
• alternative detection systems.
The initial GFP test took about 24 hours to provide a response. It could be 
used to assess drug susceptibility and detect rifampicin and  streptomycin 
resistance. Further work is needed to develop assays that can produce 
results in cells in 1 hour. Jacobs stated that GFP tests using fluoromyco-
bacteriophages have considerable potential. They can provide a simple, 
inexpensive, quick, and reliable method for drug susceptibility testing and 
offer multiple platforms for detection. Efficient recovery of M.tb. from 
sputum is needed, as are second-generation phages with enhanced fluores-
cence and specificity. Current studies evaluating the efficacy of these tests 
are under way in Durban, South Africa. 
CHALLENGES OF LABORATORy CAPACITy5
Coetzee observed that South Africa’s response to MDR TB has been 
limited by the unsatisfactory performance of its laboratory services and 
inadequate human resources. In 2009 nearly 1 million cultures were per-
formed in South Africa, most of which were followed up with drug sus-
ceptibility testing, and these tests identified 9,000 new MDR TB cases. Yet 
many communities still are not receiving adequate laboratory services. The 
National Health Laboratory Service now has well over 100 MGIT (myco-
bacteria growth indicator tube) machines, but little progress is being made 
in identifying all MDR TB cases.
In 2008, the World Health Organization (WHO) endorsed the use of 
line probe assays (LPAs) capable of detecting resistance to rifampicin and 
isoniazid (MDR TB is defined by resistance to both of these drugs). The 
new WHO TB guidelines, which became operational on April 1, 2010, 
have led to a doubling of laboratory investigations. The roll-out of this 
test in South Africa is currently being organized. As of the middle of 2009, 
5 laboratories were able to conduct a substantial volume of LPA tests. It 
was decided that by the end of 2010, 20 more secondary (not academic) 
5  This section is based on the presentation of Gerrit Coetzee, National Health Laboratory 
Services, South Africa.
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laboratories would be rolled out; 11 of these are already functioning. The 
objectives of the roll-out include
• achieving rapid diagnosis of MDR TB;
• providing effective treatment to patients at the appropriate time;
• preventing further resistance to anti-TB drugs;
• preventing further TB transmission;
• decreasing the cost of treating TB by reducing unnecessary trans-
mission through earlier diagnosis, as well as by preventing the 
development of drug resistance, which is more expensive to treat; 
and 
• realizing financial savings by eliminating drug susceptibility tests 
from the diagnostic process (it is expected that these savings will 
fund the implementation of LPAs).
A procedure was developed for the early detection of MDR TB. Every 
new smear-positive patient in South Africa will receive an LPA test to rule 
out MDR TB. A 7-day sputum will be taken at the facility, and an MGIT 
culture will be performed on patients who are still symptomatic. Positive 
patients will again receive an LPA test. 
Because the existing infrastructure could not accommodate new labora-
tory space, modular park home units were specially designed to be suitable 
for use as laboratories, and specifically for polymerase chain reaction (PCR) 
testing. Staffing these facilities has presented the biggest obstacle to rolling 
out the 20 additional laboratories. A new category of laboratory staff called 
“TB technician” has been approved, and a 2-year training program for 
these staff is due to commence. Sixty new laboratory staff were employed 
during 2009, and a further 60 will join the National Health Laboratory 
Service during 2010.
One of the concerns with regard to the roll-out of additional laboratories 
is quality control. Currently, no international quality assurance program is in 
place for LPAs, and only interim measures have been taken to accommodate 
quality control in laboratories. The biggest technical problem has been the 
variability of LPAs; to address this problem, a scanner was developed that 
automatically reads and quantifies the results and actual mutations.
One workshop participant cited another concern with the implementa-
tion of the LPA test: to the extent that many more undiagnosed cases of 
MDR TB will be diagnosed through use of this test, it will be necessary 
to consider how the health care system will treat those additional cases.6 
6  In December 2010, WHO released a guidance document providing recommendations for 
governments on how to address difficult ethical issues that arise in efforts to combat the TB 
(both drug-susceptible and drug-resistant) epidemic (WHO, 2010e).
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Community-based care beyond present practice may be a potential solution 
(see Chapter 6). Current policy is that all MDR TB cases must be admitted 
until culture conversion is seen. In KwaZulu-Natal Province and the West-
ern Cape, however, pilot studies are under way on community-based care 
that will be decentralized by strengthening existing hospitals and other TB 
facilities and by creating satellite centers in communities, with teams that 
travel throughout an area. Integration of MDR TB and HIV care will take 
place at the primary care level.
USE OF BIOMARKERS TO DIAGNOSE TB7
Parida reported that sub-Saharan Africa experiences 12 times more 
deaths from TB every hour than Europe. More needs to be known about 
the outcomes associated with exposure to M.tb. to devise interventions, 
he suggested, and one way to learn more is to reduce the gap between 
the research laboratories and clinics. There are important differences in 
immune response between individuals who are exposed to TB and protected 
from the disease and those who develop active disease. Particularly for 
people coinfected with M.tb. and HIV, the design and testing of new TB 
vaccines, drugs, and diagnostics will be critical. 
The project Biomarkers of Protective Immunity against TB in the Con-
text of HIV/AIDS in Africa, which involves 15 partner institutions from 
Africa, Europe, and the United States, has been seeking to identify cor-
relates of protective immunity and host biomarkers of TB that have prog-
nostic potential for delineating disease susceptibility and protection.8 The 
project’s objectives are to
• investigate differences in immune response between individuals 
who are exposed to TB and protected from the disease and those 
who develop active disease; and
• coordinate to promote the design and testing of new TB vaccines, 
drugs, and diagnostics, especially in areas with high HIV infection 
rates. 
Particular attention is being paid to people coinfected with both M.tb. and 
HIV, whether or not they are receiving antiretroviral therapy.
7  This section is based on the presentation of Shreemanta K. Parida, TB Research Specialist, 
Berlin, Germany.
8  More information on the Biomarkers of Protective Immunity against TB project can be 
found at: http://www.grandchallenges.org/NewVaccines/Challenges/Learnabout Immunological 
Responses/Pages/Biomarkers.aspx (accessed February 22, 2011).
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The different platforms for biomarkers are immunologic, transcriptomic, 
proteomic, and metabolomic. Most likely, a combination of these markers 
will prove to be useful. Specific biomarker needs in the context of TB are
• surrogate markers of immune protection for assessing potential 
vaccine candidates,
• a surrogate marker of bacterial clearance (the clinical end point) 
for assessing potential drug candidates,
• markers of relapse, 
• markers of treatment failure (drug resistance),
• diagnostic markers,
• markers for infection, and
• prognostic markers for reactivation of disease.
The project has been structured around five different cohorts, or work 
packages (WPs). WP1 is focused on pathogens; WP2 is focused on host 
responses to infection; and WPs 3, 4, and 5 are prospective cohorts in Afri-
can field sites used to study the natural history of TB. WP1 and WP2 are 
based on cross-cutting methods carried out in the northern laboratories in 
collaboration with the field sites to narrow down the biomarkers to 25–50. 
As noted, the focus is on pathogen and host, respectively, which then can be 
assessed in longitudinal prospective studies in the field sites. WP5 is being 
used to assess the immune responses to BCG vaccination and the effects on 
disease progression. About 17,000 individuals from different age groups 
with a varied spectrum of TB with or without HIV in five African countries 
are being followed. The group characteristics are as follows:
• 898 HIV-negative TB index patients,
• 3,935 HIV-negative subjects with latent TB infection free of any 
disease symptoms and signs,
• 6,363 adolescents with latent TB infection free of any disease 
symptoms and signs,
• 894 HIV-positive subjects with latent TB infection and 304 HIV-
positive and TB-positive patients, and
• 5,663 neonates plus 200 children following BCG vaccination.
At the start of the project, the hypothesis was that different clinical 
strains of M.tb. would show differences in gene expression levels. At that 
time, this hypothesis faced considerable skepticism. After a series of discus-
sions with experts, two of the most divergent strains in the phylogeny—one 
from Gambia (a strain of M. africanum that is prevalent in West Africa) 
and the other from Uganda (an M.tb. strain of the same phylogeny of 
Euro-American lineage to which the laboratory strain H37Rv and clinical 
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strains such as CDC1551 belong)—were compared with the H37Rv refer-
ence strain. The analysis found striking geographic variations among the 
clinical strains, with the implication that effective universal vaccines and 
diagnostics cannot be produced. Rather, the uniqueness of the strains must 
be considered in the development of vaccines and must be reflected in the 
treatment of drug-resistant TB.
The project addressed about 100 genes, focusing on latency and 
 reactivation, and made 86 novel antigens that were studied in five sites. The 
antigens were initially screened in a 7-day whole-blood stimulated assay, with 
interferon-gamma (IFNg) as readout in the antigen-stimulated supernatants. 
Then the antigens were subjected to 42 cytokines in an effort to uncover 
combinations that would result in biomarkers. It was speculated that a com-
bination of antigens and cytokines might lead to a possible biomarker profile. 
Host biomarkers in disease and protection were assessed using microarray 
analysis of total ribonucleic acid (RNA) from whole blood from TB patients, 
tuberculin skin test−positive (latently infected) subjects, and tuberculin skin 
test−negative (noninfected) subjects. An earlier study with Caucasian subjects 
had identified three host biomarkers—CD64, LTF, and Rab33A—that could 
differentiate between TB patients and healthy contacts.
The TB contact study (cohorts WP3 and 4) followed the subjects over 
a 2-year period, with a focus on those both infected and clinically healthy. 
These subjects were followed up clinically over the 2 years, with blood sam-
ples being taken at three time points—0, 6, and 18 months. The objective 
was to assess immune responses over time using all the platforms described 
earlier and to identify biomarkers of disease susceptibility and protection, 
comparing subjects who contracted disease during the course of this follow-
up period with those who remained healthy without succumbing to disease 
progression. Based on studies performed earlier, it was expected that 5 to 10 
percent of subjects would develop TB during the 2-year period. The current 
follow-up status shows only 63 secondary cases from among almost 4,000 
subjects in the HIV-negative cohort. However, the reactivation rate is about 
2 percent rather than the 5 to 10 percent expected (which, according to 
Parida, has been a convention in the field that has never been verified). The 
ramifications of the TB contact study are complex and time and resource 
intensive, involving multiple teams working in tandem. There currently are 
22 (about 2.5 percent) secondary TB cases based on  progressors in WP4 
(the HIV-positive cohort). 
The current status of the project is as follows. Recruitment of the 
cohorts has been completed, and follow-up will be concluded in October 
2010 (Parida and Kaufmann, 2010). Additional recruitment has been initi-
ated and is ongoing to obtain more secondary cases, assay qualification 
is being completed at all sites, and large-scale production of antigens has 
been achieved. There are plans to perform analysis centrally on all second-
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ary cases and matched controls at the end of the follow-up period and to 
validate patterns showing an association with protection. A complementary 
analysis using longer-term assays to delineate soluble cytokine expression 
patterns associated with protection also is planned.
This biomarker study for drugs and treatment outcomes has looked at 
the normal patient therapy seen in clinics. The aim of the study has been to 
make it possible to differentiate among patients at the time they seek medi-
cal help so they can be assigned directly to the correct regimen. According 
to Parida, the objectives include
• bringing together basic scientists from the laboratories and clini-
cians from clinics in the communities and hospitals through effec-
tive communication and interaction;
• achieving a holistic understanding of resistance, susceptibility, and 
protective immunity, taking an open-minded, global approach;
• coordinating initiatives and finding synergies within the scientific 
community, including interdisciplinary approaches and cross- 
fertilization of ideas;
• establishing global, shared, and comprehensive biorepositories;
• aligning vaccine trials and intervention studies;
• creating an open access policy and enforcing it through the buy-in 
of all stakeholders;
• generating public−private−philanthropic partnerships; and
• enhancing functional collateral/symbiotic interactions between 
basic science and real lives in clinics to translate research knowl-
edge into products of public health importance.
The following issues require further consideration:
• the natural history of infection in the context of drug-resistant TB 
and immune responses; and
• differential gene expression patterns of MDR and XDR TB strains, 
with virulence depending on the host environment.
Parida also noted that a number of conventionally accepted “ dogmas” 
in the field have not been systematically questioned. According to Parida, 
evidence-based studies are needed in areas that include microbial persis-
tence, immune evasion mechanisms, strain diversity, limitations of animal 
models, extrapolations of experimental results, ways to bridge the experi-
mental results with clinical observations, and integration of multiple obser-
vations rather than a reductionist approach. Ultimately, lessons learned in 
the clinical setting need to be brought back to the laboratory to close links 




Treatment of Drug-Resistant TB
The workshop presentations and discussions highlighted a number of 
challenges and open questions for consideration in efforts to improve the 
treatment of drug-resistant TB. First, as a precursor to successful treatment, 
early diagnosis of drug-resistant TB is essential; otherwise, delays in treat-
ment lead to higher mortality (see Chapter 5). Second, emerging informa-
tion from a study of patient-specific resistance profiles and appropriate 
treatment regimens was presented (Keshavjee and Seung, 2008). Successful 
treatment outcomes for both MDR and XDR TB have been observed in 
low- and middle-income countries with a low prevalence of HIV infection, 
but this observation may not be applicable in a setting such as South Africa 
where HIV prevalence is high. With HIV coinfection, drug-resistant TB 
Key Messages
•  Existing treatment programs in South Africa have been insufficient to 
prevent the spread of drug-resistant TB and extensive mortality.
•  Financial support for treatment in locations such as Tugela Ferry has 
greatly improved the rate and outcomes of treatment.
•  The success of community-based care for drug-resistant TB in South 
Africa has led to greater support for decentralized treatment programs.
•  Antiretroviral therapy has a substantial protective effect for TB. 
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appears to take a different and more aggressive course. Most patients with 
HIV-associated MDR and XDR TB die within 6 to 8 weeks, which is also 
the time typically required to make the diagnosis by conventional culture 
and drug sensitivity testing. Thus, the majority of patients die before their 
diagnosis can be documented and before second-line drug treatment can be 
initiated.1 A third issue concerns the locus of treatment. On the one hand, it 
was noted that XDR TB treatment, especially in the earliest stages, should 
take place in a hospital to ensure management of side effects, treatment 
literacy in patients, nutritional support, and infection control. On the other 
hand, it was argued that a move toward a decentralized model of care is 
necessary for prevention of transmission. For example, as the number of 
patients on antiretroviral therapy increases, antiretroviral therapy facili-
ties will become more crowded with patients, many of whom are highly 
susceptible to TB. It is important to recognize that combining HIV and TB 
programs could result in spreading TB among HIV-infected people. A final 
set of challenges relates to limitations of health care systems and cost issues.
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General Principles
Presenters offered general principles for the treatment of drug-resistant 
TB, including the need for a comprehensive approach that includes intensi-
fied case finding, preventive therapy, improved treatment literacy, and good 
infection control. In addition, presenters suggested that patients should 
have increased access to anti-TB drugs as well as other treatment modali-
ties, including thoracic surgery and immune modulators. 
Nesri Padayatchi, University of KwaZulu-Natal, elaborated on the 
objectives of MDR TB management in KwaZulu-Natal Province:
• to make the diagnosis of MDR TB in patients,
• to ensure that the best possible treatment is available,
• to provide support for each patient to ensure access to treatment,
• to facilitate the continuation of care for each patient,
• to factor the management of HIV into the treatment of TB, and
• to explore other options for treatment.
Gandhi described the program that has been instituted in Tugela Ferry, 
which has three main components:
1  As noted in Chapter 2, World Health Organization (WHO) and International Standards 
for Tuberculosis Care (ISTC) guidelines promote the use of an empiric regimen of second-line 
drugs in suspected MDR TB patients (TBCTA, 2009).
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• Prevention—Preventing the development of drug resistance by 
strengthening the DOTS program to curb the creation of drug-
resistant strains and by implementing an infection control program 
to prevent the transmission of such strains.
• Diagnosis—Facilitating early diagnosis by testing and implement-
ing rapid diagnostic assays, which may reduce the time required 
for diagnosis of drug resistance from 6−8 weeks to 1−10 days.
• Treatment—Decentralizing access to second-line TB therapy to 
reduce delays in referral, increase capacity, and improve treatment 
completion rates. When necessary, second-line drugs have been 
initiated for HIV-infected patients suspected of MDR or XDR 
TB, and antiretroviral therapy has been integrated into the drug-
resistant TB treatment program. 
Finally, Padayatchi described some of the common concerns about 
treatment default rates. The extent to which the current data may under-
estimate the default rate is unclear. Loss to follow-up is often due to the 
toxicity of drugs and the duration of treatment for drug-resistant TB, as 
well as the patient’s distance from the place of treatment. With respect to 
adverse drug effects, sudden deaths from hypokalemia have been found 
to be caused by capreomycin; however, renal failure may be related to the 
presence of a renal condition. More intensive monitoring may decrease 
deaths related to the drug.
Treatment of Drug-Resistant TB in South Africa
Presenters summarized the findings from studies conducted to char-
acterize TB patients in South Africa and to evaluate the effectiveness of 
treatment regimens that have been used in those with drug-resistant TB.
King George V Hospital
Padayatchi presented findings of a study conducted at King George V 
Hospital. She noted that historically, the outcomes of MDR TB in South 
Africa have been documented to a limited extent. One of the first outcome 
studies, by Simon Schaaf in the late 1980s, showed a 33 percent cure rate 
for MDR TB, with 48 percent of patients dying (Schaaf et al., 1996). In 
the late 1990s, a national study of outcomes showed that after 6 months 
of MDR TB treatment, more than 70 percent of patients discontinued the 
treatment. This remains a huge public health problem in South Africa and 
particularly in KwaZulu-Natal, where the cure rates are below 50 percent. 
Figures from 2005 to 2007 in Tugela Ferry show that by 30 days from 
sputum collection, the mortality rates in MDR and XDR TB patients were 
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already 40 percent and 53 percent, respectively (Gandhi et al., 2010). Most 
of the deaths occurred within 2 months, accentuating the need to diagnose 
MDR and XDR TB earlier.
At King George V Hospital, MDR TB cases increased exponentially 
from 1994 to 2008. Padayatchi’s team evaluated more than 1,200 patients 
at the hospital between 2000 and 2003 (Brust et al., 2010). The cure and 
completion rate was about 44 percent, 21 percent of patients defaulted, 
18 percent died, and 17 percent failed treatment.
The 12-month outcomes for patients with XDR TB at King George V 
Hospital showed that antiretroviral therapy increases survival. Mortality 
was highest in the first 2 months after XDR TB treatment. Among those 
who survived 2 months on second-line drugs, survival rates were higher for 
those on antiretroviral therapy and those with CD4 cell counts above 200. 
Decentralized management will allow earlier access to care and initiation of 
treatment of MDR and XDR TB, as well as HIV coinfection, at decentral-
ized sites (O’Donnell et al., 2009).
Padayatchi noted that several new and existing drugs are undergo-
ing randomized controlled trials in South Africa, including TMC207, 
linezolid, and fluoroquinolones (e.g., moxifloxacin). The outcomes of the 
TMC207 study were published in the New England Journal of Medicine 
toward the end of 2009 (Diacon et al., 2009). Clearly this is a drug with 
potential, Padayatchi said. Linezolid has been known to have in vitro 
and in vivo activity against M.tb. and increasingly has been used in drug-
resistant TB patients. Adverse side effects include anemia and peripheral 
and optic neuropathies related to mitochondrial toxicity. These neu-
ropathies tend to occur after about 4 months of therapy and may not be 
resolved with the discontinuation of linezolid.
Several studies have examined the sensitivity of various strains of 
M.tb. to fluoroquinolones, and independent studies have confirmed that 
 moxifloxacin is among the most active of the drugs tested. Use of this 
effective group of drugs needs to be continued, despite the levels of resis-
tance that have been indicated, Padayatchi said. Except for linezolid and 
TMC207, other new classes of drugs have not yet been studied in random-
ized controlled trials for drug-resistant TB.
Padayatchi referenced a study in Europe evaluating 425 patients with 
fluoroquinolone-resistant versus fluoroquinolone-susceptible MDR TB. 
Study data reveal that a higher proportion of deaths and treatment fail-
ures occurred in the fluoroquinolone-resistant patient group (Migliori et 
al., 2008). According to Padayatchi, the judicious use of fluoroquinolones 
needs to be encouraged.
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Eastern Cape Province
Charlotte Kvasnovsky of the South African Medical Research  Council 
(MRC) reported findings from a 2008 MRC retrospective analysis of 
patients diagnosed between October 2006 and January 2008 in South 
 Africa’s Eastern Cape Province, where MDR TB cases have been diag-
nosed and treated with a standardized regimen since 2000 (Kvasnovsky et 
al., 2010). The study looked at data collected during site visits to two TB 
hospitals in June 2008 and January 2009, with the data being censored 
(cessation of data collection) at 12 months of treatment or upon the death 
of a patient. The objectives of the study were
• to describe the characteristics of HIV-negative and HIV-positive 
patients with XDR TB in the Eastern Cape,
• to determine patient mortality after 12 months on XDR TB 
treatment,
• to elucidate risk factors for early mortality,
• to ascertain the role of HIV in mortality due to XDR TB, and
• to consider the effect of treatment regimens on patients with 
XDR TB.
Over the 15 months, 274 patients were diagnosed with XDR TB; 65 of 
those patients, or 23.7 percent, died before starting XDR TB treatment. Of 
the 206 patients in whom treatment was initiated, the HIV status of 195 
was known: 108 patients, or 55 percent, were HIV-positive, and 87 patients, 
or 45 percent, were HIV-negative. Patients were treated with individualized 
regimens composed of the six first-line and second-line anti-TB drugs avail-
able in the province at the time, which were capreomycin, p-aminosalicylic 
acid, ethionamide, terizidone, ethambutol, and  pyrazinamide. Capreomycin 
and p-aminosalicylic acid, which were available for treatment of XDR TB 
beginning in October 2006, formed the backbone of the regimen. The effec-
tiveness of each drug was assessed, and drug resistance was tested. Most 
patients had undergone at least 7 months of previous MDR TB treatment 
and were dealing with a large burden of TB disease when the XDR TB 
treatment began. 
Among the 206 patients, there were 95 deaths in the first year of 
treatment. Overall, 36 percent of HIV-negative patients died, as com-
pared with 51 percent of HIV-positive patients. Most of the HIV-positive 
patients who died were not on antiretrovirals. HIV-positive patients not 
on anti retrovirals had 2.5 greater odds of death at 12 months compared 
with known HIV-negative patients. More than 90 percent of HIV-positive 
patients were diagnosed with HIV prior to admission for XDR TB treat-
ment, and 55 percent of the HIV-positive patients were on antiretrovirals 
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at the time XDR TB treatment was initiated. As in the model including all 
patients, patients aged 25−42 or smear positive at the start of treatment had 
poorer 12-month survival. In assessing the effectiveness of the treatment 
regimens, a drug was considered effective if (1) it is recognized as an agent 
for the treatment of TB by the World Health Organization (WHO), (2) the 
patient had either never received it or received it for less than 3 months 
prior to XDR TB treatment, and (3) patient isolates were not found to be 
resistant to the drug by drug susceptibility testing.
Patients were treated with an average of 5.2 different drugs. Of those 
total drugs, patients received an average of 1.7 drugs that were considered 
effective. WHO recommends the use of at least four drugs to which the 
patient’s TB is considered susceptible. It was suggested that, in light of 
the overall poor outcomes for XDR TB, even the WHO recommendation 
may not be sufficient to cure patients with XDR TB, at least using those 
drugs available in the Eastern Cape at the time of the study.
Serious adverse effects were noted when a provider withheld a drug 
because of side effects or when a patient refused to continue with a drug. 
Overall, 36 patients (18 percent) experienced a severe adverse reaction to 
at least one anti-TB medication. HIV-negative patients experienced severe 
adverse effects at three times the rate of HIV-positive patients—31 percent 
compared with 9.3 percent. It was found that the use of antiretrovirals made 
no difference in the rate of adverse effects among HIV-positive individuals.
Of the 195 patients, 190 were culture positive at the start of treat-
ment. Sixteen patients (8.4 percent) achieved sputum culture conversion 
in a median of 143 days, demonstrating the possibility that XDR TB can 
be cured. There was no difference in the frequency of culture conver-
sion between HIV-positive (10/108, 9.2 percent) and HIV-negative (6/87, 
6.9 percent) patients. In the year since these data were collected, four 
patients have been cured of XDR TB, and follow-up data continue to be 
gathered.
Kvasnovsky stated that this research confirmed the benefit of using 
antiretrovirals in HIV-positive XDR TB cases. Therefore, although the 
current protocol in South Africa is to start antiretroviral therapy when 
the CD4 count is under 200 and after the first month of XDR TB treatment, 
 Kvasnovsky recommended the early initiation of antiretroviral therapy in 
all HIV-positive patients irrespective of CD4 count.2
2  South Africa updated its guidelines for antiretroviral therapy to give priority to treatment 
of individuals coinfected with TB and HIV. Taking effect in April 2010, the national eligibility 
criteria for adults and adolescents to start antiretroviral therapy regimens include HIV−drug-
susceptible TB patients with a CD4 count below 350, as well as all MDR and XDR TB patients 
coinfected with HIV, regardless of CD4 count. In addition, MDR and XDR TB patients are 
required to start antiretroviral therapy on a fast track (within 2 weeks of being eligible [i.e., 
diagnosed with MDR or XDR TB]).
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Treatment of Drug-Resistant TB in Other Countries
For purposes of comparison, speakers described treatment of drug-
resistant TB in two other countries—Ethiopia and South Korea.
Ethiopia
Anne Goldfeld, Harvard University, described treatment of drug- 
resistant TB in Ethiopia. Ethiopia has the second-largest population in 
sub-Saharan Africa, with approximately 80 million people. WHO esti-
mates that there are 129,000 new TB cases per year in the country and 
ranks Ethiopia seventh among the 22 countries with the highest TB burden 
worldwide. Based on a survey conducted in 2003−2006, 1.6 percent of 
these cases are MDR TB, and WHO estimates that there are at least 6,000 
new cases of MDR TB each year. According to Goldfeld, the backlog of 
MDR TB cases needing treatment in Ethiopia is significant, and diagnosis 
remains a challenge. 
In 2008, 221 MDR TB cases had been documented at the Ethiopian 
National Reference Laboratory in Addis Ababa. The Ethiopian Federal 
Ministry of Health submitted a funding application to the Green Light 
Committee (GLC) and received approval for treating a cohort of 45 patients 
in August 2008, with arrival of drugs anticipated in October 2008. 
The Cambodian Health Committee conducted the first MDR TB train-
ing for doctors, nurses, health workers, and pharmacists in Addis Ababa in 
October 2008. As follow-up, the Ethiopian MDR TB team attended MDR 
TB training in Cambodia led by the Cambodian Health Committee. This 
program involved both didactic and hands-on training in the Cambodian 
Health Committee’s hospital-, community-, and home-based MDR TB care 
program. Along with a donation of capreomycin from Eli Lilly, other drugs 
were acquired with support from the Jolie-Pitt Foundation to begin treating 
the first cohort of Ethiopian MDR TB patients.
A cohort of 8 patients was started on treatment in February 2009, a 
second cohort of 12 patients was started in June 2009, a third cohort of 
16 patients was started in August 2009, and a fourth cohort of 14 patients 
was started in October 2009. Treatment of these cohorts was initiated 
prior to the arrival of the GLC drugs later in 2009, a year after they were 
expected. When those 45 courses of drugs eventually arrived in Ethiopia, 
patients were rapidly initiated on them. The 92 patients started on therapy 
by March 2010 had received an average of three prior treatments for drug-
sensitive TB, which had been given because no second-line drugs were avail-
able. Fifty patients completed the intensive phase of treatment and have 
been placed in the continuation phase at home using a community-based 
approach pioneered by the Cambodian Health Committee in collaboration 
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with the Ethiopian Federal Ministry of Health, with no defaulters. Approxi-
mately 25 percent of the 92 patients were HIV-positive. Three patients died 
in therapy, two of whom were HIV-positive. 
Of the 221 patients who had been diagnosed with MDR TB as of 
August 2008, all eligible backlog patients who could be traced were 
started on therapy. Unfortunately, a house-to-house search for these 
patients revealed that 20 percent were confirmed dead and 50 percent 
could not be found, some of whom presumably had also died while await-
ing therapy. 
Goldfeld noted that many of the issues involving TB and MDR TB care 
in Ethiopia have previously been addressed in Cambodia. One of the first 
effective programs using short-course chemotherapy with directly observed 
treatment was begun on the Thai−Cambodian border in a refugee camp 
in an open war zone in 1980. Subsequently in Cambodia, beginning in 
1994, the Cambodian Health Committee began to develop a community-
based care approach, “community DOTS,” that has been scaled up to the 
entire country in recent years. A home-based care approach also has been 
developed and has been highly successful. In addition, the Cambodian 
Health Committee initiated integrated TB and HIV care in a provincial TB 
program and in the TB ward of the largest public hospital in Cambodia. 
 Clinical research performed by the Cambodian Health Committee, sup-
ported by the National Institutes of Health (NIH) and the French National 
Agency for AIDS Research (ANRS), has addressed the question of the 
optimal timing for the introduction of antiretrovirals in immunosuppressed 
AIDS patients with TB. This research provided an opportunity for the coun-
try to obtain first-line AIDS drugs and then drugs for MDR TB cases. The 
Cambodian Health Committee subsequently obtained second-line drugs 
for MDR TB through the GLC process and initiated treatment for 136 
patients throughout the country by March 2010. Twenty percent of these 
patients were initiated on MDR TB therapy at home in accordance with the 
 community- and home-based models. An extensive community network of 
patient sup porters administers the drugs with the help of health  workers 
and local health centers. Goldfeld suggested that these approaches are 
eminently suitable for application in Ethiopia and that this South-to-South 
transfer of knowledge can serve as a model for expansion.
South Korea
In southern Africa, there is little doubt that HIV infection is accelerat-
ing the development of resistance to TB drugs, said Clifton Barry III, NIH. 
However, resistance is also a natural consequence of treatment with drugs, 
as is demonstrated by the fact that the same phenomenon is taking place in 
regions where HIV infection is not common.
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Barry described the experience of South Korea, where HIV infection is 
rare. The National Masan Tuberculosis Hospital is the largest TB referral 
hospital in the country. It treats about 800 newly admitted patients every 
year and has about 350 outpatient visits per day. Patients are staying for 
an increasingly long time, with the mean average duration of admission 
currently being about 130 days.
Closely tied to the work of the National Masan Tuberculosis Hospital 
is that of the International Tuberculosis Research Center, which was estab-
lished in 2005 in South Korea with the aim of improving the diagnosis and 
treatment of drug-resistant TB and the methodology used for clinical trials 
of new drugs, as well as understanding the virulence of drug-resistant TB. 
About 800 patients are currently on four open protocols, the first of which 
started in 2005. A natural history collection is used to benchmark every 
patient who comes to the hospital, and the treatment duration is 2 years. In 
South Korea, a diagnosis of TB requires a mandatory report to the ministry 
of health, which results in perfect recall for patients who relapse.
Barry reported on a study begun in 2005 at the center, which involves 
collecting all the strains from patients infected with MDR TB, determin-
ing host genetic information, and characterizing different responses to 
therapy in a large cohort of infected patients. An extensive database of 
information has been collected by following patients essentially for life. 
Cohort A includes patients who have never before been treated for TB. 
Cohort B includes patients for whom retreatment is documented. The cure 
rate is approximately 58 percent. About 10 percent withdraw from the 
study for various reasons: 11 percent die; 18 percent default; and 3 per-
cent are chronic cases, almost all of whom have TDR TB (where total 
drug resistance is defined operationally). Most of the strains are either 
MDR or XDR TB.
Genotyping and clustering were performed in the cohort enrolled from 
May 2005 to December 2006, which included 208 culture-positive patients. 
Even though the rate of clustering was not insignificant, it could be con-
cluded that the XDR TB was not spreading effectively. However, the strains 
responsible for the individual branches of the epidemic were definitely 
expanding. In northern parts of South Korea, one subset of the Beijing 
strain was expanding; in the southern region, a different subset was found.
To date about 1,400 bacterial isolates have been collected. Patients 
who are on therapy can be followed individually, and drug susceptibility 
tests can be compared. The injectable drugs used to treat drug-resistant TB 
are associated with very different rates of adverse reactions, which consti-
tute a significant and underappreciated problem for the management of 
these patients. Individualized regimens are used wherever possible and are 
adjusted for adverse reactions. The major predictor of adverse reactions is 
previous treatment history.
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Researchers have compared the results of drug sensitivity testing with 
clinical outcomes and have found groups of organisms with discrete resis-
tance patterns. They also have detected the major mutations associated 
with each strain. Four major allele changes are associated with injectable 
drug resistance, some of which confer cross-resistance. Streptomycin and 
capreomycin resistance involves discrete genotypic changes. Prior acquisi-
tion of kanamycin resistance confers capreomycin cross-resistance, but 
prior acquisition of capreomycin resistance does not confer kanamycin 
cross-resistance. Kanamycin and amikacin have particularly high levels of 
cross-resistance and therefore should be reserved for last use. This approach 
would require a change in policy guidelines, but it would bring some order 
to the way these drugs are used clinically and improve outcomes.
Barry stated that within a year or two, resistance will be determined 
using genotypic resistance determinations. Genotypic drug susceptibility 
testing has performed well in predicting clinical outcomes, as measured by 
6-month sputum conversion.
Treatment and Management of HIV-Associated MDR TB
Padayatchi discussed the recently published SAPiT (Starting Anti-
retro viral therapy at three Points in Tuberculosis therapy) study, the first 
randomized controlled trial that corroborated previous evidence on the 
need to integrate TB care and antiretroviral therapy (Abdool Karim et al., 
2010). The study showed that mortality was 56 percent lower in patients 
who began antiretroviral therapy as soon as possible compared with those 
who waited until TB treatment had been completed. There have been 
concerns about potential overlapping toxicities in drugs for MDR TB and 
HIV; some of the common concerns are peripheral neuropathy, psychiatric 
symptoms, and hepatitis. However, there are many ways in which these and 
other potential toxicities can be managed.
Of South Africa’s approximately 500,000 TB cases per year, 73 percent 
are associated with HIV infection, compared with about 12,000 such cases in 
the United States. It is impossible to “treat our way out of the epidemic,” said 
Stephen Lawn, University of Cape Town. Prevention strategies are essential.
Lawn cited recent data on nine cohorts around the world from both 
high- and low-prevalence countries showing that antiretroviral therapy 
substantially reduces TB rates in HIV-positive people, with a range of 
54 to 92 percent protection (Lawn et al., 2009) and a pooled estimate 
of 67 percent (95 percent confidence interval [CI], 61−73 percent) (Lawn 
et al., 2010). The data demonstrate that there is a time-dependent reduc-
tion in TB rates, but the maximum benefit is probably acquired within the 
first 2 years of treatment. This represents a major advance in preventing 
TB across different settings, in patients with both moderate and advanced 
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immunodeficiency, and in both skin test−positive and skin test−negative 
patients. It is likely that this observation applies to both drug-sensitive and 
MDR TB, said Lawn.
Patients referred into the antiretroviral therapy program in Gugulethu 
in the Western Cape, where the burden of TB is high, undergo a 1-month 
period of screening and investigation for TB before starting antiretroviral 
therapy. This period is one of great risk for nosocomial TB transmission. 
More than half of patients referred to the antiretroviral therapy program 
have already undergone one or more courses of completed TB treatment in 
the past, a quarter have prevalent disease at baseline, and 11 percent develop 
TB during the first year of antiretroviral therapy (Lawn et al., 2006). Forty 
percent of patients are newly diagnosed with TB and commencing treatment 
for TB at the time they begin antiretroviral therapy, showing that presenting 
for antiretroviral therapy is unmasking cases of TB that would otherwise go 
undiagnosed. If these patients were rigorously screened for TB using active 
microbiological screening prior to starting antiretroviral therapy, the risk of 
nosocomial TB and MDR TB transmission could be decreased. 
Observations made in Tugela Ferry from 2005 to 2007 provided valu-
able data concerning drug-resistant TB. Virtually all the cases of MDR and 
XDR TB were associated with HIV and occurred in patients with very low 
CD4 cell counts (see Box 6-1 for a discussion of CD4 count as a predic-
tor of mortality among MDR and XDR TB patients).3 The proportion of 
patients who were on antiretroviral therapy upon diagnosis of MDR and 
XDR TB was 15 percent and 22 percent, respectively (Gandhi et al., 2010). 
Almost two-thirds of patients had received a previous diagnosis, most 
within the previous year and most of drug-susceptible TB. Thus, many of 
these patients had been under the care of the health care system for some 
time prior to acquiring MDR TB, and an opportunity to prevent these infec-
tions using antiretroviral therapy was missed. 
Because many MDR TB outbreaks are driven by HIV-positive patients 
with very low CD4 cell counts, antiretroviral therapy has a potent preven-
tive effect. The development of new drugs to treat MDR and XDR TB 
patients effectively will be extremely costly and will take a very long time. 
By contrast, more than 20 antiretroviral drugs are currently available, and 
the potential to use them more effectively to prevent HIV-associated TB 
and MDR TB is currently being squandered. An aggressive scale-up of 
antiretroviral therapy at the earliest opportunity is warranted, said Lawn. 
3  In October 2006, the National Health Laboratory Service began second-line drug suscepti-
bility testing for amikacin and ofloxacin, allowing for the diagnosis of XDR TB in the Eastern 
Cape. From October 2006 to June 2007, second-line drug susceptibility testing was available 
only for patients on MDR TB treatment. After July 2007, isolates from all newly diagnosed 
MDR TB patients received such testing as well.
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BOX 6-1 
CD4 Count as a Predictor of Mortality  
Among MDR and XDR TB Patients
 Preliminary data from a case control study conducted in Tugela Ferry to 
determine risk factors for death among MDR and XDR TB patients show 
that the CD4 count at TB diagnosis appears to be the best  predictor of 
mortality. Those patients with the lowest CD4 counts are at the highest 
risk (Lawn et al., 2009). The CD4 count rises during antiretroviral therapy, 
and the TB incidence falls dramatically. Patients are safest when their 
CD4 count has passed the threshold of 500, and this should be the goal, 
according to Lawn. The cumulative lifetime HIV−TB risk depends on the 
total time spent in different CD4 strata, both before and during antiretroviral 
therapy. The recently revised WHO guidelines recommend that anti retro-
viral therapy be started for all people living with HIV at a CD4 count of 350 
or less, which will decrease the risk of acquiring TB (WHO, 2010c). 
 Salim Abdool Karim, University of KwaZulu-Natal, Center for the AIDS 
Programme of Research in South Africa (CAPRISA), pointed out that 
the average CD4 count at the initiation of antiretroviral therapy is around 
100 because the bulk of these patients have come to the service with an 
opportunistic infection. If people were put on treatment at a CD4 count 
of 350 instead of 200, the result would be a roughly 30 percent increase 
in the number of patients, as it is impossible to test millions of people 
who look healthy to identify those who are infected. Furthermore, if test-
ing were extended in this way, not enough health services would exist 
to treat the number of patients. The shift from 200 to 350 would have a 
greater effect on mortality than on the prevention of HIV or TB, Abdool 
Karim said. Patients identified with a CD4 count of 350 could receive 
antiretroviral therapy, but this is not the miracle people are seeking. 
It is important that antiretroviral therapy be initiated as soon as possible, 
with patients receiving treatment immediately upon presenting to the health 
care system. Lawn noted that current WHO guidelines recommend that 
antiretroviral therapy be initiated in all HIV-infected individuals with active 
TB as soon as practicable after the start of TB treatment, irrespective of 
CD4 cell count (WHO, 2010c).4
4  South Africa’s national guidelines for antiretroviral (ARV), which took effect in April 
2010, provide that antiretroviral treatment (ART) regimens should be commenced in HIV/
drug susceptible TB patients with a CD4 count less than 350, and in all HIV/MDR or XDR 
TB patients, regardless of CD4 count. MDR and XDR TB patients are required to start ART 
on a fast-track (within 2 weeks of being eligible [i.e., diagnosed with MDR or XDR TB]).
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Several workshop participants noted that physicians can inadvertently 
increase the non-TB patient population’s exposure to important anti-TB 
drugs. For example, common infections, such as urinary tract infections, 
often are treated with fluoroquinolones (which are also used to treat MDR 
TB), a practice that can increase an individual’s resistance to this important 
category of antibiotics. Doctors may need an intensified education program 
concerning the management of TB and the importance of accurate diag-
noses, suggested one participant.
In addition to the cotoxicities of antiretrovirals and second-line TB 
drugs, the risk of immune reconstitution inflammatory syndrome (IRIS) is 
greater when the interval between the start of TB treatment and the start 
of antiretroviral therapy is shorter. Patients thus need to be monitored for 
cotoxicities and IRIS, said Lawn. An early start on antiretroviral therapy 
can lead to toxicity problems, but given the positive effect of antiretroviral 
therapy on lowering mortality and morbidity rates, an option to be treated 
early is necessary. At the same time, Lawn suggested, research is needed 
to assess the relationship between the early initiation and the toxicity of 
antiretroviral therapy, and ways must be found to make early anti retroviral 
therapy sustainable. Moreover, Lawn noted, the recent revision of the 
WHO guidelines has promoted a phasing in of less toxic antiretroviral 
regimens (WHO, 2010c). According to the WHO guidelines, initial anti-
retroviral therapy should include a non-nucleoside reverse transcriptase 
inhibitor plus two nucleoside reverse transcriptase inhibitors, one of which 
should be zidovudine or tenofovir. WHO also recommends that countries 
begin to phase out the use of stavudine (d4T) in first-line antiretroviral 
regimens because of its toxicities. 
Research Needs
Chaisson suggested that much more clinical research on the treatment 
of MDR TB is needed. For example, more research is needed on existing 
drugs and their effectiveness against particular TB strains. 
Jacobs emphasized the potential of research on preventing the emer-
gence of drug resistance with simple compounds available in the diet. He 
explored the possibility that particular compounds can block the mutations 
that lead to resistance. When excess cysteine was added to a culture under-
going selection for isoniazid resistance, it sterilized the culture. In other 
words, mutants were unable to arise from the persistent cell population 
when cysteine was present. The effect is dose- and time-dependent, and the 
thiol group of cysteine is essential for activity. Jacobs suggested that this 
idea should be examined in the search for compounds that can prevent the 
emergence of drug resistance.
Sturm noted that the variation among strains in southern Africa is 
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much greater than is suggested by the broad categories of MDR and XDR 
TB. Standardized treatment regimens for these categories are therefore 
inadequate and will lead to greater resistance; however, the region is not yet 
at the point at which individualized treatments can be instituted, according 
to Sturm. Much more needs to be known about resistance patterns for TB 
strains throughout southern Africa to support the development of individu-
alized treatment regimens, he noted. Barry pointed out that XDR TB is not 
a biological descriptor of the strain; the question that should be asked is 
how the structure has changed and what is seen in the patient.
COMMUNITy-BASED CARE5
Wallengren explained that the experience in KwaZulu-Natal demon-
strates some of the challenges and opportunities of community-based care. 
As MDR TB cases have increased, there has been an increase in admission 
of MDR TB patients to King George V Hospital in Durban, South Africa, 
which has only 320 beds. It takes approximately 16 weeks to initiate 
treatment once a sputum culture has been taken and the patient has been 
 admitted to the hospital. To accommodate the dramatic increase in admis-
sions, it has become necessary to discharge patients, many of whom are not 
yet healthy and are still infectious. The average length of stay in the hospital 
has decreased from 6 months to 2 months. In 2006, more than 30 percent 
of patients were culture positive, and more than 15 percent were smear 
positive when they left the hospital. These patients went home to house-
holds that were unprepared to manage side effects or practice infection 
control. Patients had to return to King George V Hospital once a month for 
follow-up visits, sometimes traveling distances of up to 500 km. A lack of 
infrastructure support for patients has resulted in poor treatment outcomes 
and a cure rate of just 40 percent over the last few years at the hospital.
Today hospitalization is not feasible because of the high numbers of 
MDR TB patients. In KwaZulu-Natal Province, alternative treatment is 
already taking place, with many patients returning to their households and 
communities, where treatment is continued. The challenge is to provide 
these patients with the support they need.
To this end, decentralized MDR TB treatment is being piloted at four 
sites situated in four districts of KwaZulu-Natal; patients began treat-
ment in the decentralized system in 2008. King George V Hospital has a 
supervisory role and provides technical support to the decentralized sites. 
Complicated cases are admitted to the hospital. Eligible patients are started 
on the intensive phase of treatment. They receive appropriate education 
5  This section is based on the presentation of Kristina Wallengren, South African Medical 
Research Council.
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about their disease, their homes are assessed with respect to decentralized 
care, and a plan for continued care is issued. When patients are discharged 
from the hospital, they are assigned to teams within the decentralized unit. 
The teams administer injections, monitor side effects, support treatment, 
refer complications to the unit, and continue patient and family education 
in TB and infection control. The teams are assisted by DOTS supporters or 
family members who are trained as treatment supporters. Family members 
are involved in both the intensive phase and the continuation phase of treat-
ment. Patients return to the decentralized clinics for a monthly visit, where 
treatment is assessed and side effects are addressed. The teams transport 
drugs in cooler boxes and use a GPS unit to locate patients. When roads are 
impassable, team members sometimes have to walk considerable distances 
to get to patients. The selection criteria for decentralized care are as follows:
• Patients must have noncomplicated MDR TB.
• The decision to place a patient under community care is made by 
a multidisciplinary group consisting of a medical doctor, a nurse, 
an MDR TB coordinator, and a social worker.
• The patient should be smear negative and have stable accommoda-
tions and nutritional support.
• The patient and family must have received adequate education and 
be able to follow the plan for the administration of drugs.
Since July 2008, 420 patients have been placed in decentralized care, 
and their progress has been compared with that of patients in centralized 
care at King George V Hospital. Some early results are as follows:
• Most patients are tested for HIV, and the HIV-positive rate is 74 
to 78 percent.
• Decentralized sites have been effective in ensuring that HIV-positive 
patients receive antiretroviral therapy.
• Integration of antiretroviral therapy into the MDR TB treatment 
program has been problematic. A lack of communication among 
vertical programs is a notable challenge. Moreover, it seems that 
the TB/HIV integration itself has become a vertical program. 
 Wallengren noted that the challenge for both TB and HIV treatment 
lies in the clinics delivering the care, rather than in the patients not 
complying with treatment.
• Mean TB smear positivity at diagnosis is 73 percent in the decentral-
ized sites and 57 percent in the centralized hospital.
• The treatment delay is shorter at the decentralized sites, with an 
average of 90 days from diagnosis to treatment, compared with 
108 days at King George V Hospital.
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• TB culture conversion is 66 percent in the decentralized sites.
• With respect to early treatment outcomes, 14 percent died, 3 per-
cent failed, and 2 percent defaulted.
According to Wallengren, the challenges faced by the decentralized 
program include high staff turnover, inadequate staff training, inadequate 
support for nurses (clinically, monetarily, and administratively), drug short-
ages (due to either reduced orders at the district level or problems with 
procurement and distribution at the provincial level), and integration of 
antiretroviral therapy.
LIMITATIONS OF HEALTH CARE SySTEMS AND COST ISSUES
The current TB epidemic is reminiscent in some ways of the HIV epi-
demic in the late 1980s and early 1990s, said Robin Wood, University of 
Cape Town. The numbers of patients were so great that the capacity of exist-
ing health care facilities was inadequate. There was great fear among health 
professionals, some of whom shunned infected patients. A major difference, 
however, is that the HIV epidemic was more linked with human rights issues, 
and patient and activist groups served as advocates for change.
Because sufficient beds are not available, drug-resistant TB patients 
diagnosed in the general ward of a hospital generally remain there while 
they wait for a bed to become available at a referral hospital. These patients 
are being cared for by people who are insufficiently trained and unaware of 
both the needs of the patients and infection control. Building more capacity 
requires money and time. A short-term solution, said Wood, is to modify 
existing health care facilities, improve infection control, and incorporate 
community-based management of TB. Wood emphasized that concern for 
the human rights of patients should underpin any strategy used to manage 
TB. Of equal concern is the health of health care workers.
Padayatchi called for simultaneous advances on several fronts. She cited 
the need for (1) rapid diagnostics and new TB agents; (2) health systems 
research to analyze such options as decentralized treatment and integrated 
management of HIV, MDR TB, and XDR TB; (3) better referral and out-
reach systems to minimize the default rate; (4) advocacy; (5) improved 
surveillance; (6) an appropriate prophylactic for contacts (for both adults 
and children); and (7) further exploration of empiric treatment, which is 
already being started in Tugela Ferry.
Lerole David Mametja, Department of Health, South Africa, stressed 
the need for financial support. When WHO reviewed South Africa’s TB 
control program in July 2009, it estimated that 1 percent of the population 
or approximately 490,000 South Africans had TB in 2008 and that 2 per-
cent of the TB cases were MDR. Data from the National Health Laboratory 
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Service showed that about 6,200 cases of MDR TB were diagnosed in 2008, 
but only 4,600 became part of the treatment program. Thus a large number 
of MDR TB cases are disappearing from the system.
WHO has estimated that successful TB control and management in 
South Africa would require R5.2 billion. Mametja stated that not enough 
funding is available to produce the required response to TB in the country. 
Challenges involving the interactions between national and provincial gov-
ernments have resulted in the inability of the national TB program to access 
all the funds assigned to it. These challenges have impeded the reversal of 
the spread of TB and drug-resistant TB. 
According to government policy, all drug-resistant TB cases must be 
hospitalized, but only 2,000 beds are available for this purpose. Thus the 
policy is unworkable, said Mametja. Although South African governments 
have tried to expand the bed capacity, funding this expansion has been dif-
ficult. Moreover, the solution will have to go beyond creating more beds; it 
may require returning to the basics of TB control and management so as to 
preempt the onset of MDR and XDR TB. One workshop participant added 
that the cost of drugs is an issue as well, with a course of moxifloxacin and 
capreomycin, for example, costing thousands of U.S. dollars. Barry said 
that the choice is either to add to the problem by using suboptimal drugs 
or to design a regimen that contains the epidemic. Pressure must be applied 
to bring the price of drugs down, said a participant.
Cassell noted that a good DOTS program will not necessarily prevent 
the spread of MDR TB, which has continued to increase even in areas with 
such programs. However, a major requirement for accessing global funds 
is to have a good DOTS program in place. In fact, patients are spreading 
resistant strains for almost 2 years until drugs arrive. 
Gandhi observed that since 2007, Tugela Ferry has seen a major influx 
of resources, primarily financial, that have allowed staffing for the TB treat-
ment program to be increased. From two nurses in 2004, the TF CARES 
facility now has more than 30 staff members working in the program. As 
a result, treatment for drug-susceptible TB has improved from a little more 
than 60 percent to more than 83 percent at present, and the default rate 




Drug-Resistant TB in Children
An increasing number of children in southern Africa are contracting 
drug-resistant TB. Simon Schaaf, Department of Paediatrics and Child Health, 
University of Stellenbosch, reviewed special issues in the diagnosis and man-
agement of pediatric MDR TB, illustrated by the family case study in Box 7-1.
EPIDEMIOLOGy OF PEDIATRIC DRUG-RESISTANT TB1
Drug susceptibility testing and DNA fingerprinting have demonstrated 
that MDR TB in children results mainly from transmitted drug resistance. 
1  The remainder of this chapter is based on the presentation of Schaaf.
Key Messages
•  An increasing number of children in southern Africa are contracting 
drug-resistant TB, mainly through transmission.
•  Diagnosis of drug-resistant TB and assessment of side effects are 
often more difficult in children than in adults.
•  The optimal duration of treatment in children is unknown but is likely 
shorter than in adults.
•  Better data on mortality and causes of death would clarify the extent 
of the epidemic among children.
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BOX 7-1a
A Family Case Study Illustrating Issues in Pediatric MDR TB
 MDR TB and drug-susceptible TB cases commonly live in the same 
household in South Africa. In one family, the maternal grandmother had 
her fourth episode of TB in 2007 and had previously been identified as 
an MDR TB case. The grandfather died of MDR TB before 2004. An uncle 
had drug-susceptible TB during that same period and has since been 
treated and cured.
 When the uncle left the household, the mother and a child aged 
10 months remained. At the time, the child was asymptomatic and 
had a negative Tine tuberculin skin test;b it was unknown whether a 
chest xray had been taken. He was started on a regimen of isoniazid 
 prophylaxis. The child presented 4 months later when the grandmother 
was again  admitted for confirmed MDR TB. The child had had a cough 
for a week; his weight was in the 75th percentile; he was clinically well, 
but his  Mantoux testc converted to positive at 30 mm and was ulcerat-
ing; his chest x-ray showed some nodes and opacification; and he was 
HIV-negative.
 The child was started on a treatment regimen of isoniazid,  pyrazinamide, 
ethambutol, ethionamide, ofloxacin, and amikacin. Gastric aspirates were 
taken, two of which were culture positive, resistant to isoniazid and 
 rifampicin, and susceptible to ethambutol. The grandmother’s second-
line drug resistance returned a few months later—this time not only to 
isoniazid and rifampicin but also to amikacin. The child’s treatment was 
changed from amikacin to capreomycin, and terizidone was added.
 During the child’s follow-up, hearing tests could not be administered 
 because the child was too young, but renal function was normal. Each of 
the six monthly follow-up cultures was negative. The child was treated for 
18 months after the first negative culture. The capreomycin was stopped 
after 4 months, for a total of 6 months of injectable drug treatment. The 
child was discharged in April 2008. The grandmother was diagnosed with 
pre-XDR TBd and died in March 2008.
 The mother was pregnant and moved to live with the paternal grand-
mother in a nearby town. She was diagnosed with TB in August 2008, 
4 months after the child was discharged, and did not disclose that the 
paternal grandmother had MDR TB. The child was still on MDR TB treat-
ment. The mother started treatment but defaulted and, not surprisingly, 
did not respond to the treatment. She was smear positive at 2 months, 
when her baby was born, and MDR TB was confirmed in December 
2008. She died of MDR TB 3 months later. It was confirmed 3 months 
after her death that her TB had been susceptible to second-line drugs.
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 The baby was not given a BCG vaccine at birth and was started on a 
low dose of isoniazid treatment a few weeks after birth (as prophylaxis 
because the mother had TB). The local doctor interpreted a chest x-ray 
as normal. The baby’s treatment was changed to isoniazid (high dose), 
ethambutol, and ofloxacin, with questionable compliance, as prophylaxis 
against MDR TB (when the mother was confirmed to have MDR TB). 
The baby’s first visit to the local clinic was in March 2009. He was a 
healthy-looking baby who had good weight gain, a 1-week fever, and 
no other symptoms. The prophylactic treatment was defaulted for only 
2 weeks during the mother’s funeral. The baby was HIV-negative, and 
his Mantoux test was 10 mm. A chest x-ray showed progression of 
the disease despite the prophylaxis, and the regimen was changed to 
isoniazid, pyrazinamide, ethambutol, ethionamide, ofloxacin, terizidone, 
para-aminosalycilic acid, and capreomycin. Baseline renal function and 
liver function tests were normal, and the baby was progressing well on 
the treatment. However, the culture results and drug susceptibility tests 
showed that his TB was resistant to isoniazid, rifampicin, and ofloxacin. 
The paternal grandmother took over the care of both children once the 
injectable drug regimen had been completed, and both are doing well.
 According to Schaaf, lessons learned from this case study include the 
following:
 •  It is critical to take a full history of all adult TB cases, and it is 
 important to know when to screen for MDR TB.
 •  Screening for TB is important in child contacts. If there is no dis-
ease, children need the appropriate prophylaxis, and they must 
be put on the correct regimen at the right time. Follow-up must be 
done to ensure that they are well.
 •  Screening with chest x-rays is necessary for children, but the 
x-rays must be interpreted correctly.
 •  TB in children should be treated according to the drug susceptibility 
tests of the adult source case until the results of the child’s own 
culture and drug susceptibility tests are available.
 •  Good weight gain is not always a sign of a good clinical response.
 •  Management of MDR TB in pregnancy needs to be studied and 
discussed further.
 •  MDR TB and pre-XDR TB are curable diseases.
aThis box is based on the presentation of Simon Schaaf, University of Stellenbosch.
bThe Tine test is a multiple-puncture tuberculin skin test used to aid in the medical diagnosis 
of TB. It uses a small “button” that has four short needles coated with TB antigens (tuber-
continued
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culin). The needles are pressed into the skin (usually on the inner side of the forearm), forcing 
the antigens into the skin. The test is read by measuring the size of the largest papule that 
emerges. A negative result is the presence of no papules.
cThe Mantoux test (also known as the Mantoux screening test, Tuberculin Sensitivity Test, 
Pirquet test, or PPD test [for purified protein derivative]) uses a glycerol extract of the tubercle 
bacillus. PPD tuberculin is a precipitate of non-species-specific molecules obtained from 
filtrates of sterilized, concentrated cultures. A standard dose of 5 tuberculin units (0.1 mL) 
is injected intradermally and read 48 to 72 hours later. A person who has been exposed to 
the bacteria is expected to mount an immune response in the skin containing the bacterial 
proteins.
dPre-XDR TB refers to MDR TB plus one-half of the resistance equation for XDR TB. As 
 defined in Chapter 1 (Box 1-1), XDR TB is resistant to the same drugs as MDR TB (isoniazid 
and rifampicin), as well as any fluoroquinolone (levofloxacin, moxifloxacin, or ofloxacin) and 
at least one second-line injectable drug (kanamycin, amikacin, or capreomycin). Pre-XDR 
TB is MDR TB that displays resistance to one of the fluoroquinolones or a second-line 
injectable drug.
BOX 7-1 Continued
Acquisition of MDR TB is more difficult because of the paucibacillary 
nature of the primary disease, but it is possible with cavitary pulmonary 
disease. Disease in children usually develops within 12 months of infection. 
Epidemiological surveillance undertaken at the Tygerberg Children’s 
Hospital in the Western Cape between 1994 and 2009 produced several 
important findings related to the epidemiology of drug-resistant TB in 
children:
• There is a high prevalence of drug-resistant TB in the Western 
Cape.
• Despite previous treatment, more than 90 percent of all drug- 
resistant TB in children was most likely due to transmitted 
resistance.
• Hospital-based surveys are potentially biased because sicker chil-
dren or children with complications usually are referred to a 
hospital. However, no significant difference was found in drug-
resistant TB in children in a community-based versus a hospital-
based survey.
• Drug resistance is not significantly different between HIV-infected 
and HIV-uninfected cases.
• A lack of drug susceptibility tests in adult source cases hampers 
effective management of child TB contacts.
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PROPHyLAXIS AND DIAGNOSIS OF 
PEDIATRIC DRUG-RESISTANT TB
Contact tracing and follow-up of children exposed to MDR and XDR 
TB should receive high priority so prophylactic treatment can be initi-
ated, suggested Schaaf. When adults present with TB, the entire household 
should be screened. A 2002 study showed that giving a child two drugs to 
which the adult case is susceptible can prevent MDR TB cases. A combina-
tion of high-dose isoniazid plus ethambutol or ethionamide plus ofloxacin 
for 6 months has been used in the Western Cape, but studies are needed 
to determine whether a single drug could be used. Failure of isoniazid 
or  isoniazid plus rifampicin to prevent MDR TB has been reported in 
many cases. The solution to isoniazid monoresistance is to give  rifampicin 
for 4 months. Rifampicin monoresistance is treated with isoniazid for 
6 months. Pre-XDR or XDR TB cases can be given only a high dose of 
 isoniazid (15–20 mg/kg). In both MDR and XDR TB cases, regular follow-
up for a minimum of 12 months is essential.
In general, the prophylactic treatment of children in South Africa is not 
optimal, said Schaaf, although there is a policy that children under age 5 
and all HIV-infected children should be screened for TB and if there is no 
disease, should be placed on prophylactics. Schaaf’s policy is to start chil-
dren with HIV infection, who constitute about 30 percent of his pediatric 
patients, on antiretrovirals as soon as possible. He has experienced very few 
problems with antiretrovirals and second-line TB drugs.
Diagnosis of MDR and XDR TB in children requires a microbiological 
diagnosis, which is often difficult because of paucibacillary TB. The use of 
line probe assays for diagnosis of children may mean that about 10 per-
cent of MDR TB cases are misdiagnosed as rifampicin-monoresistant TB. 
Drug-resistant TB is probable, however, if a child has had known contact 
with an adult drug-resistant pulmonary TB case. Drug-resistant TB should 
further be suspected if a child is adhering to treatment and fails therapy or 
if an adult source case with an unknown drug susceptibility test result is a 
treatment failure, is a retreatment case, or has died of TB during adherent 
treatment.
DRUG TREATMENT REGIMENS FOR 
PEDIATRIC DRUG-RESISTANT TB
According to the 2008 updated WHO guidelines on drug-resistant TB, 
the drugs used to treat MDR TB in children fall into five groups:
• Group 1—Remaining first-line drugs: a combination of a high 
dose of isoniazid and ethionamide can create one effective drug. 
78 DRUG-RESISTANT TUBERCULOSIS IN SOUTHERN AFRICA
Although ethambutol and pyrazinamide are used, they are not 
regarded as reliable, and 50 percent of cases of MDR TB in chil-
dren are resistant to ethambutol.2
• Group 2—Second-line injectables: kanamycin, amikacin, and 
 capreomycin. The reason for using amikacin is that it causes 
fewer side effects in children, and the doses are relatively easy to 
administer.
• Group 3—Fluoroquinolones: although said not to be suitable for 
children, maximum doses are used. These are very important drugs 
in MDR TB therapy.
• Group 4—Second-line oral bacteriostatic drugs: split into two 
doses per day initially to alleviate any adverse effects.
• Group 5—Drugs that have an unclear role in the treatment of drug-
resistant TB. Linezolid and clarithromycin are sometimes used, 
although they are very expensive and difficult to obtain.
Schaaf emphasized the importance of documenting and trying to prevent 
adverse effects associated with these drugs. About 30 percent of children 
have experienced hearing loss, and a high percentage have developed hypo-
thyroidism. Other common adverse effects in adults are not common in 
children.
The optimal duration of treatment in children is still unknown.  Cavitary 
or extensive pulmonary TB needs to be treated as for adults. Primary, non-
cavitary MDR TB is often culture negative, and treatment for 12 to 15 months 
should suffice. Treatment in the intensive phase includes a  second-line inject-
able drug, which is usually discontinued in the continuation phase.
Schaaf said health care providers have become more aware of potential 
adverse effects of drug treatment in children and need to monitor patients 
carefully to detect such effects and determine when the drugs must be 
stopped. The World Health Organization (WHO) calls for the administra-
tion of drugs for 2 years, but Schaaf believes children can be treated for 
shorter times, particularly for early, paucibacillary disease. He has treated 
many patients for 12 months and has seen no relapses, but the length of 
treatment for each child needs to be evaluated individually. In addition, 
new drugs should be tested on children as well as adults, said Schaaf. 
Not enough is known about the pharmacokinetics and adverse effects of 
2  During the discussion period, Schaaf was asked whether he has noticed problems with 
vision in children caused by ethambutol. He responded that it is difficult to test vision in 
younger children, and only color charts are used. Studies have shown that as long as the dose 
of the drug is lower than 25 mg/kg, the chances of developing such problems are small, and 
none of Schaaf’s patients have had adverse reactions related to vision. Ethambutol is used in 
drug-resistant as well as drug-susceptible cases since isoniazid resistance is very high in the 
Western Cape.
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drugs in children, including their interactions with antiretrovirals. Finally, 
management of children and adolescents to ensure compliance with drug 
regimens is necessary.
MANAGEMENT OF PEDIATRIC DRUG-RESISTANT TB
The management of MDR TB in children should be carried out as 
 follows, according to Schaaf:
• Confirm MDR TB if at all possible.
• If MDR TB is confirmed, also do drug susceptibility testing for 
second-line drugs.
• Manage cases at a specialized MDR TB clinic.
• Use first-line drugs to which the isolate is susceptible plus second-
line drugs, taking into account that 50 percent of cases of MDR 
TB in children are resistant to ethambutol.
• Be aware of different drug groups and cross-resistance.
• Recognize that second-line drugs are generally more toxic than 
first-line drugs.
• Recognize that adverse events can be more difficult to assess in 
children than in adults.
• Be mindful of the difficulty of preserving the correct dosage when 
breaking tablets up to make them easier for the child to swallow.
• Isolate children who are infected with TB. In practice, this can be 
difficult since the adults accompanying children are often infected 
with MDR or XDR TB but not diagnosed.
Schaaf outlined the following principles of childhood MDR TB treatment:
• Directly observed therapy with daily treatment is essential.
• Three, four, or more drugs to which the patient’s isolate is suscep-
tible and/or naïve should be administered, depending on the extent 
of the disease.
• If a treatment regimen is failing, a single drug should not be added 
(combination therapy should be used).
• The drug susceptibility test pattern of the adult index case’s isolate 
should be used if no isolate from the child is available.
• Patients, parents, and family members should be counseled at every 
visit with respect to adverse events and the importance of adher-
ence to treatment, as well as to offer support.
• It is essential to ensure that follow-up occurs, including clinical and 
radiological follow-up, as well as cultures.
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OUTCOMES OF PEDIATRIC DRUG-RESISTANT TB
Very few studies have reported on the outcomes of drug-resistant TB 
in children. One such study is from Peru, where 36 of 38 MDR TB cases 
were cured (Drobac et al., 2006). Another, conducted in South Africa in 
2003, showed that of 39 confirmed MDR TB cases, the majority were 
clinically cured (Schaaf et al., 2003). More data on morbidity and long-
term  mortality in children, as well as on HIV-infected and HIV-uninfected 
children, are needed, said Schaaf.
Asked about the mortality figures for children with MDR and XDR 
TB, Schaaf replied that data since 2003 show 150 culture-confirmed cases 
of MDR TB, with a mortality rate of about 10 percent. There are currently 
6 confirmed XDR TB cases, 3 with culture confirmation and 3 having had 
contact with adults with XDR TB. Schaaf said he has not had a child die 
from XDR TB. 
Schaaf emphasized that if children are treated incorrectly when there 
is a known adult index case with MDR TB in the household, much lung 
 damage can be done, leading to chronic lung disease. He suggested that 
mortality and morbidity should both be examined in looking at the out-
comes of pediatric patients with MDR TB.
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Convergence of Science and Policy 
to Create a Blueprint for Action
In the final session of the workshop, Enriqueta Bond and Salim Abdool 
Karim summarized the major conclusions and recommendations offered by 
the speakers. A panel consisting of Gail Cassell; Norbert Ndjeka, Depart-
ment of Health, South Africa; Sidney Parsons,1 Council for Scientific and 
Industrial Research (CSIR); Janet Tobias, Ikana Media; and Martie van 
der Walt, then raised additional issues and responded to questions from 
workshop participants. This chapter synthesizes the points made, as well 
as a number of individual suggestions for actions to address urgent needs 
related to drug-resistant TB, in the areas of epidemiology, infection con-
trol, diagnostics, treatment, pediatric TB, research needs, and the need for 
partnerships. It should be noted that this synthesis is offered as part of the 
factual summary of the workshop, and should not be construed as reflect-
ing consensus or endorsement by the workshop, the Drug Forum, or the 
National Academies.
EPIDEMIOLOGy
Bond stated that the alarming epidemiology of MDR and XDR TB 
creates a new urgency for action. Drug-resistant TB is a difficult-to-treat 
disease that is spreading in the community and is exacerbated by HIV infec-
tion. Growing evidence that drug-resistant TB is being transmitted from 
person to person supports the conclusion that the number of cases seen in 
southern Africa are only the visible portion of a much larger phenomenon.
1  Deceased.
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Abdool Karim remarked that, as Friedland’s presentation highlighted, 
when patients are placed on antibiotics, pressure to select resistance grows. 
The experience in Tugela Ferry (Chapter 2) illustrates the person-to-person 
spread of drug-resistant TB and the fact that fatalities can occur quickly 
following infection with XDR TB, particularly among patients with HIV 
coinfection. Abdool Karim added that a steady increase in resistance even-
tually will make TDR TB a serious and common problem. Cassell com-
mented that another disturbing observation is the 60 percent rise in XDR 
TB incidence rates in the Eastern Cape. 
As Chaisson noted, a good definition of TDR TB in terms of either the 
molecular detection of resistant genes or clinical failures does not yet exist. 
According to Abdool Karim, given the variability in drug susceptibility test-
ing among patients in the region, susceptibility testing on second-line drugs 
is not necessarily a good way to define TDR TB. Instead, the definition of 
TDR TB could be based on a clinical diagnosis after failure of treatment 
for MDR/XDR TB. A workshop participant stressed the importance of 
accurately measuring the magnitude and distribution of the spread of TDR 
TB as part of efforts to confront and reverse the epidemic.
INFECTION CONTROL
Improved infection control and contact tracing could lower morbidity 
and mortality from drug-resistant TB and lead to the treatment of many 
more cases. In addition, the creation of a culture of safety through infection 
control policies could provide greatly increased protection for patients and 
health care workers. Abdool Karim stated that infection control should be 
a part of every TB intervention and needs to begin when a patient is identi-
fied, diagnosed, and hospitalized. To support infection control, there is a 
need for further investigation of the mechanisms and sites of the spread of 
TB within communities, said Abdool Karim, and once infection control 
measures have been implemented, it will be important to evaluate their 
effectiveness and make them more broadly available. Improvement in the 
safety of existing health care facilities is warranted, as is incorporation of 
infection control in the design and construction of new health care facilities.
An important problem is the lack of district nurses to visit schools and 
homes. Part of the solution, Cassell suggested, could be to train community 
workers to become specialists in infection control, with a certificate pro-
gram that could offer practical training and raise the profile of the role of 
the community worker. When community health workers are paid, trained, 
and qualified, they can help ensure that everyone becomes an active partici-
pant in health care. Abdool Karim highlighted Lawn’s remarks that contact 
tracing should be part of all TB programs and should include TB education 
as a component of the intervention.
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Abdool Karim added that, as noted in Thotolo’s presentation, better 
systems are also needed for the prevention, diagnosis, and treatment of TB 
and HIV for special populations, including mine workers, ex-miners, and 
their families; incarcerated populations; and others in difficult-to-reach 
congregate settings. In addition to health care interventions, it is essential 
to address the legal, human rights, and socioeconomic issues affecting TB 
and HIV control among these populations.
DIAGNOSTICS
Abdool Karim noted that, in the discussions about diagnostics, it 
became clear that additional screening mechanisms and new assays, includ-
ing point-of-care TB diagnostics, could transform the ability to deal with 
drug-resistant TB. Developing these tools will require a greatly expanded 
research effort. At the same time, current diagnostic approaches require safe 
laboratory infrastructure to protect against drug-resistant TB. Bond added 
that meeting the pressing need for laboratory and health care infrastructure 
will require ongoing, long-term capacity building. 
Parsons added that unsuspected cases are a danger. These cases are 
causing great concern and putting health care workers, communities, and 
households at risk. Parsons suggested that a process for making interim 
diagnoses while awaiting the results of more detailed yet time-consuming 
diagnostics is needed to identify potential TB cases and the strains involved 
so health care workers can assist with managing patients in the community.
TREATMENT
Although the cure rate of MDR TB in South Africa and surrounding 
countries remains uncertain, drug-resistant TB clearly is not being managed 
well enough, suggested Ndjeka. Abdool Karim highlighted the growing 
prevalence of resistance to multiple agents and the especially dire observa-
tion that increasing numbers of isolates are resistant to ten key anti-TB 
drugs. A workshop participant noted that the field of therapeutics for drug-
resistant TB has been neglected, and there is a lack of adequate evidence 
to guide best practices in treatment. Thus, there is a critical need for basic, 
translational, clinical, and operational research in this area. As Barry sug-
gested, the available evidence must be carefully weighed to determine the 
sequence in which various antibiotics should be used to avoid resistance 
while taking into account that cost is also an issue in the choice of drugs. 
In addition, Abdool Karim remarked, Friedland’s presentation highlighted 
that the default rate must be addressed if a reasonably high cure rate is to 
be achieved. Good adherence to treatment and prevention of person-to-
person spread of drug-resistant TB are essential to controlling the disease.
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Cassell remarked that existing drugs need to be used to maximum 
effect through the application of available evidence and the results of 
micro biological and pharmacokinetic studies. In the discussion of Schaaf’s 
experience in treating children with TB (Chapter 7), it was suggested that 
pediatric MDR and XDR TB cases should be treated for 12 months, not 
24 months as stipulated by the World Health Organization (WHO). A par-
ticipant observed that, given the adverse effects of second-line drugs, this is 
an important suggestion, but it needs to be confirmed by rigorous studies. 
Another suggestion was that drugs used for cross-resistance be reserved for 
later in treatment regimens. One workshop participant recommended that 
a group of experts be convened in South Africa to study side effects and 
cross-resistance.
Van der Walt noted that individualized regimens based on drug sensitiv-
ity testing and drug toxicity have become necessary, but in reality, manage-
ment of MDR TB must be both simplified and decentralized to clinics and 
other sites, and treatments for TB and HIV need to be integrated. This is a 
challenge for clinics, one that requires translating policies into practice and 
applying research evidence in the field. Health care workers will also need 
training in the diagnosis and treatment of coinfection with HIV, according 
to van der Walt.
Parsons remarked that funding of $13−$15 million was recently 
received to increase bed capacity in South Africa. Models are being devel-
oped for treatment facilities, most of which will be built to have seven 
units, each with 40 beds. A minimum of 280 additional beds will be 
available by December 2010. These beds should be used specifically for 
intensive-phase treatment and for initial management of patients. How-
ever, even these new facilities will not be adequate for the hospitalization 
of MDR and XDR TB patients, according to Parsons. Van der Walt added 
that, according to South Africa’s current policy, MDR TB patients must be 
hospitalized until culture conversion. Hospitalization provides the patient 
and the family with treatment management and aids their well-being, 
and the additional beds will be extremely beneficial. With the increasing 
numbers of MDR TB cases, however, there will continue to be a shortage 
of beds. 
A related problem is that the success rate of MDR TB treatment within 
6 months at a facility is extremely low. Gandhi commented that document-
ing a negative culture means that 10 weeks must pass before results are 
returned, which doubles the duration of a typical hospital stay. Defaulters 
are often stigmatized, but in reality the structure makes it very difficult for 
them to adhere to treatment.
Parsons added that being a patient in a typical facility for 10 months 
or more is difficult to imagine. While the treatment is good, the hospital 
environment is not the best place for healing the patient. The process 
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needs to be humanized, with attention to patients’ dignity and comfort, 
good meals, and the like, and for most patients, particularly from rural 
areas, closer proximity to their families and loved ones. A comprehensive 
approach, including outpatient and community-based treatment and care 
management, is warranted.
Coetzee commented that patients can be treated effectively and 
humanely within the community. However, discharging TB patients into 
the community poses a risk. Patients should not be discharged until appro-
priate structures are in place to provide adequate treatment and care, 
especially since DOTS supporters are already overburdened. Gandhi stated 
that parts of KwaZulu-Natal Province have made the necessary transition 
to community-based care over the last few years. In 2007, as a result of the 
overwhelming burden of MDR TB, many people were receiving outpatient 
treatment in an informal way. Since then, care has been decentralized to 
centers, to communities, and to homes. When this is done in a structured 
way, as has been the case in Tugela Ferry, outcomes are very good. In Tugela 
Ferry, an intensive monitoring system is in place, with teams that visit 
patients’ homes. Community health workers who are doing the monitoring 
are paid, which has made a difference. 
Parsons noted that one problem with community-based care is that 
many different types of communities exist in southern Africa. For example, 
although more study is warranted, community-based care programs appear 
more likely to succeed in rural communities than in informal settlements. 
As another example, work in the Eastern Cape to understand the dynamics 
of rural communities has uncovered a network of traditional leaders and 
healers who will need to be included in community- and home-based care. 
Because of the diversity of communities, Parsons said, a multidisciplinary, 
community-appropriate approach is needed to combat the disease.
Ndjeka remarked that the first draft of a policy to decentralize MDR 
TB treatment in South Africa has been circulated, but more input and con-
sultation are needed. Because of the diversity of South Africa, each prov-
ince will have different needs in implementing the policy, with a standard 
package of requirements being made available across all programs. More 
generally, said Ndjeka, the actions necessary to control the epidemic need 
to be clearly articulated, and a plan for moving forward, including costs, 
needs to be formulated at the highest levels of government.
XDR TB cases will continue to pose great therapeutic challenges. The 
burden of untreatable cases needs to be assessed based on the available 
scientific and medical evidence, as do the reasons for these cases being 
potentially untreatable. Van der Walt noted that new policies could raise 
human rights concerns and foster public panic; nevertheless, the extent of 
the problem needs to be communicated, and policy makers will need assis-
tance with the ethical issues associated with untreatable cases.
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Abdool Karim noted that the presentations highlighted the challenge 
of managing TB−HIV coinfection. He suggested that both diseases should 
be treated concomitantly, and systems of care for each should be better 
integrated. Separation of TB and HIV treatment reduces the likelihood of 
therapeutic success and survival of patients. As Lawn suggested, antiretro-
viral therapy should be initiated immediately in all HIV-positive individuals 
irrespective of CD4 count to lessen vulnerability to TB infection. Studies 
are under way to test this hypothesis.
Finally, Ndjeka noted that WHO’s review of the South Africa TB 
program in 2009 found that the management of MDR TB in the country 
does not comply with WHO guidelines. Indeed, it does not comply with 
the guidelines of the country’s own Department of Health. Monitoring and 
evaluation are not being performed efficiently, the time required for inject-
able drug treatments contributes to defaulting, and patients and communi-
ties need more information about MDR TB. 
PEDIATRIC TB
According to Bond, a key problem identified during the workshop was 
that an increasing number of children in southern Africa are contracting 
drug-resistant TB, mainly through transmission. Children serve as sentinels 
of the burden of disease, but knowledge of the sources of transmission and 
of what drug regimens are best for children, as well as pregnant women, is 
still lacking. Policies and strategies need to accommodate specific situations 
and scenarios, suggested Bond.
Abdool Karim remarked that as treatment is decentralized not just 
into district-level facilities but into community-based care, special popula-
tions such as children and pregnant women may be easier to reach. One 
way to improve identification of TB in children is to take a full history of 
all adult TB cases, including screening for TB in child contacts. Counsel-
ing of patients, parents, and family members at every visit would provide 
support and information about adverse events and the importance of 
adherence to treatment and follow-up. TB in children could be treated 
according to the results of drug susceptibility tests of the adult source 
case until the results of the child’s own culture and drug susceptibility 
tests were available. Improved pediatric diagnosis is a priority, as most 
cases are treated empirically without microbiological confirmation and 
thereby go unrecognized.
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RESEARCH NEEDS2
Over the course of the workshop, individual participants suggested a 
number of research questions that, in their judgment, need to be pursued, 
such as the following:
• How many cases of drug-resistant TB are occurring in south-
ern Africa that are not being diagnosed? How can diagnosis be 
improved?
• What is the current extent of MDR, XDR, and TDR TB? How can 
cases be identified more rapidly?
• What is the benefit of intensive case finding in health care facilities 
and community settings in terms of earlier detection, improved 
outcomes, and reduced transmission of drug-resistant TB?
• How should information systems be developed and implemented 
for the management of laboratory and surveillance data?
• What are the best available and future treatment regimens? How 
can clinical trials be designed and executed to test existing drugs, 
new drugs, and drug combinations to optimize treatment of MDR 
and XDR TB?
• How can TB programs be strengthened and suboptimal adherence 
to treatment regimens be addressed?
• What are the cure rates for MDR and XDR TB?
• What proportion of cases can be attributed to health care facilities, 
transmission in the community, or evolution of the organism?
• How can preventive, diagnostic, and therapeutic operations in 
health care facilities, including infection control, be changed and 
improved? How can steps to that end be taken in lower-level hos-
pitals, and how can households be reached?
• How can the protection of health care workers be enhanced?
THE NEED FOR PARTNERSHIPS
Bond and Abdool Karim offered closing remarks addressing the need 
for partnerships and multidisciplinary approaches to the problem of drug-
resistant TB. Bond stated that TB is not just a medical problem. Many of 
the challenges involve social issues such as poverty, migrant labor, over-
crowding, poor nutrition, and inadequate ventilation. Solutions entail not 
just new diagnostics, vaccines, and treatments but also behaviors of patients 
2  The workshop held by the National Institute of Allergy and Infectious Diseases (NIAID), 
National Institutes of Health, in Pretoria, South Africa, 2 days prior to the Drug Forum’s 
South Africa workshop reviewed the latest TB research and highlighted areas for further 
research. A summary of this meeting can be found in Appendix C.
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and health care workers, health systems, political commitments, and social 
mobilization. Ultimately, as has been the case in developed nations, address-
ing issues of health disparities and social inequities that lie at the root of TB, 
drug-resistant TB, and HIV will be necessary to combat these convergent 
epidemics successfully. Actions taken today can help prevent the crisis from 
worsening. A sense of urgency needs to be communicated to the public and 
policy makers to mobilize efforts against MDR and XDR TB, said Bond. 
Central to fostering this agenda is the creation of a strong patient advo-
cacy culture to champion the need for increased resources, help educate 
the  public and policy makers, and raise awareness of human rights issues.
Abdool Karim remarked that the patient, the community, and the fam-
ily must be regarded as partners if information about TB is to be communi-
cated successfully. This information often needs to be provided proactively, 
with the proper balance of fear and awareness. Different advocacy partners 
are needed at different levels. Members of the scientific and medical com-
munities must communicate the realities of drug-resistant TB to the public 
and to policy makers, and they must translate data into policies commen-
surate with the magnitude of the problem, said Abdool Karim.
Bond concluded that the collaboration of the IOM and ASSAf at this 
workshop demonstrates the need for as well as the potential benefit of 
engaging neutral bodies to assess the evidence; build and share expertise; 
and prepare medical and educational institutions to play roles in preven-
tion, diagnosis, treatment, training, and research. Bond noted that ASSAf is 
in an excellent position to continue to convene groups to address the issues 
surrounding MDR and XDR TB and to solicit the input of a broad array 
of groups that include patients; health care workers; public health officials; 
policy makers; the academic community; and groups from the sectors of 
industry, government, academia, and advocacy.
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With the development of antibiotics in the twentieth century, tuberculosis 
gradually lost its central position as a global health concern—it was consid-
ered a disease of the past or one that was only associated with the extreme 
poverty of the developing world. However, this view of tuberculosis is out 
of date. 
Tuberculosis is today one of the leading causes of death in the world—
4,500 people die daily from the disease. Although many cases of TB can 
be cured by available antibiotics, multidrug-resistant TB (MDR TB) is a 
major and growing threat worldwide. Strains of TB resistant to even the 
second-line therapies (XDR TB) are documented in over 50 countries, 
including the United States, and we are seeing the emergence of strains 
that are fully resistant to treatment. And while the epidemic of TB is still 
primarily centered in the developing world, the reach of MDR extends to 
every continent, including both rich and poor countries. The global battle 
against TB, once thought won, is today very real. 
The Institute of Medicine (IOM) Forum on Drug Discovery, Develop-
ment, and Translation is conducting a series of workshops in the United 
States and in high-burden countries—including South Africa, Russia, 
China, and India. The first workshop, held in November 2008, included 
experts from around the world, and was framed by a commissioned paper 
developed by Partners in Health that provided new data on the nature and 
spread of MDR TB. In addition, in February 2009, the Forum held a public 
briefing on MDR TB for Congressional staff in Washington, DC. Details of 
both meetings, including the agendas and speaker presentations, are avail-
able on the Forum’s website (www.iom.edu/drug).
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IOM is partnering with the Academy of Science of South Africa (ASSAf) 
to convene a 2-day workshop on MDR TB. The workshop will bring 
together disease experts, community leaders, policy makers, and patient 
advocates to examine the state of MDR TB in the South Africa region, to 
learn from the experiences of the South African public health community in 
its fight against MDR TB, and to draw lessons regarding best practices and 
novel approaches that can be applied both within and beyond the region. 
Proceedings of the workshop will be published and disseminated globally. 
The South Africa meeting will focus on various aspects of MDR TB:
1. Epidemiology. The latest information on the spread of MDR/XDR 
TB in Africa and globally, including the nature of the coinfection 
with HIV, will be presented and discussed.
2. Diagnostics and Preventive Therapies. The challenges associated 
with rapid diagnosis of TB and resistance testing in resource- 
constrained environments will be explored, as well as opportunities 
for expansion of laboratory capacity and point-of-care diagnosis.
3. Treatment. The limitations of current treatment, including the 
capacity of current health systems to address the needs of TB 
patients, the limited numbers of patients receiving appropriate 
treatment, and challenges in treating migrant workers, will be 
examined. 
4. Transmission and Infection Control. The meeting will explore our 
growing understanding of the modes of transmission of MDR TB, 
and the strategies needed to address them.
5. Pediatric TB. The devastating spread of MDR TB among children 
and the unique challenges they pose for prevention and treatment 
will be explored. 
6. Policy. The workshop will analyze the effects of MDR TB beyond 
patients in order to highlight areas for improved policy and next 
steps. 
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 Breakfast and coffee will be served at this time.
9h00-9h30 Welcome and Opening Remarks
 Roseanne Diab, ASSAf
 Lerole David Mametja, Ministry of Health, South Africa
9h30-9h45  Perceptions vs. Realities: Summary of 2008 MDR TB 
Workshop in Washington, DC
 Gail Cassell, Eli Lilly and Company
9h45-11h45 Session 1: A Realistic Assessment of the Spread of MDR/
XDR TB in Sub-Saharan Africa with an Emphasis on 
South Africa
 Moderator: Gerald Friedland, Yale School of Medicine
 Capacity for Health Care Across Southern Africa and 
MDR/XDR TB
 Tomas Zimba, Maputo Central Hospital, Mozambique
 Evolution of XDR TB in KwaZulu-Natal
 Willem Sturm, Nelson Mandela School of Medicine, 
University of KwaZulu-Natal
 Prevalence of Drug Resistance at the Initiation of 
Second-Line Drugs and Existence of Totally Drug-
Resistant TB
 Martie van der Walt, Medical Research Council of South 
Africa
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 Putting Resistance in Perspective: The Korean Experience 
and Polymorphisms Associated with Resistance and 
Cross Resistance
 Clifton Barry, National Institutes of Health
11h30-11h45 Discussion with Audience 
11h45-12h45 LUNCH
12h45-13h45 Keynote Address 
 Moderator: Janet Tobias, Ikana Media
 Epidemiology and Management of MDR TB in Children
 Simon Schaaf, Department of Paediatrics and Child 
Health, Stellenbosch University
13h30-13h45 Discussion with Audience
13h45-15h15 Session 2: Coinfection with HIV/AIDS: Clinical 
Outcomes and Consequences
 Moderator: Richard Chaisson, Center for Tuberculosis 
Research, Johns Hopkins University
 Tugela Ferry Experience in a Community Hospital
 Neel Gandhi, Tugela Ferry Care and Research 
Collaboration (TF CARES) 
Albert Einstein College of Medicine 
 Outcomes from TB Referral Hospitals, KwaZulu-Natal
 Nesri Padayatchi, University of KwaZulu-Natal
 Outcomes from the Eastern Cape
 Charlotte Kvasnovsky, Medical Research Council
 Mortality and Causes of Death in South Africa
 Maletela Tuoane-Nkhasi, Statistics South Africa
15h00-15h15  Discussion with Audience
15h15-15h30 BREAK
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15h30-17h00 Session 3: Alternative Strategies 
 Moderator: Robin Wood, University of Cape Town
 Community-Based Care
 Kristina Wallengren, Medical Research Council
 ART for the Prevention and Treatment of MDR TB
 Stephen Lawn, University of Cape Town
 Intensified TB Case Finding Among HIV-Infected 
Patients
 Sabine Verkuijl, International Center for AIDS Care and 
Treatment Programs (ICAP-SA), Mailman School of 
Public Health, Columbia University
 South-to-South Assistance to Initiate MDR TB Care in 
Ethiopia (Note: via phone)
 Anne Goldfeld, Harvard University
16h45-17h00  Discussion with Audience
17h00  ADJOURN
18h00 Group Dinner for Speakers
Day 2
March 4, 2010
8h00-10h00  Session 4: Transmission and Strategies for Infection 
Control 
 Moderator: Neel Gandhi, Tugela Ferry Care and 
Research Collaboration (TF CARES)
 Proof of Principle: Transmission of MDR TB in the AIR 
Facilities
 Matsie Mphahlele, Medical Research Council
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 Epidemic in Tugela Ferry: Transmission and Impact of 
Infection Control
 Gerald Friedland, Yale School of Medicine (in place of 
Anthony Moll, Church of Scotland Hospital)
 Household Contacts
 Claudio Marra, Church of Scotland Hospital
 Careworkers
 Karen Shean, University of Cape Town
 Migrant Workers in Lesotho
 Maketekete Thotolo, Adventist Development and Relief 
Agency
 An Evaluation of Infection Control Infrastructure and 
Health Worker KAP in MDR/XDR TB Care Settings
 Jason E. Farley, Johns Hopkins University
9h45-10h00  Discussion with Audience
10h00-10h30 BREAK
10h30-12h15  Session 5: Application of Molecular Biology to Shape 
Policy 
 Moderator: Elaine Gallin, Doris Duke Charitable 
Foundation
 Drug-Resistant Genotypes: Implication for Point-of-Care 
Detection of Resistance in Different Geographies 
 Paul van Helden, Stellenbosch University
 Genetic Analysis of Drug-Resistant Strains in South 
Africa
 Robin Warren, Stellenbosch University
 Bench to Bush in Biomarker Studies in Africa: 
Implications for MDR TB Treatment and Drug 
Development
 Shreemanta Parida, Max Planck Institute for Infection 
Biology, Berlin, Germany
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12h00-12h15 Discussion with Audience
12h15-13h00 LUNCH
13h00-14h15  Session 6: How Close Are We? 
 Moderator: Martie van der Walt, Medical Research 
Council of South Africa 
 Current Status of Diagnostics Globally for the Detection 
of Drug Resistance with Emphasis on Point of Care 
 William Jacobs, Einstein School of Medicine
 Challenges in Laboratory Capacity in Diagnosing Drug-
Resistant TB in South Africa
 Gerrit Coetzee, National Health Laboratory Services, 
South Africa
 Information Solutions to Enhance Laboratory Capacity 
in Evaluation of New Diagnostics and Therapies 
 Dale Nordenberg, Novasano Health and Science
14h00-14h15  Discussion with Audience
14h15-15h15 Session 7: Research Gaps, Priorities, and Opportunities—
Report from NIH Workshop
 Valerie Mizrahi, National Health Laboratory Service
 Barbara Laughon, National Institutes of Health
15h00-15h15  Discussion with Audience
15h15-15h30  BREAK
15h30-16h45 Session 8: Convergence of Science and Policy to Create a 
Blueprint for Action
 Moderator: Queta Bond, Burroughs Wellcome Fund 
(retired) 
 Where Are We and Where Do We Go from Here?
 Salim Abdool Karim, University of KwaZulu-Natal
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 Panelist Response:
  Gail Cassell, Eli Lilly and Company
  Norbert Ndjeka, Department of Health, South Africa
  Sidney Parsons, Council for Scientific and Industrial 
Research




Report from the  
National Institute of Allergy and 
Infectious Diseases (NIAID) Workshop
On March 1 and 2, 2010, during the 2 days before the workshop sum-
marized in this volume, NIAID held the United States−Southern Africa Joint 
Research Forum on Tuberculosis in Pretoria, South Africa. The purpose of 
the workshop was to discuss research on TB that is taking place in south-
ern Africa, to identify opportunities for collaboration within both South 
Africa and its neighboring countries, and to explore opportunities for col-
laboration between southern African countries and the United States. The 
highlights of that workshop were presented during the proceedings of the 
Institute of Medicine (IOM)−Academy of Science of South Africa (ASSAf) 
workshop by Valerie Mizrahi of the National Health Laboratory Service 
and University of Witwatersrand and Barbara Laughon of the National 
Institutes of Health, and are summarized below.
THE INCIDENCE OF DRUG-RESISTANT TB
• HIV is a key driver of the TB epidemic in southern Africa, bringing 
about a six-fold increase in incidence in South Africa, Lesotho, and 
Swaziland.
• There is a large burden of undiagnosed TB in the community.
• The same epidemiological model cannot be used for TB and HIV 
epidemics in different countries.
1  This Appendix B summarizes the presentation made by Valerie Mizrahi of the National 
Health Laboratory Service and University of Witwatersrand and Barbara Laughon of the 
National Institutes of Health.
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THE TRANSMISSION OF DRUG-RESISTANT 
TB AND INFECTION CONTROL
• Most TB disease, both drug-sensitive and drug-resistant, is 
recently transmitted via social interactions away from the house-
hold. Thus, there is a need to understand the adult and childhood 
social networks in South African townships that contribute to TB 
transmission.
• Surrogate biomarkers are essential for public health interventions.
• Transmission and infection need to be studied intensively. 
• A TB control program must be able to rapidly identify cases and 
commence therapy.
• Operational research and implementation science are needed to 
enhance feasible and available infection control strategies and sup-
port the development and testing of new approaches. 
THE MOLECULAR EPIDEMIOLOGy OF DRUG-RESISTANT TB
• Strains of TB are more diverse than previously appreciated.
• The immense amount of variation occurring between strains sug-
gests that purifying selection is reduced in Mycobacterium tuber-
culosis (M.tb.).
• Strain variation is extensive within individual study sites and across 
regions, with the University of Stellenbosch group reporting more 
than 150 strains per square kilometer in the study areas.
• The population structure of M.tb. is highly variable, with a domi-
nance of Beijing genotype (both typical and atypical) being uncov-
ered in some study areas and playing a major role in driving drug 
resistance in South Africa. Intriguingly, Beijing strain has not (yet) 
been observed in Zambia, and the KZN strain predominates in 
XDR TB cases in that area.
• DNA sequence data are highly informative and will soon be the 
standard for molecular epidemiology.
• Although genetic and molecular epidemiology is powerful, it has 
been studied only in some areas of the region.
DIAGNOSING DRUG-RESISTANT TB
• While new diagnostics could detect 400,000 cases each year, the 
realities of using new versus current diagnostics need to be taken 
into account.
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• Novel diagnostics being evaluated in Africa, all of which have 
 various advantages and disadvantages, include
 — Light emitting diode (LED) microscopy
 — GeneXpert
 — Line probe assay (LPA)
 —  Urine lipoarabinomannan (LPA) immunochromatographic (ICT) 
strip test
 — Interferon-gamma release assay (IGRA)
 — Microscopic observation drug susceptibility (MODS)
• Key questions beyond the performance characteristics of a new 
diagnostic involve delivery, roll-out, and scale-up, as well as the 
impact on patient outcomes, program performance, the burden of 
disease, and global TB control.
• The experience of the National Health Laboratory Service in mov-
ing from validation of new technology to roll-out of the LPA was 
illuminating. Fitting the LPA into an algorithm for TB diagnosis 
and the development of an algorithm for early detection of MDR 
TB involved several challenges:
 —  the plan to roll out the LPA to an additional 20 laboratories 
by December 2010;
 —  requirements for laboratory space, equipment, staff recruit-
ment training, the implementation of the assay, and review of 
its success;
 —  preparation for the roll-out of GeneXpert to four additional 
laboratories later in 2010; and
 —  human resource limitations particular to South Africa, some of 
which relate to policy.
• the GeneXpert M.tb./Rifampicin test is being evaluated in five 
countries with differing HIV and MDR TB status.
• The search for TB antigens is under way for a proof-of-concept 
test.
• The Foundation for Innovative New Diagnostics has 20 trial sites 
for TB diagnostics in Africa.
• The establishment of more laboratories and the development of 
proof-of-concept tests should not be viewed as mutually exclusive.
• Molecular diagnostic technology is moving toward being less com-
plex and more robust, with the potential for a proof-of-concept 
diagnostic in 2015.
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THE TREATMENT OF DRUG-RESISTANT TB
• Many drug-resistant TB cases are untreatable with existing or 
available antibiotics.
• New drug regimens are needed now to treat drug-resistant TB. In 
particular, combination therapy is needed with new classes of drugs 
and novel mechanisms of action.
• Better tolerability, less toxicity, and shorter treatment courses are 
needed.
• Three to four new drugs need to be developed against which resis-
tance is not established.
• The number of new drugs that have novel targets and mechanisms 
of action is not adequate. More basic research is needed to increase 
the number of compounds entering the pipeline. In particular, there 
are gaps in candidates with preclinical safety.
• Going from discovery to the launch of a successful drug takes 10 
to 15 years. Five to 10 new entities generally need to enter human 
trials to yield one drug that will be safe, sufficiently effective, and 
affordable to be used for TB treatment. The estimated cost of a new 
entity is $1−$1.5 billion. Most of the drugs are being developed by 
public−private partnerships and by philanthropic organizations.
• There is a huge R&D funding gap. More funds are needed to facili-
tate preclinical development, to build capacity at trial sites, to per-
form clinical trials, and to provide enabling infrastructure.
• In terms of pharmacology and pharmacokinetics, there is a need to 
optimize dosing in neglected subpopulations, such as children and 
pregnant women. This goal can be facilitated by new technology.
• Surrogate markers to monitor response to therapy quantitatively 
are critically needed. Large cohorts are required to validate bio-
marker studies of treatment efficacy, relapse, and latent TB infec-
tion and should be built into drug trials.
• The pulmonary route of delivery is underexplored. Preliminary 
work suggests that the formulation of TB drugs and vaccines as 
spray-dried powders using large porous particles for inhaled deliv-
ery holds promise in the future.
• Directly Observed Treatment Short Course (DOTS) coverage is 
reasonably good in the African region but is clearly inadequate to 
curb the epidemic.
• The Malawi Public Health system offers lessons in best practice.
• Botswana has close-to-universal access to antiretrovirals and IPTG 
(isopropyl-β-D-thio-galactoside), which may be a reason for the 
slight reduction in the case rate there. An important message from 
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the latest Botswana study is that there is no evidence for isoniazid 
preventive therapy fueling isoniazid resistance.
• An African regional collaboration is essential in order to:
 —  establish a clinical trials network for TB treatment and preven-
tion regimens,
 —  establish more registration-qualified clinical sites with adequate 
laboratories for future Phase III efficacy trials, and
 —  establish regulatory agencies to harmonize and improve approval 
processes so that studies can be started more quickly.
• Regional collaboration also could make possible a “20 communities 
study” of regional epidemiology, including molecular epidemiology.
• A working group on new drugs is making information available on 
the website www.newtbdrugs.org.
VACCINES FOR TB
• The goal is for a new vaccine to be developed by 2016, with 20 
candidates in Phase 1 by 2015 and 9 in Phase II by 2018. These 
are ambitious targets.
• Highlights of the work done on immune responses induced by new 
vaccines include
 —  Novel boost vaccines induce T cells in distinct patterns.
 —  Differences in response may reflect an interaction with the 
innate immune system.
 —  Candidates differ in terms of local and systemic side effects.
 —  Patterns of immune activation may differ in infants and adults.
• Some points concerning biomarkers of protection were:
 —  Cytokine expression does not correlate with protection.
 —  Soluble IFNg levels do not correlate with protection.
 —  T cell expression of cytotoxic markers may delineate protection.
 —  Models based on combinations of markers may have value as 
biomarkers in the future.
 —  Unbiased approaches to biomarker discovery (such as gene 
expression profiles) need to be pursued.
• In terms of clinical preparedness for new vaccines, challenges include
 —  costs, site development, a lack of immunological correlates of 
protection, TB diagnoses in children, and the need for clinical 
end points for determining efficacy; and
 —  key issues regarding the regulatory environment.
• Important issues involving efficacy trials in HIV-infected and 
-exposed adults against TB include
 —  whether vaccines are safe and immunogenic, and
 —  the size of the sample required to achieve an efficacy outcome.
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• Sustained commitment and extensive collaboration are required 
within and between developed and developing countries.
DRUG-RESISTANT TB IN CHILDREN
• TB in children has been neglected; it is underreported and extremely 
difficult to diagnose, and has a limited evidence base on which to 
base treatment decisions.
• Diagnostics need to be child friendly, cost-effective, and operation-
ally feasible. Application in pediatric TB should be considered in 
the development of any new diagnostics as early as possible.
• New tools for clinical management, epidemiology, and surveillance 
are urgently needed, as is an end point for Phase III trials.
• Extra-short-course therapy is needed for less severe forms of TB in 
children, but needs confirmation.
• The value of targeted screening in high-risk populations needs to 
be explored.
• The degree of exposure needs to be assessed as a possible predictor 
of infection, persistent infection, or disease.
• Additional pharmacokinetic studies are needed in children.
• An Extrapulmonary TB Trials Consortium needs to be created.
CONCLUSIONS AND POLICy DISCUSSION
• Rapid and accurate drug sensitivity testing should be a prerequisite 
for the commencement of therapy, given the amplifying role of 
drugs in the evolution of resistant strains.
• The South African government should collaborate in the develop-
ment of capacity and infrastructure. There is only one supra national 
TB reference laboratory in the region, and there is insufficient capac-
ity to cope in the regional laboratories. In addition, the capacity to 
conduct clinical trials is very limited.
• Lessons can be learned from the HIV field, where major National 
Institutes of Health (NIH) grants for research have been linked with 
development and capacity development grants. Synergy between 




Salim S. Abdool Karim, MBchB, Ph.D., is pro vice-chancellor for research 
at the University of KwaZulu-Natal in Durban, South Africa. He is also 
director of the Centre for the AIDS Programme of Research in South 
Africa (CAPRISA), a professor at Columbia University, and an adjunct 
 professor at Cornell University. A clinical infectious disease epidemiolo-
gist, Dr. Abdool Karim performed research on TB and HIV treatment that 
shaped the current therapeutic approach to treating coinfected patients. He 
is coinventor of part of South Africa’s first HIV subtype C vaccine and sub-
sequently led the first HIV vaccine trial in South Africa. His recent research 
on microbicides showed that an antimicrobial gel may prevent HIV infec-
tion in women. Dr. Abdool Karim is chair of the World Health Organiza-
tion (WHO) Scientific Advisory Group for Reproductive Health and is 
a member of the WHO Expert Advisory Panel on Sexually Trans mitted 
Infections and HIV.
Clifton E. Barry, III, Ph.D., received his Ph.D. in organic and bioorganic 
chemistry in 1989 from Cornell University, designing and  synthesizing inhib-
itors to study the mechanism of a complex enzyme involved in  actinomycin 
D biosynthesis. He then spent 2 years doing postdoctoral research at The 
Johns Hopkins University in one of the leading laboratories involved in 
beta-lactam synthesis before joining the Intramural Research Laboratories 
of the National Institute of Allergy and Infectious Diseases in Hamilton, 
Montana, to study bacterial pathogens. After studying the pathogenesis of 
Chlamydia trachomatis, the leading cause of blindness in the developing 
world, he was given the opportunity in 1993 to start his own laboratory on 
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the pathogen of his choice—Mycobacterium tuberculosis (M.tb.). TB was a 
natural choice given the reemerging epidemic that was gaining public atten-
tion in the early 1990s and Dr. Barry’s increasing interest in global health. 
Over the next 5 years, his laboratory focused on understanding some of the 
basic biochemistry of the cell wall of TB, a rich source of potential drug tar-
gets. In 1998, Dr. Barry was tenured as chief of the Tuberculosis Research 
Section (TBRS) and relocated his laboratory to the main campus of the 
National Institutes of Health (NIH) in Maryland. In addition to his research 
group at NIH, with more than 30 members focusing on drug and diagnostic 
development, he has developed an active clinical research program in South 
Korea, where he has five ongoing trials with more than 700 participants. 
Dr. Barry’s group contributed to the development of PA-824, a new drug 
for TB now in Phase II clinical trials, and developed SQ109, another new 
TB drug now in Phase Ib trials. Dr. Barry is a member of several editorial 
boards and has authored more than 130 research publications on TB since 
entering the field. In 2009 he was named by ScienceWatch as the most 
highly cited researcher working in the field of TB.
Enriqueta C. Bond, Ph.D., retired in August 2008 as President of the 
 Burroughs Wellcome Fund (BWF), a private foundation whose mission is 
to advance the medical sciences through the support of research and educa-
tion. Dr. Bond is a founding partner of QE Philanthropic Advisors and now 
consults with philanthropic and nonprofit organizations on program devel-
opment and governance. Previously Dr. Bond served for nearly 20 years 
as staff officer and division director at the Institute of Medicine, National 
Academy of Sciences, serving as executive officer from 1989–1994. She 
serves on numerous board and advisory groups such as the Scientific Advi-
sory Committee on Stewardship for Research on Infectious Diseases of 
Poverty at WHO’s Program for Research and Training in Tropical Diseases, 
the NIH Council of Councils, the board and executive committee of the 
Hamner Institute for Health Sciences, the board of the Health Effects Insti-
tute and the James B. Hunt Jr. Institute for Educational Leadership. She 
currently chairs a National Academies Board on Developing the Capacity 
of African Academies of Science, is a member of the National Research 
Council (NRC) Committee on Research Universities, a member of a Task 
Force on the Organization of the National Academies, and serves as a 
frequent reviewer of Academy Reports. Dr. Bond previously chaired the 
Institute of Medicine Clinical Research Roundtable and was a member of 
the Council of the Eunice Shriver National Institute of Child Health and 
Human Development. Dr. Bond is a member of the Institute of Medicine 
and is a fellow of the Association for the Advancement of Science. She was 
educated at Wellesley College (A.B.), the University of Virginia (M.A.), and 
Georgetown University (Ph.D.) in genetics and molecular biology.
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Gail Cassell, Ph.D., is a Visiting Professor in the Department of Social Med-
icine, Harvard Medical School, and Vice President of TB Drug Discovery of 
the not-for-profit Infectious Disease Research Institute in Seattle. Dr. Cassell 
has recently retired as Vice President, Scientific Affairs and Distinguished 
Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company in 
Indianapolis, Indiana. In this capacity among other things, she was respon-
sible for initiating and leading the not-for-profit Lilly TB Drug Discovery 
Initiative launched in 2007. In 2003, she was one of two individuals at Lilly 
who initiated and developed the Lilly Multidrug Resistant Tuberculosis 
(MDRTB) Partnership. The partnership has resulted in company support 
to date of $135 million dollars and is the largest philanthropic effort in 
Lilly’s 125-year history. The partnership now involves over 20 partners, 
including WHO and CDC. She is the former Vice President of Infectious 
Diseases Drug Discovery and Clinical Development of Eli Lilly where she 
led the program of a hepatitis C protease inhibitor from the discovery phase 
to clinical candidate. The compound is now in phase III clinical trials under 
the direction of Vertex. Prior to moving to Lilly in 1997, Dr. Cassell was 
the former Charles H. McCauley Professor and Chair of the Department 
of Microbiology at the University of Alabama Schools of Medicine and 
 Dentistry at Birmingham, a department which ranked first in research fund-
ing from the National Institutes of Health during the decade of her leader-
ship. She obtained her B.S. from the University of Alabama in Tuscaloosa 
and in 1993 was selected by that institution as one of the top 31 female 
graduates of the 20th century. She obtained her Ph.D. in Microbiology from 
the University of Alabama at Birmingham and was selected as its 2003 
Distinguished Alumnus. She is a past President of the American Society for 
Microbiology (the oldest and single largest life sciences organization with a 
membership of over 42,000). She was named to the original Board of Sci-
entific Counselors of the Center for Infectious Diseases, Centers for Disease 
Control and served as Chair of the Board. She has served on the Advisory 
Board of the Director of National Institutes of Health, the Director of 
the Centers for Disease Control, and the Secretary of Health and Human 
Services Advisory Council of Public Health Preparedness, the FDA Science 
Board: Advisory to the Commissioner. Currently she is a member of the 
NIH Science Management Board, the newly appointed “NIH Board of 
Trustees” and the Advisory Council of the Fogarty International Center 
of NIH. Since 1996 she has been a member of the U.S.–Japan Cooperative 
Medical Science Program responsible for advising the respective govern-
ments on joint research agendas, (U.S. State Department/Japan Ministry 
of Foreign Affairs). She has served on several editorial boards of scientific 
journals and has authored over 350 articles and book chapters. Dr. Cassell 
has received national and international awards and two honorary degrees 
for her research in infectious diseases, including the CDC Honor Award in 
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Public Health for exceptional leadership and contributions in the develop-
ment and implementation of CDC’s Emerging Infectious Disease Plan 1997 
and a Citation from the FDA Commissioner for her role as chair of the 
review of science and technology at the FDA and the Report FDA: Science 
and Mission at Risk 2008 and the Emmy Klineberger-Nobel Award in 2008 
by the International Organization for Mycoplasmology for outstanding 
and sustained research contributions to the field of mycoplasmology. She 
is a member of the Institute of Medicine (IOM) of the National Academies 
and has recently completed a second 3-year term on the IOM Council, the 
governing board. Dr. Cassell has been intimately involved in establishment 
of science policy and legislation related to biomedical research and public 
health. For nine years she was chairman of the Public and Scientific Affairs 
Board of the American Society for Microbiology; has served as an advisor 
on infectious diseases and indirect costs of research to the White House 
Office of Science and Technology Policy, and has been an invited partici-
pant in numerous congressional hearings and briefings related to infectious 
diseases, antimicrobial resistance, and biomedical research. She has served 
two terms on the LCME, the accrediting body for U.S. medical schools as 
well as other national committees involved in establishing policies in train-
ing in the biomedical sciences. She is an  Emeritus Member of the Board of 
Research!America and a former member and Chair of the Board of Direc-
tors of the Burroughs Wellcome Fund. She has completed a term on the 
Leadership Council of the School of Public Health of Harvard University. 
Currently she is a member of the Morehouse School of Medicine Board of 
Trustees, Executive Committee of the Board of Visitors of Columbia Uni-
versity School of Medicine, the Advisory Council of the School of Nursing 
of Johns Hopkins, and the Advisory Council of the University of North 
Carolina Gillings School of Global Public Health.
Richard E. Chaisson, M.D., is professor of medicine, epidemiology, and 
international health and director of the Center for Tuberculosis Research at 
The Johns Hopkins University in Baltimore. His research focuses on TB and 
HIV infection, including global epidemiology, prevention, treatment, and 
public health interventions. He is principal investigator of the Consortium 
to Respond Effectively to the AIDS/TB Epidemic (CREATE), an interna-
tional research consortium funded by the Bill and Melinda Gates Founda-
tion to assess the impact of novel strategies for controlling HIV-related 
TB. Dr. Chaisson has published more than 350 scientific papers and book 
chapters. He was awarded the 2006 American Thoracic Society World Lung 
Health Award for his contributions to global control of pulmonary infections.
Gerrit Coetzee is a pathologist currently living in Johannesburg, South 
Africa. He is the head of the National Tuberculosis Laboratory (NTBRL) 
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at the National Institute for Communicable Diseases (NICD), a division 
within the National Health Laboratory Service of South Africa (NHLS). His 
main interests include anti-TB resistance within national program settings—
particularly MDR and XDR TB, the epidemiology of TB in high-burden 
settings, molecular epidemiology and outbreak investigations, and surveil-
lance of TB (especially MDR/XDR TB). He is currently managing a large 
2-year line probe assay (LPA) roll-out project in South Africa, aimed at the 
very early detection of MDR TB and early initiation of optimal treatment.
Roseanne Diab, Ph.D., is executive officer of the Academy of Science of 
South Africa (ASSAf) and a senior professor at the University of KwaZulu-
Natal in Durban. Her research interests are broadly based in the atmo-
spheric sciences, with a particular focus on air pollution and air quality 
management and climate change. Dr. Diab serves on the editorial board 
of the South African Journal of Science, the Clean Air Journal, the South 
African Geographic Journal, and Atmospheric Environment. She has served 
on a number of international commissions, including the Commission on 
Atmospheric Chemistry and Global Pollution and the International Ozone 
Commission. Dr. Diab is a fellow of the South African Geographical Society 
and of the University of Natal. She holds a Ph.D. in environmental sciences 
from the University of Virginia.
Jason E. Farley, Ph.D., M.P.H., CRNP, is an assistant professor at The 
Johns Hopkins University School of Nursing and a nurse practitioner in 
the Division of Infectious Diseases within The Johns Hopkins AIDS Service. 
He also holds an adjunct faculty appointment at Stellenbosch University 
in Cape Town, South Africa. Dr. Farley has been working in the arena of 
infection control for the past 10 years and is member of the Association of 
Professionals in Infection Control, as well as the Infectious Disease Society 
of America. He is presently on the editorial board of the American Journal 
of Infection Control. Dr. Farley’s current research is assessing the epide-
miologic interactions of patients with HIV and drug-resistant infections 
in both domestic (U.S.) and international settings. His research projects 
include an evaluation of treatment outcomes in patients with multidrug-
resistant (MDR) TB in the context of a high HIV/AIDS prevalence in South 
Africa in collaboration with the South African Medical Research Council 
(MRC). Further, his team recently completed a countrywide assessment of 
knowledge, attitudes, and practices related to infection control in MDR/
extensively drug-resistant (XDR) TB hospitals in South Africa. This project 
successfully enrolled 24 of these hospitals, 100 percent of such hospitals 
across all nine provinces of the country. In addition, his team enrolled 499 
health care workers across these sites. In the United States, Dr. Farley is 
working to assess methicillin-resistant Staphylococcus aureas (MRSA) colo-
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nization and infection among patients with HIV/AIDS in Maryland. He is 
also the principal investigator on a grant addressing adherence to guidelines 
for cardiovascular disease among providers of HIV care within The Johns 
Hopkins AIDS Service. 
Gerald Friedland, M.D., is professor of medicine and epidemiology and 
public health at Yale School of Medicine and adjunct professor at the 
 Mailman School of Public Health, Columbia University. He is a former 
member of the Governing Council of the International AIDS Society, 
National Advisory Council, Office of AIDS Research, and currently serves 
on the WHO HIV/TB Working Group, the NIH/NIAID−Department of 
Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for 
Adults and Adolescents, and the NIH International HIV Research Planning 
Group. He also serves as chairman of the board of directors of the Aaron 
Diamond AIDS Research Center in New York City. Dr. Friedland is actively 
involved in international research on HIV/AIDS and TB, with a major 
focus on the integration of care and treatment in coinfected patients and 
the aim of improving diagnosis, treatment, and outcomes for both diseases. 
This work has led to the uncovering of XDR TB as a major cause of death 
among HIV/TB coinfected patients in South Africa. With U.S. and South 
African colleagues, Dr. Friedland formed Tugela Ferry Care and Research 
(TF CARES), a clinical and research collaboration in rural KwaZulu-Natal. 
The work of TF CARES currently focuses on defining the epidemiology, 
reducing the transmission, and decreasing the morbidity and mortality from 
MDR and XDR TB. 
Elaine K. Gallin, Ph.D., is currently a senior advisor at the Doris Duke 
Charitable Foundation (DDCF). From 1999 through February 2010, she 
served as DDCF’s first program director for medical research, leading 
the creation and management of a portfolio of grant programs that has 
committed approximately $185 million to supporting clinical research. 
Dr. Gallin also designed and led the foundation’s $60 million African 
Health Initiative. Launched in September 2007, this initiative is supporting 
large-scale health service delivery projects in sub-Saharan Africa that are 
linked to rigorous operations and implementation research. Before joining 
the foundation, Dr. Gallin spent two decades, first as a research physiologist 
and then as a research administrator, with the U.S. government, last serving 
as deputy director of the Office of International Health Programs in the 
U.S. Department of Energy. She has participated on numerous professional 
committees and review panels. Currently, she is member of the board of 
directors of the Health Research Alliance (an alliance of non governmental 
research funders); the IOM’s Forum on Drug Discovery, Development 
and Translation; and the Sickle Cell Disease Advisory Committee at the 
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National Heart, Lung and Blood Institute. Dr. Gallin received her Ph.D. 
from the City University of New York and completed postdoctoral fellow-
ships at The Johns Hopkins University Medical School and Columbia 
University Medical School. 
Neel Gandhi, M.D., is an assistant professor of medicine and epidemiol-
ogy at Albert Einstein College of Medicine and Montefiore Medical  Center 
and a principal investigator in TF CARES. He has been engaged in clinical 
research on TB/HIV coinfection since 1998. In November 2006, he was the 
lead author for a study describing high rates of mortality in patients with 
XDR TB and HIV coinfection. This study has been credited for uncover-
ing a rapidly expanding MDR and XDR TB epidemic in South Africa. 
Dr. Gandhi continues to focus on the converging epidemics of drug-resistant 
TB and HIV in South Africa. A particular emphasis of his work is on elu-
cidating the role of primary transmission in the expansion of this epidemic 
and on developing optimal treatment strategies for MDR TB/HIV coinfected 
patients. Dr. Gandhi is currently funded through a Clinical Scientist Devel-
opment award and an Operations Research on AIDS Care and Treatment 
in Africa award from DDCF. These grants provide support to elucidate 
risk factors for developing MDR and XDR TB, to test the microscopic-
observation drug-susceptibility (MODS) assay (a rapid TB drug resistance 
assay) in a high HIV prevalence setting, to create a  community-based treat-
ment program for MDR TB in HIV coinfected patients, and to develop a 
comprehensive airborne infection control program in a rural district hos-
pital. Additionally, Dr. Gandhi is a coinvestigator on grants to expand TB/
HIV integration efforts in rural South Africa (President’s Emergency Plan 
for AIDS Relief [PEPFAR], U.S. CDC), to examine the risk of household 
transmission of MDR and XDR TB in rural South Africa (NIH Fogarty 
Institute), and to elucidate the molecular epidemiology of drug-resistant TB 
in rural South Africa (Einstein Center for AIDS Research).
Anne Goldfeld, M.D., attended Brown University and the University of 
California, Berkeley, where she earned a bachelor’s degree in zoology. After 
receiving her M.D. from Albert Einstein College of Medicine, she completed 
a residency in internal medicine and a clinical fellowship in infectious 
disease at the Massachusetts General Hospital, followed by postdoctoral 
research training at Harvard University and the Dana-Farber Cancer Insti-
tute. Dr. Goldfeld has been a devoted advocate for health and human rights, 
particularly as related to refugees working in many postconflict settings 
around the world. In 1994 she cofounded the Cambodian Health Commit-
tee with Sok Thim. She has pioneered community-based TB treatment and 
more recently AIDS treatment strategies in southeastern Cambodia that 
integrate basic scientific discovery with operational models. Dr. Goldfeld is 
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a senior investigator at Uganda’s Infectious Diseases Institute (IDI), a pro-
fessor of medicine at Harvard Medical School, and a physician in medicine 
in the Division of Infectious Disease at Brigham and Women’s Hospital.
William R. Jacobs, Ph.D., is a professor of microbiology and immunology 
and a professor of molecular genetics at the Albert Einstein College of 
Medicine, and a Howard Hughes Medical Institute (HHMI) investigator. 
He is an expert in TB and other diseases in the mycobacteria family. His 
research uses bacterial viruses—called phage—to introduce foreign DNA 
into the bacteria that cause TB, (M.tb.). That work has revolutionized 
scientists’ understanding of TB bacteria. Prior to Jacobs’ development 
of gene transfer mechanisms, little was known about the genetics behind 
M.tb., including which genes were related to virulence and drug resistance. 
Jacobs and former Einstein colleague and HHMI investigator Barry Bloom 
collaborated on a series of experiments that led to the first genetic manipu-
lation of M.tb. Dr. Jacobs, who wrote his doctoral dissertation on leprosy, 
is currently developing a multipurpose vaccine that could attack malaria, 
HIV, and TB.
Charlotte Kvasnovsky, M.D., M.P.H., is a guest researcher with the Divi-
sion of TB Elimination at CDC, where she has served since 2007 on the 
Global Preserving Effective TB Treatment with Second-line drugs (PETTS) 
Coordinating Team and as coordinator for South Africa. She conducts 
research with the MRC on XDR TB. Dr. Kvasnovsky received her medi-
cal degree from Emory University in May 2010, as well as an M.P.H. in 
epidemiology from the Rollins School of Public Health. She is a resident in 
general surgery at the University of Maryland. 
Barbara Laughon, Ph.D., is senior scientist for TB Drug Development 
Partnerships at NIAID. She is the primary NIH liaison with the Lilly TB 
Drug Discovery Initiative. She also serves as chair of the Scientific Advi-
sory Committee of the TB Alliance and was one of the original founding 
stakeholders of this public−private partnership. Dr. Laughon is an active 
participant in the Stop TB Partnership, serving on working groups on new 
drugs and TB/HIV coinfection; she will be serving as executive secretary of 
the board of advisors. 
Stephen Lawn, M.D., is an associate professor of infectious diseases at the 
University of Cape Town, South Africa, and a reader in infectious diseases 
and tropical medicine at the London School of Hygiene and Tropical Medi-
cine. He trained in infectious diseases in London and has also worked in 
Ghana, west Africa, and at CDC in the United States. Dr. Lawn has been 
based in Cape Town since 2005, funded by the Wellcome Trust. His princi-
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pal research focus has been on HIV-associated TB in the context of scale-up 
of antiretroviral therapy (ART).
Lerole David Mametja, M.P.H., is currently the Chief Director for TB 
Control and Management in the National Department of Health. He 
has more than 15 years of experience in the social sector, in particular, 
 public health. As Executive Director of the Health Systems Trust (HST) he 
gained experience in setting up processes needed to facilitate implementa-
tion of organizational policies and decisions and managing an annual bud-
get of between R60 and R200 million. He has managed senior employees, 
and has interacted with both governmental (including ministerial levels), 
and non- governmental institutions. He was also Regional Health Sector 
Manager for RTI International, overseeing its health program operating in 
the Southern African Development Community (SADC). In this capacity, 
he was responsible for the identification of opportunities for research and 
development projects, negotiating partnerships, project proposal design, 
management and monitoring of projects, particularly in Mozambique, 
 Lesotho,  Swaziland and Namibia. He was also the Chief Executive Officer 
of the Health and Welfare Sector Education Training Authority (HWSETA), 
an entity that focuses on providing training and skills development oppor-
tunities for South Africans. He holds a master’s degree in public health 
(M.P.H.) in Health Policy and Management from Columbia University, 
New York. While working on his M.P.H. he served as an Assistant to the 
Deputy Chief Medical Officer and Vice President, Health and Hospital Cor-
poration, City Health Department, New York City, where he was respon-
sible for reviewing and evaluating hospital quality care systems.
Claudio Marra, M.D., graduated from the Università La Sapienza in Rome 
in 1978, and specialized in internal medicine in 1983. For the past 15 years 
he has been working in public health in both development and emergency 
settings in Kenya, Somalia, Mozambique, Malawi, and South Africa with 
international nongovernmental organizations (NGOs), the Italian Devel-
opment Cooperation, the Italian National Institute of Health, and United 
Nations agencies. In all these countries he has worked in close partnership 
with the respective local health authorities and other stakeholders. His 
focus has been on health system development, in particular on develop-
ment of district health systems; prevention and control of communicable 
diseases, including coinfection with TB and HIV/AIDS; prevention, care, 
and treatment of HIV/AIDS and malaria; maternal health; and emergency 
preparedness and response in the area of health. Since 2005 Dr. Marra has 
been providing technical assistance to the KwaZulu-Natal (KZN) provin-
cial Department of Health in understanding and addressing the complexity 
of MDR and XDR TB, as well as the challenges posed by coinfection with 
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TB and HIV/AIDS. In the Umzinyathi district of KZN, the district with the 
largest number of cases of MDR and XDR TB in South Africa, he devel-
oped an innovative household surveillance and community-based tracing 
system using GPS mapping software. The report documenting the experi-
ence in Umzinyathi district is available online on the KZN Department of 
Health website at www.kznhealth.gov.za.
Valerie Mizrahi, Ph.D., was born and raised in Zimbabwe. She obtained 
her Ph.D. in chemistry from the University of Cape Town in 1983. She 
completed a postdoctoral fellowship at the Pennsylvania State University, 
and worked at SmithKline and French Research and Development in King 
of Prussia, Pennsylvania, before returning to South Africa in 1989 to estab-
lish a research unit at the South African Institute for Medical Research 
in Johannesburg. Currently, she is director of the MRC/National Health 
Laboratory Service (NHLS)/University of Witwatersrand (WITS) Molecular 
Mycobacteriology Research Unit at NHLS and research professor at the 
University of the Witwatersrand. She is also codirector of the Department 
of Science and Technology (DST)/National Research Foundation (NRF) 
of South Africa Centre of Excellence for Biomedical TB Research, which 
she leads together with Professor Paul van Helden from the University 
of  Stellenbosch. Dr. Mizrahi is the two-time recipient of an International 
Research Scholar’s grant from the Howard Hughes Medical Institute in 
the United States (2000 and 2005). She has received numerous awards and 
honors in South Africa, and in 2009 was elected a fellow of the Ameri-
can Academy of Microbiology. Dr. Mizrahi has published 80 articles and 
book chapters in the fields of organic chemistry, enzymology, and myco-
bacteriology. In 2002, she shifted the focus of her research to the field of 
TB. Her research team played an instrumental role in developing genetic 
tools for validating new drug targets and vaccine candidates for TB and 
is internationally recognized for its work on molecular mechanisms of 
DNA metabolism, stress responses, resuscitation, and drug action in myco-
bacteria. Dr. Mizrahi is an active member of the TB research community. 
She chaired the Gordon Research Conference on Tuberculosis Drug Devel-
opment in Oxford in August 2007 and organized the Keystone Symposium 
on Pathogenesis and Control of Emerging Infections and Drug Resistant 
Organisms in Bangkok in 2008. She chairs the International Scientific 
Advisory Committee of the Institute of Infectious Disease and Molecular 
Medicine (University of Cape Town) and serves on the scientific advisory 
boards of numerous local and international research programs and insti-
tutes. She has served on the editorial advisory boards of four international 
journals and on the Department of Science and Technology’s South Africa 
Reference Group for Women in Science.
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Matsie Mphahlele, M.Phil., is a senior scientist at the MRC’s TB Epide-
miology and Intervention Research Unit, which she joined in 1997. She 
has worked as a laboratory manager in the unit, responsible for oversee-
ing Supranational Reference Laboratory (SRL) activities including rapid 
surveys, laboratory support, and capacity strengthening for South African 
Development Community (SADC) countries. She is responsible for the 
clinical, laboratory, and experimental work undertaken at the MRC Air-
borne Research Facility in Witbank, which is currently investigating the 
transmission dynamics of MDR TB and the efficacy of various environ-
mental infection control interventions in reducing the transmission of TB. 
Ms. Mphahlele holds an M.Phil. degree in international health from the 
University of Bergen in Norway and an M.Sc. degree in microbiology from 
the University of Pretoria.
Norbert Ndjeka, M.D., is a specialist family physician with an interest in 
TB and HIV. He is employed as director, drug-resistant TB, TB and HIV 
under the TB Cluster, Department of Health, Republic of South Africa. He 
has extensive clinical and programmatic experience in the management of 
TB and HIV. Dr. Ndjeka also serves as WHO temporary MDR TB advisor 
and is a member of the TB TEAM Experts Roster, serving as an experienced 
expert in M/XDR-TB under the Stop TB Department of WHO. Previously, 
he worked as medical officer at Kgapane Hospital and Botlokwa Hospital 
in Limpopo, South Africa. He was also senior medical superintendent at 
St. Rita’s Hospital and Warmbaths Hospital in Limpopo and clinical head 
of Limpopo’s MDR TB unit. Previously, he was a senior specialist and 
senior lecturer in family medicine at the University of Limpopo. Dr. Ndejka 
was also an MDR TB and infection control advisor with the University 
Research Corporation, LLC. He holds a medical degree from the Uni-
versity of Kinshasa, Democratic Republic of the Congo; a postgraduate 
diploma in health services management from Witwatersrand University, 
Johannesburg, South Africa; a diploma in HIV medicine from the College 
of Medicine of South Africa; and a master’s degree in family medicine from 
the University of Limpopo, Medunsa.
Dale Nordenberg, M.D., is a principal with Novasano Health and Science. 
He is a physician executive who leverages his experience as a  pediatrician, 
medical epidemiologist, and informatician to deliver strategic, operational, 
and scientific services to domestic and international clients in the health 
care and health information technology arenas. Recent projects include the 
development of a public−private partnership to build laboratory capacity for 
MDR TB across diverse international settings, which he is currently leading; 
development of governance structures for the National Bio surveillance Sys-
tem for Human Health; development of a multi-institutional collaboration 
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to revise U.S. Food and Drug Administration (FDA) regulatory processes to 
establish standards for national laboratory data exchange; and the evalua-
tion of emerging diagnostics related to the gut microbiome from both the sci-
entific and clinical perspectives. For the past few years, Dr. Nordenberg has 
been working as a health care consultant, first with  PricewaterhouseCoopers 
and then with Novasano. From 2002 through 2007, he held various posi-
tions at CDC, including associate director and chief information officer 
and senior advisor for strategic planning. Dr. Nordenberg has led and par-
ticipated in many disease surveillance, outbreak response, and bioterrorism 
preparedness and response activities and associated informatics initiatives. 
He has worked extensively in the arena of pandemic influenza prepared-
ness and response. He was detailed part time to the Office of the National 
Coordinator for Health Information Technology in 2004−2005 to catalyze 
a national strategy for children’s health information technology. In 2007 
and 2009, Dr. Nordenberg was a member of the Science and Technology 
Subcommittee of the FDA’s Science Advisory Board, which was tasked 
with the evaluation of science and technology at the FDA. Prior to serving 
with CDC, Dr. Nordenberg was a founding executive of a company that 
launched  VeriSign affiliates in Latin America and Asia and was a member 
of the faculty of the Emory School of Medicine, where founded and directed 
the Office of Medical Informatics for the Emory University Children’s Cen-
ter. He has served on the boards of numerous companies. Dr. Nordenberg is 
a board-certified pediatrician. He received a B.S. in microbiology from the 
University of Michigan and his medical degree from Northwestern Univer-
sity, and completed his training in pediatrics at McGill University, Montreal 
Children’s Hospital. He completed his fellowship in epidemiology and public 
health in the Epidemic Intelligence Service program at CDC.
Nesri Padayatchi, M.D., is the CDC Durban site manager for the Starting 
Tuberculosis and Anti-Retroviral Therapy (START) project of Centre for 
the AIDS Programme of Research in South Africa (CAPRISA). She has 
18 years of clinical and research experience in the management of TB and 
related problems. She was manager of the Provincial Tuberculosis Referral 
Hospital for 14 years. She was also acting director of the MRC’s Tuber-
culosis Lead Program from 1999 to 2003. Dr. Padayatchi has received the 
Columbia University−South Africa Fogarty AIDS International Training 
and Research Program (AIRTP) fellowship and completed her M.S. in 
epidemiology from Columbia University. The focus of her M.S. was on 
temporal trends in drug-resistant TB (1998−2001). She has extensive expe-
rience participating in multicenter clinical trials from 1996 to the present.
Shreemanta K. Parida, M.D., Ph.D., is a physician scientist from India 
working in the field of infectious diseases, with a particular focus on 
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mycobacterial diseases over the last 23 years. His expertise encompasses 
clinical, field, and laboratory settings; clinical trials of vaccines; immuno-
pathology; molecular pathogenesis; molecular immunology; epidemiology; 
and vaccinology. Dr. Parida obtained his Ph.D. from the National Institute 
of Immunology (NII) in India. Since 1990, he has worked in several institu-
tions in Europe, including the WHO Immunology Research and Training 
Center (IRTC) in Geneva, the University of Giessen in Germany, the Pasteur 
Institute of Brussels, and Oxford University. From 2003 to early 2006, he 
worked in Africa at Armauer Hansen Research Institute in Addis Ababa, 
Ethiopia, and thereafter at the Max-Planck-Institute für Infektionsbiologie 
(MPIIB) in Berlin. He also received an advanced diploma in vaccinology 
from Foundation Merieux, France, in 2003. Dr. Parida started his research 
career with Phase II and III clinical trials of a leprosy vaccine based on an 
atypical mycobacterium—M.w (M. indicus pranii)—at NII. The vaccine has 
been licensed as an immunotherapeutic agent for leprosy. Dr. Parida was an 
early proponent of postexposure T cell boosting vaccine for nonreplicating 
persistent TB and received a vaccine innovation grant from Sequella and 
WHO/Special Programme for Research and Training in Tropical Disease 
(TDR) in 2000−2002. In his current position, he has been instrumental in 
building a cohesive and functional team focused on the quest for TB bio-
markers; the team includes 15 partners from Africa, Europe, and the United 
States. Dr. Parida is committed to translating research from the bench to 
the clinic to combat the TB emergency in the developing world. He is pas-
sionate about science and translational research in the pursuit of solutions 
to public health problems, and has particular skills in networking, initiating 
collaborations, and coordinating multicenter studies. 
Sidney Parsons, Ph.D.,1 is an international expert in energy management 
of buildings. His expertise and research also include indoor air quality and 
environmental control for building-related illnesses, in particular the spread 
of hazardous biological agents such M.tb., as well as commissioning pro-
cesses for buildings, particularly within the health care sector. Dr. Parsons 
is a professional engineer registered with the Engineering Council of South 
Africa and with the International Society for Professional Engineers. His 
research interests are in the fields of indoor air quality, building-related 
illnesses, and infection control. Dr. Parsons has worked as a consulting 
engineer for more than 28 years. While in private practice, he undertook 
a broad spectrum of work for the public and private sectors in the areas 
of university campus utility planning; health care, research, and phar-
maceutical facilities (clean room applications); commercial developments; 
and mechanical installations for industrial applications. During 2002 and 
1  Deceased.
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2003, he took a sabbatical from his practice and was contracted to Arup 
Consulting Engineers to provide support in developing its health care port-
folio. He also conducted a course in air-conditioning and refrigeration at 
the University of KwaZulu-Natal. Dr. Parsons has coauthored a number of 
publications and presented peer-reviewed papers and presentations at inter-
national conferences and seminars. He has also been an invited copresenter 
in professional development programs, focusing on indoor air quality and 
occupational safety influences, including energy management and efficiency 
strategies. Over the past 8 years, he has worked with the MRC, CDC, and 
the Harvard School of Public Health on investigations into the efficacy of 
electro/mechanical building service systems for the protection of health care 
workers against airborne infectious diseases such as TB. 
Simon Schaaf, MBChB, DCM(SA), MMed(PAED), is a pediatrician with a 
subspeciality in infectious diseases in the Department of Paediatrics and Child 
Health, Faculty of Health Sciences, Stellenbosch University, and  Tygerberg 
Children’s Hospital. He has focused most of his clinical and research efforts 
on TB, especially drug-resistant TB in childhood. His doctoral studies were 
on drug-resistant TB in children and included a pharmacokinetic study on 
isoniazid and its possible role in low-level isoniazid-resistant TB cases. Cur-
rently he is involved in ongoing drug resistance surveillance in children in 
the Western Cape of South Africa, as well as in several studies on children 
as contacts of MDR TB cases and children with drug-resistant TB. His other 
area of interest is the pharmacokinetics of anti-TB drugs in children. Pro-
fessor Schaaf completed both pre- and postgraduate studies at Stellenbosch 
University. He has authored or coauthored many articles, most on childhood 
TB, and is, together with Ali Zumla, coeditor of the book Tuberculosis: A 
Comprehensive Clinical Reference, published by Saunders Elsevier in 2009.
Karen Shean, PN, is a professional nurse and has been a member of the 
Lung Infection and Immunity Unit (LIIU) at the University of Cape Town 
(UCT) for the past 2 years. Enrolled at UCT, she is presently completing her 
MscMed and operates as MDR TB study coordinator. She has a vast wealth 
of experience in TB, specifically drug-resistant TB. Prior to joining the LIIU, 
Ms. Shean had worked in the provincial TB program since 1990, eventually 
attaining the position of TB advisor and provincial TB hospital MDR/XDR 
TB coordinator. She has presented at many conferences internationally, 
nationally, and locally on MDR TB, XDR TB, infection control, and health 
care worker issues. In 2007 she was the provincial nominee for the Interna-
tional Council of Nurses (ICN)/Lilly Award for Nursing Excellence in TB 
Care. In 2009 she received the Investigator Award on Multidrug-Resistant 
Tuberculosis for the best abstract submitted to the European Respiratory 
Society in that category. 
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School of Medicine at the University of KwaZulu-Natal in Durban, South 
Africa. He is also interim director of the new KwaZulu-Natal Research 
Institute for Tuberculosis and HIV (K-RITH). During his career as a medi-
cal microbiologist, Dr. Sturm has studied TB, HIV, and sexually trans mitted 
diseases. He was a leading scientist investigating the first outbreak of XDR 
TB in KwaZulu-Natal Province and a principal investigator on the project 
that sequenced the genetic code of that pathogen. Dr. Sturm began his 
research career in the Netherlands and became chair of the microbiology 
department at Aga Khan University in Pakistan in 1990. He came to the 
University of KwaZulu-Natal in 1993 and has served as a professor, head 
of the medical microbiology department, and dean. He is also director of 
the MRC’s genital ulcer disease research unit at the university.
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and Relief Agency (ADRA) in Lesotho as a treatment literacy and advo-
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June 2007, Mr. Thotolo worked as national HIV/AIDS coordinator for the 
Seventh-Day Adventist Church in Lesotho. He holds a diploma in science 
education from the National University of Lesotho. He taught mathematics 
and science in a number of high schools in Lesotho from 1986 to 2005, 
when he started working full time in the field of HIV/AIDS. From July 1997 
to March 2001, Mr. Thotolo worked in South Africa for the Professional 
Assignment Group (PAG) as a payroll officer; he also worked as a payroll 
helpdesk officer and an HIV/AIDS coordinator. Mr. Thotolo took an active 
part in the formation of the Lesotho Teachers’ Trade Union in 1990, where 
he served for a number of years as Leribe District chairperson. He also 
served as chairperson for the Leribe District Math Teachers coalition, and 
was instrumental in the formation of community support groups in various 
districts of Lesotho.
Janet Tobias is a media/technology executive and an Emmy award−winning 
director/producer with 20 years of experience working for three American 
networks—PBS, Discovery, and MSNBC. Ms. Tobias started her career 
with 60 Minutes as Diane Sawyer’s associate producer, where she distin-
guished herself working on a wide range of domestic and international 
stories. Ms. Tobias then moved with Ms. Sawyer to ABC News to launch 
Prime Time Live, where she produced/directed both domestic and interna-
tional stories. Subsequently, she served as a national producer for Dateline 
NBC and also continued to produce and direct her own stories. Moving to 
VNI (which became New York Times Television) as an executive producer, 
she supervised the production of a foreign news show and reporting on a 
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editorial activities at its newly created Law and Justice Unit. In 1998, she 
began working as an executive with PBS, where she developed and pro-
duced programming not only for PBS but also for joint projects with ABC 
and Discovery. She continued her directing and writing career, winning two 
American Bar Association silver gavels. In 2001, she launched LIFE 360, 
a weekly PBS series. In 2002, Ms. Tobias joined Sawyer Media Systems, a 
creator of video technology for the web, where she served as vice president 
of production and a member of the executive committee. She also contin-
ued to be involved in documentary production through her own company, 
Sierra/Tango Productions. In 2004, she was a founding partner of Ikana 
Media, a digital strategy and production company whose primary focus is 
on health care information. Over the last 5 years she has worked with a 
variety of clients in the health care arena on subjects ranging from broad-
based delivery of health care information to communications efforts around 
obesity and HIV/AIDS. Ms. Tobias has received a number of additional 
awards, including two Cine Golden Eagles, two Casey medals for merito-
rious journalism, a National Headliner award, a Sigma Delta Chi award, 
and honorable mention Robert F. Kennedy Journalism and Overseas Press 
awards. She is a member of the Writers Guild of America and a graduate 
of Yale University. She serves on the boards of Healthright International, 
Mindset Media Society, Rwanda Works, and SochiReporter. She served 
from January to September 2009 as a senior fellow at the University of 
British Columbia, Sauder School of Business Centre for Sustainability and 
Social Innovation.
Maletela Tuoane-Nkhasi, Ph.D., holds her Ph.D. in social statistics from the 
University of Southampton, a master’s degree in population studies from 
the University of Ghana, and a bachelor’s degree in statistics and demogra-
phy from the National University of Lesotho. She has worked as a lecturer 
and senior lecturer in demography at the National University of Lesotho 
and as research project manager at the Department of Social Development 
in South Africa. Dr. Tuoane-Nkhasi is currently a manager in the Births and 
Deaths component of the Health and Vital Statistics Division at Statistics 
South Africa. She is responsible for management of data processing for 
information on mortality and causes of death from civil registration sys-
tems, and for the production of statistical reports on mortality and causes 
of death and recorded live births.
Martie van der Walt, MScAgric, M.B.A., Ph.D., is interim director for the 
TB Epidemiology and Intervention Research Unit and joined TB research at 
the MRC in 1998. She has more than 9 years of experience in research on 
drug-resistant TB, operations research, diagnostics evaluation, and TB 
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infection control. She has worked in close collaboration with the Ministry 
of Health in research translation, policy development, and policy implemen-
tation, especially for drug-resistant TB and the uptake of new diagnostics. 
Dr. van der Walt has been responsible for the large-scale rapid MDR TB 
diagnosis project, which is providing evidence to WHO for evaluating rapid 
assays for routine use in developing countries. She has also been oversee-
ing the 5-year cooperative agreement between CDC and the Unit, which 
has included managing subpartners (for example, the THAT’S IT pro-
gram). She is also responsible for the Unit’s operational research program 
and for projects covering such areas as program implementation, Directly 
Observed Treatment Short course (DOTS) evaluation, and drug-resistant 
TB and epidemiology. Through the Unit’s operations research activities, 
Dr. van der Walt has a network encompassing TB control programs on 
both the national and provincial levels. She is a member of the Stop TB 
New Diagnostics Working Group, the Drug Resistance Working Group, 
and the WHO Global XDR TB Task Force, and served on the Green Light 
Committee from 2005 to 2007 as the MRC alternate. She received her 
basic training in microbiology (MScAgric) from the University of Pretoria, 
a master’s degree in business administration from the University of Pretoria, 
and a Ph.D. in biotechnology from the University of Pretoria.
Paul van Helden, Ph.D., obtained his doctorate in biochemistry in 1978 
and has served on the Faculty of Health Sciences at Stellenbosch University, 
Cape Town, since January 1979. He is professor and head of the Divi-
sion of Molecular Biology and Human Genetics and also director of the 
MRC Centre for Molecular and Cellular Biology, as well as codirector of 
the Department of Science and Technology/National Research Foundation 
(DST/NRF) Centre of Excellence for Biomedical TB Research. He has been 
associated with the MRC since 1979 and employed by the Council since 
1990. He has been awarded the Vice-Chancellors’ Award for Excellence in 
Research (University of Stellenbosch, 2000); the Gold Medal Award, South 
African Society for Biochemistry and Molecular Biology (2001); the MRC 
Silver Medal for Research (2004); and the National Science and Technol-
ogy Forum (NSTF) Award for Outstanding Contribution to Science and 
Technology in the Republic of South Africa (RSA) over 5 years (2005). 
Dr. van Helden’s interest in TB began in 1989. This interest has grown and 
is now a major focus of the Division and faculty. The Division operates 
across diverse areas of TB research, from diagnostics, to immunology and 
genetics, to clinical trials and veterinary TB. Dr. van Helden has published 
more than 220 research publications, and his team has extensive global 
networks. He describes their efforts as attempting to develop a continuum 
of activities to span the divide between basic research and clinical practice 
in hospitals, clinics, and community settings. A disease such as TB not only 
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has scientific components, but also is intimately linked to culture, society, 
poverty, and local and international norms and activities, which cannot be 
ignored.
Sabine Verkuijl, M.D., has worked in South Africa since 1998. She holds a 
DTM&H from the Royal Tropical Institute in Amsterdam (The  Netherlands) 
and an MMed (FamMed) degree from UNITRA (South Africa). From 1998 
to 2002, Dr. Verkuijl was employed as a senior/principal medical officer in 
Bambisana Hospital, a rural district hospital in the  former Transkei (O.R. 
Tambo District, Eastern Cape). With funding from the Netherlands, she ini-
tiated and supervised a community-based DOTS project in primary health 
care facilities under Bambisana. Between 2002 and 2006, Dr. Verkuijl 
worked with the Health Systems Trust, first as a facilitator for the Initiative 
for Sub-District Support (ISDS) around district health systems development 
in the OR Tambo District, and later as Eastern Cape provincial coordinator 
for the Technical Assistance Service Contract for Tuberculosis (TASC-TB) 
program, in collaboration with University Research Corporation (URC) 
and Management Sciences for Health (MSH). From 2006 to 2007, she was 
a part-time HIV and TB/HIV clinician in primary health care facilities and 
a TB Hospital in East London. Since 2006 she has been employed by the 
International Center for AIDS Care and Treatment Programs (ICAP), under 
Columbia University, as a technical advisor for TB/HIV integration, sup-
porting selected districts in the Eastern Cape, KwaZulu-Natal, Free State, 
and Northern Cape Provinces to improve TB/HIV collaborative activities.
Kristina Wallengren, Ph.D., technical advisor to the Provincial TB Control 
Programme, Department of Health, KwaZulu-Natal (KZN), since 2007, is 
presently evaluating piloting of decentralized MDR TB treatment in KZN 
with support from IZUMI Foundation. Supported by WHO, Dr. W allengren 
conducted a situational analysis of MDR and XDR TB in KZN following 
the XDR TB outbreak reported by Church of Scotland Hospital (CoSH). 
Dr. Wallengren has worked as TB and HIV research investigator with 
Harvard University in KZN since 2005, and has also undertaken an HIV 
seroprevalance and knowledge, attitudes, and practice (KAP) survey in the 
apparel industry in Lesotho. Currently, Dr. Wallengren is the Acting Clinical 
Core Manager at KwaZulu-Natal Research Institute for Tuberculosis and 
HIV (K-RITH). She holds an MPH in international health from Harvard 
School of Public Health and a PhD in molecular biology and virology from 
Karolinska Institute in Sweden.
Rob Warren, Ph.D., obtained his doctorate in biochemistry from the Uni-
versity of Cape Town in 1995 and subsequently joined the Department of 
APPENDIX C 127
Medical Biochemistry, Stellenbosch University. He was appointed associ-
ate professor in the department in 2004. Under his guidance, the study 
of the molecular epidemiology of M.tb. in a high-incidence setting (Cape 
Town, South Africa) has been brought to the forefront of international TB 
research. This study now represents the largest molecular epidemiological 
data set in the developing world and has been referred to as a national 
heritage. Much of this work has provided new understanding that has 
allowed long-standing dogmas to be challenged. Dr. Warren has published 
more than 110 papers in international peer-reviewed journals in the fields 
of molecular epidemiology, drug resistance, and bacterial evolution since 
1996. From this work, five patents have been registered, which hold prom-
ise for the development of novel vaccines, new diagnostics, and genetic 
manipulation of M.tb. Dr. Warren’s current research focuses on (1) the 
disease dynamics of drug-sensitive and MDR/XDR TB in the Western 
Cape, (2) the development of novel diagnostics that are applicable to the 
developing world, (3) discovery of the mechanisms whereby drug resistance 
develops, (4) speciation of mycobacteria causing disease in humans and 
animals, (5) application of novel methods to improve the speed of diagnos-
ing smear-positive disease, (6) host−pathogen compatibility, (7) identifica-
tion of highly pathogenic strains of M.tb., (8) pathogen evolution, and 
(9) mycobacterial epigenetics. 
Robin Wood, M.D., is director of the Desmond Tutu HIV Research Centre 
and Professor of Medicine at the University of Cape Town, visiting scien-
tist at Harvard University Medical School, and a member of the governing 
council of the International AIDS Society. He received his undergraduate 
training at London University and his medical degree from Oxford Uni-
versity. His internist specialization was at the University of Cape Town, 
and he completed an Infectious Disease Fellowship at Stanford University. 
Dr. Wood’s research interests include treatment of HIV infection and inter-
actions between HIV and TB; he has published more than 200 scientific 
articles. He has acted as a consultant on HIV and TB issues to international 
pharmaceutical industries, the South African mining industry, and WHO. 
Tomás Zimba, M.D., MMed, is director of the Clinical Laboratories at 
Hospital Central de Maputo in Maputo, Mozambique, and a lecturer in 
virology at at Instituto Superior de Ciências e Tecnologia de Moçambique. 
From 2007 to 2009, Dr. Zimba served as director of the laboratory course 
in Instituto Superior de Ciências de Saúde. From 1999 to 2000, he served 
as a general practitioner at Provincial Hospital of Tete, clinical director of 
the Department of Medicine and Provincial Laboratory, clinical counselor 
at the provincial level of the National Program against Tuberculosis, and 
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clinical counselor at the provincial level of the Essential Drugs Program 
at Provincial Hospital of Tete. Dr. Zimba received his M.D. from the 
First Medical University of St. Petersburg, Russia, and holds an MMed in 
medical microbiology from the Nelson Mandela School of Medicine of the 
University of KwaZulu-Natal in South Africa. 
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